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ABSTRACT 
 
Ovarian cancer is the third most common gynaecologic malignancy and the main cause of death from 
gynaecologic cancer. Despite in the last 30 years an improvement of the overall survival of ovarian cancer 
patients has been observed, an increased cure rate was not registered. The high mortality associated with 
ovarian cancer is mainly due to a late diagnosis and resistance to treatment, barring ovarian cancer cure.  
Given the lack of a specific therapy against ovarian cancer, the treatment depends essentially on the use 
of generalised and comprehensive cytotoxic drugs, most of them belonging to the group of 
alkylating/oxidative agents, as platinum salts. Chemotherapy imposes high selection pressures in cancer 
cells, which may affect their evolutionary trajectories, selecting the chemoresistant ones, which will continue 
the progression and relapse of the disease, contributing to morbidity and mortality. 
In recent years, cancer metabolism has acquired a central position in oncobiology, being the metabolic 
remodelling a requirement for tumour progression, allowing cancer cells to respond to the selective pressures 
of the microenvironment, such as hypoxia and cytotoxic drugs. These selective pressures promote cell death 
in non-adapted cells and positively select cells that exhibit growth advantage that will further sustain cancer 
progression and metastasis. Endogenous metabolism also limits drugs response. A role of cysteine in cancer 
by contributing for H2S generation and as a precursor of the antioxidant glutathione (GSH), were already 
reported. GSH has a crucial role as an antioxidant and also as a detoxifying system allowing the 
physiological maintenance of metabolic pathways, being intimately associated with chemoresistance. H2S is 
involved in several biological processes, acting also as an antioxidant and being associated with cancer 
progression and chemoresistance. 
As a solid tumour grows, such as an ovarian tumour, due to inefficient vascularisation, cancer cells are 
exposed to regions of hypoxia, known as a boost factor for tumour progression, metastasis and resistance to 
therapy. 
The present thesis aimed to clarify the relevance of cysteine metabolism in ovarian cancer cells 
adaptability to both hypoxia and platinum salts (carboplatin). These stressful conditions impose strong 
evolutionary selection pressure on cancer cells.  
Our results have provided evidence that cysteine metabolism has a role in ovarian cancer cells fast 
response and adaptation to hypoxic conditions that, in turn, are capable of driving chemoresistance. 
Moreover, cysteine showed to present a widespread protective effect against both hypoxia and carboplatin-
induced death among ovarian cancer cell lines. Importantly, our findings were also supported in a clinical 
context, as an overall increase of thiols concentration was found in serum from patients with ovarian 
neoplasms, regardless malignancy. Strikingly, the free levels of cysteine together with protein-S-
cysteinylation levels were able to distinguish patients with malignant tumours from patients with benign 
tumours and also from healthy individuals, supporting that the levels of cysteine and protein-S-cysteinylation 
can be putative biomarkers for ovarian cancer early diagnosis. Cysteine was also the prevalent thiol and S-
cysteinylation was the most abundant form of S-thiolated proteins in the ascitic fluid from patients with 
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advanced disease. The ascitic fluid is an important compartment of the ovarian cancer cells 
microenvironment, supporting a clinical relevance of cysteine also in the progression of the disease.  
Given the protective effect of cysteine in hypoxic ovarian cancer cells, we also aimed to address the 
possible mechanisms by which cysteine would be beneficial under hypoxia. Our results have supported a 
role of a higher thiols turnover in the adaptation to this environment, especially in ES2 cells. Moreover, 
results have also supported a role of cysteine in energy production mediated by the xc- system, that requires 
cysteine metabolism instead of H2S per se. However, the direct role of cysteine in ATP production is still 
uncertain as this amino acid can have an indirect contribution to ATP synthesis driven by an increased GSH 
content, allowing the redox equilibrium crucial for the overall cellular metabolism. Strikingly, 1H-NMR 
results have suggested that cysteine impacted profoundly ES2 cells metabolism under hypoxia, allowing a 
metabolic reprogramming, that probably underlies ES2 cells adaptation to hypoxia.  
Taken together, this thesis has shed light on new paths for ovarian cancer screening, diagnosis, 
prognosis and therapy, where cysteine metabolic profile might allow the design of new and useful 
approaches to fight this disease, thus overcoming its poor prognosis. 
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RESUMO 
 
Apesar de todo o progresso na prevenção e no desenvolvimento de novas abordagens terapêuticas, o 
cancro é a segunda principal causa de morte a nível mundial. Cancro refere-se a um conjunto de doenças 
complexas, sendo que existem mais de 200 diferentes tipos de cancro. No entanto, foi proposto que as 
alterações fisiopatológicas implicadas na transformação maligna são comuns à maioria dos tumores 
humanos: auto-suficiência em sinais estimuladores de proliferação celular (mitogénese), insensibilidade a 
sinais que inibem a proliferação, evasão da morte celular programada, capacidade de replicação ilimitada, 
indução de angiogénese, capacidade de invasão de tecidos e de metastização, reprogramação do metabolismo 
energético e evasão ao sistema imunitário. Tanto a incidência como a mortalidade por cancro têm vindo a 
aumentar, não só devido ao envelhecimento e crescimento populacionais mas também devido ao aumento da 
exposição a factores de risco tais como o tabaco e obesidade. 
O cancro do ovário não é exceção a este cenário, sendo o terceiro tipo de cancro ginecológico mais 
comum e a principal causa de morte de cancro ginecológico. Cancro do ovário define um conjunto de 
neoplasias distintas, sendo os carcinomas (neoplasia malignas com origem epithelial) o grupo dominante. 
Apesar de nos últimos 30 anos se ter observado um aumento da sobrevivência de pacientes com esta doença, 
não se observou um aumento na taxa de cura. O mau prognóstico associado ao cancro do ovário deve-se 
essencialmente a um diagnóstico tardio e à emergência de resistência à terapia convencional, dificultando o 
tratamento da doença. O tratamento do cancro do ovário envolve geralmente cirurgia citorredutora e terapia 
combinada de sais de platina e de taxanos, ambos agentes oxidativos. Estes fármacos impõem pressões 
seletivas muito fortes nas células neoplásicas, seleccionando células resistentes responsáveis pela progressão 
e recidiva da doença. A quimioresistência contribui assim para uma grande morbilidade e mortalidade da 
doença. 
Recentemente, o metabolismo do cancro adquiriu uma relevância central em oncobiologia, sendo a 
remodelação metabólica uma característica necessária para a progressão tumoral, permitindo que as células 
cancerígenas respondam e se adaptem a inúmeras pressões seletivas diferentes impostas pelo microambiente 
tumoral, tais como hipóxia, acidez e presença de fármacos citotóxicos. O papel da cisteína em cancro já foi 
demonstrado devido ao seu envolvimento como percursor de dois compostos essenciais: o glutatião (GSH) e 
o sulfureto de hidrogénio (H2S). O GSH é o tiol não proteico mais abundante em células de mamífero, 
desempenhando diversas funções biológicas tais como uma função antioxidante, e destoxificante, 
constituindo um mecanismo de quimioresistência em vários tipos de tumores. Por sua vez, o H2S está 
também envolvido em vários processos biológicos, tendo também um papel antioxidante e estando também 
associado a progressão tumoral e quimioresistência. 
Durante o crescimento dos tumores sólidos, como os tumores de ovário, as células cancerígenas são 
sujeitas a gradientes de hipóxia, devido a uma vascularização ineficiente. A hipóxia exerce uma forte pressão 
seletiva nas células cancerígenas, estando relacionada com a progressão tumoral, metastização e resistência à 
quimioterapia. 
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Na presente tese, o nosso objectivo principal foi clarificar a relevância do metabolismo da cisteína na 
capacidade de adaptação de células de carcinomas do ovário a condições de hipóxia e à presença de sais de 
platina (carboplatina), duas condições que impõem uma forte pressão seletiva nas células cancerígenas. Para 
isto, recorremos essencialmente a duas linhas celulares de cancro de ovário de dois tipos histológicos 
diferentes: uma linha de carcinoma seroso de alto grau (HG-OSC) – OVCAR3 e uma linha de carcinoma de 
células claras (OCCC) – ES2. É importante referir que o tipo histológico carcinoma seroso de alto grau (HG-
OSC) é o mais frequente, enquanto que o OCCC, apesar de menos frequente, é geralmente resistente à 
terapia convencional. Adicionalmente, recorremos a uma linha celular de carcinoma do ovário cujo tipo 
histológico é desconhecido (A2780 sensíveis/parentais e A2780 resistentes a cisplatina) e a outra linha de 
HG-OSC (OVCAR8). Recorremos ainda a amostras de soro de mulheres com tumores de ovário benignos e 
malignos, assim como a amostras de soro de mulheres saudáveis, a amostras de carcinomas de ovário de 
diferentes tipos histológicos e a amostras de líquido ascítico de mulheres com cancro de ovário. 
No primeiro capítulo de resultados experimentais começámos por investigar qual o efeito da seleção de 
células ES2 e OVCAR3 em condições de normóxia e em hipóxia na capacidade destas se adaptarem à 
carboplatina, pretendendo ainda verificar qual o papel da cisteína na resposta a estes dois ambientes 
hipóxia/carboplatina. Os nossos resultados mostraram que a cisteína facilita a adaptação a condições de 
hipóxia que, por sua vez, é capaz de induzir quimioresistência. 
No segundo capítulo de resultados experimentais pretendemos aprofundar o papel da cisteína na 
proteção de células de carcinoma do ovário em condições de hipóxia e na presença de carboplatina. 
Pretendemos ainda verificar se a cisteína apresenta relevância em contexto clínico, averiguando a 
possibilidade para o seu uso em diagnóstico e como ferramenta de prognóstico da doença. Os nossos 
resultados indicaram que a cisteína tem um papel protetor amplamente distribuído por diferentes linhas de 
cancro de ovário, tanto em condições de hipóxia, como na presença de carboplatina. Nas células ES2, os 
dados sugeriram que as dinâmicas de síntese e degradação de tióis estão subjacentes ao efeito protetor da 
cisteína em condições de hipóxia. Relativamente ao seu papel em contexto clínico, através da quantificação 
de tióis em soros de mulheres saudáveis e em mulheres com tumores de ovário benignos e malignos, 
verificámos que os níveis totais (cisteína livre e proteínas cisteinilada) conjuntamente com os níveis livre 
totais de cisteína foram capazes de distinguir estes três grupos de mulheres, sugerindo assim que este tiol 
poderá ser usado como um marcador de diagnóstico precoce da doença. Em amostras de tumores, 
verificámos uma tendência (não significativa) para níveis de cisteína mais altos no tipo histológico OCCC e 
também em HG-OSC apenas após quimioterapia, reforçando um papel importante da cisteína no tipo 
histológico OCCC e na aquisição de quimioresistência. Para além disto, através da análise do conteúdo de 
tióis em líquidos ascíticos de pacientes com carcinoma de ovário em estadios avançados da doença, 
verificámos ainda que a cisteína foi o tiol prevalente encontrado nesta importante fracção do microambiente 
tumoral, suportando um papel relevante deste tiol também na progressão da doença. 
No terceiro capítulo referente a dados experimentais, pretendemos clarificar o mecanismo por detrás do 
papel protetor da cisteína em condições de hipóxia. Assim, para além das dinâmicas de síntese e degradação 
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de GSH, pretendemos explorar qual o papel do H2S na adaptação das células de cancro de ovário a condições 
de hipóxia. Os nossos resultados sugeriram um papel importante da cisteína na produção de ATP, mediado 
pelo sistema de transporte xc- , que requer o metabolismo da cisteína, não sendo o H2S por si suficiente para 
aumentar a produção de ATP em condições de hipóxia. No entanto, um papel direto da cisteína na produção 
de ATP é ainda incerto, uma vez que a contribuição deste tiol no metabolismo energético celular poderá ser 
devido a uma contribuição indireta, conduzido por um aumento dos níveis de GSH, permitindo assim um 
equilíbrio redox, crucial para o metabolismo celular. Através de 1H-RMN (espectroscopia por ressonância 
magnética nuclear) verificámos que a cisteína teve um impacto profundo no metabolismo das células ES2, 
permitindo uma remodelação metabólica em condições de hipóxia, o que poderá estar subjacente à adaptação 
destas células nestas condições. 
De um modo geral, este trabalho permitiu aumentar o conhecimento e conduzir a novas abordagens para 
o diagnóstico, prognóstico e terapia do cancro de ovário através do metabolismo da cisteína. Isto poderá 
permitir a implementação de novas abordagens de rastreio, diagnóstico e tratamento da doença, permitindo 
assim superar a quimioresistência e o mau prognósticos associados ao cancro do ovário. 	  
PALAVRAS-CHAVE 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
 
This chapter is partially based on the following publication: 
Nunes SC, Serpa J. Glutathione in ovarian cancer: A double-edged sword. Int. J. Mol. Sci. 
2018;19:1882–96.  
 
 
 
 
 	  	  	  	  	  	  	  
“’Begin at the beginning,’ the King said, very gravely, ‘and go on till you come to the end: then stop.’”  
Lewis Carrol 
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INTRODUCTION 
 
Despite all the progresses developed in prevention and new treatment approaches, cancer 
is the second leading cause of death worldwide [1]. In accordance with the International 
Agency for Research on Cancer, 14.1 million cancer cases [2] and 8.2 million cancer deaths 
[3] were estimated worldwide in 2012. For 2020, 17.1 million incidences and 10.05 million 
cancer deaths [2] are estimated. Metastatic disease accounts for over 90% of all cancer-
related deaths, where the treatment with surgery, conventional chemotherapy and radiation is 
ineffective [4]. The late diagnosis combined with resistance to the conventional anti-cancer 
drugs used, are the major causes of cancers poor prognosis.  
More than 200 different types of cancer exist [5], however, the physiological alterations 
that entail the malignant transformation were proposed to be common to the majority or even 
to all types of human tumours [6]. Therefore, in 2000, Hanahan and Weinberg proposed the 
existence of six core hallmarks of cancer cells: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis [6]. Eleven 
years later, the authors revisited those original hallmarks, and included energy metabolism 
reprogramming and evading immune destruction, as emerging hallmarks of cancer [7]. 
Underlying those hallmarks, the authors suggested two consequential characteristics of 
neoplasia that facilitate acquisition of both core and emerging hallmarks: genome instability, 
and inflammation [7]. The acquisition of these hallmarks is an evolutionary process, 
involving natural selection among the neoplastic cells, allowing cancer initiation, progression 
and chemoresistance [8]. 
The best characterised metabolic phenotype observed in tumour cells is the Warburg 
effect, proposing that cancer cells present an increased rate of glycolysis even under normal 
oxygen concentrations due to defective mitochondrial oxidative phosphorylation (OXPHOS) 
[9]. However, evidence accumulates showing that mitochondrial OXPHOS function is intact 
in most tumours [10–14]. Moreover, evidence also supports that the bioenergetics of tumour 
cells is highly complex, where cancer cells have the ability to use several substrates in order 
to support energy production, including glucose, glutamine, fatty acids, and acetate [14]. 
Also, in cancer cells, both glycolytic and oxidative metabolisms coexist, enhancing metabolic 
plasticity and improving tumorigenesis and metastasis [13,15], hence highlighting the 
metabolic complexity of cancer cells that allows coping with changing microenvironments. 
Recent studies have disclosed the Warburg effect as a way of cancer cells to sustain cell 
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proliferation rather than producing energy [16–18], once the glycolytic intermediates are 
deviated to serve as building blocks needed for replicating DNA and cellular machinery prior 
to mitosis [18]. Other hypothesis that explain the advantage of the Warburg effect on cancer 
cells is that it supports an ideal tumour microenvironment, sustaining cancer cells 
proliferation (e.g. acid-mediated invasion hypothesis) and that altered glucose metabolism 
alters cancer cell signalling, promoting tumorigenesis via reactive oxygen species (ROS) and 
the modulation of chromatin state (reviewed in [19]). 
In the next sections, the concept of cancer as an evolutionary disease, and the metabolic 
strategies developed by cancer cells in order to survive to several tumour environmental 
stresses, in particular hypoxia and anti-cancer drugs, will be thoroughly presented. 
 
 
1.1 CANCER AS AN EVOLUTIONARY DISEASE 
 
In 1976 Nowell’s described cancer as an evolutionary disease, proposing that the 
majority of neoplasms present a unicellular origin, and that the tumour progression results 
from acquired genetic variability within the original clone, allowing the sequential selection 
of more aggressive subclones [20]. In 1975, Cairns had also argued cancer as an evolutionary 
process, driven by mutation and natural selection [21]. Thus, cancer cells evolve under the 
same rules as Darwin’s finches on the Galapagos, in which several genetically 
heterogeneous individual cells that are present within a tumour, fight for growth and 
survival in continuously changing environments [22]. Therefore, cancer is an evolutionary 
and an ecological process, being cancer cells subject to competition for space and resources, 
predation by the immune system and cooperation to disperse and colonise new organs 
[23,24]. Strengthening the relevance of evolution and ecology on cancer, recently, Maley and 
colleagues have developed an evolutionary and ecological classification system for 
neoplasms in order to improve the clinical management of cancer. Hence, the authors 
proposed the classification of neoplasms based on the Evo-index, including the intratumoural 
heterogeneity and its changes over time, and the Eco-index, including the hazards to 
neoplastic cell survival and the resources available to these cells [25].  
Hypoxia and acidosis are common features of the tumour microenvironment, being 
highly selective and inducing genetic instability, hence promoting somatic evolution [26]. 
Cytotoxic anti-cancer drugs also drive evolution of cancer cells, by imposing strong 
evolutionary selection pressures on the surviving cells [26]. In the next sections we will focus 
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on the strategies that cancer cells evolve in order to cope both with hypoxia and with anti-
cancer drugs, allowing disease progression and resistance to treatment. 
 
 
1.1.1 HYPOXIA: A POWERFUL SELECTION PRESSURE ON MALIGNANT 
PHENOTYPES 
 
Several microenvironmental conditions such as hypoxia, ROS and acidosis, that are 
common features of the tumour microenvironment, impose highly selective pressures in 
cancer cells, inducing also genetic instability [26]. 
As a solid tumour grows, cancer cells are exposed to regions of hypoxia, strictly linked to 
oxidative stress [27,28] and known to be responsible for tumour progression and resistance 
to therapy [29,30]. Evidence suggest that 50 to 60% of locally advanced solid tumours 
contain regions of hypoxia and/or anoxia caused by an oxygen delivery and consumption 
imbalance [4,29]. This is mainly due to abnormal vasculature together with the high 
proliferation rates of cancer cells [4]. In here, we will focus on how cancer cells evolve 
adaptive mechanisms to cope with oxidative stress, an imbalanced ratio between ROS 
production and the cellular antioxidant capacity [31], addressing the role of antioxidant 
defence systems and the role of hypoxia-inducible transcription factors (HIF) in mediating 
hypoxia adaptation. 
The evolution of aerobic respiration is closely linked with the evolution of anti- oxidant 
defence systems [32]. Aerobic organisms present several antioxidant defensive systems, 
including enzymatic and non-enzymatic antioxidants that react and inactivate ROS [33]. 
Moreover, in order to maintain oxygen homeostasis, metazoan organisms present the hypoxic 
signalling pathway that allows oxygen delivery and cellular adaptation to oxygen deprivation 
[30]. 
The primary antioxidant enzymes include superoxide dismutases (SODs) (catalysing the 
dismutation of superoxide anion radical into hydrogen peroxide (H2O2)); catalase and 
glutathione peroxidase (GPX) (which convert H2O2 into water and oxygen) and glutathione 
reductase (GRx) that removes H2O2 by oxidation of reduced glutathione (GSH) into oxidised 
glutathione (GSSG). GRx then regenerates GSH from GSSG, with NADPH as a reducing 
agent. GPx also reduces lipid or nonlipid hydroperoxides concomitant with GSH oxidation 
[33,34]. Peroxiredoxins (PRXs) and thioredoxin (Trx) are other important antioxidant 
enzymatic systems. The thioredoxin redutase (Trx) system is formed by thioredoxin 
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reductase (TrxR), Trx and NADPH. TrxR is a selenoprotein involved not only in the 
regulation of the cellular redox status but also in redox control of transcription factors, 
oxidative stress defence, and cell growth [31]. Peroxiredoxins (PRXs) are considered one of 
the most important cell redox state–regulating enzymes, reducing alkyl hydroperoxides and 
H2O2 to the corresponding alcohol or water [31]. The figure 1 illustrates the cellular 
antioxidant systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cellular antioxidant systems. 
The major sources of ROS are the mitochondria, NAPH oxidase, and the endoplasmic reticulum [35]. 
Anion superoxide (O.-) is the principal form of ROS which is rapidly converted  into hydrogen peroxide 
(H2O2) by superoxide dismutase (SOD) [35]. In the cytosol, this reaction is catalysed by SOD1, whereas 
in the mitochondria, this reaction is catalysed MnSOD and SOD2 [36]. H2O2 can be then catalysed by 
GSH peroxidase (GPX), peroxiredoxins (PRXs) (dependent or thioredoxin-dependent peroxide 
reductases) and catalase. GPX reduce hydroperoxides using GSH as a substrate and generating GSSG, 
which can be then reduced by GSH reductase (GR) [35]. The thioredoxin system includes thioredoxin 
(TRX), PRX and thioredoxin reductase (TRXR) and is essential for counteracting oxidative stress by 
removing hydrogen peroxide (H2O2) [37].   
This system donates electron to thioredoxin-dependent peroxidases (Prx1 and 2 in the cytosol and 3 in 
the mitochondria). In the mitochondria PRX3 can also be reduced by glutaredoxin 2 (GRX2). 
Peroxiredoxins (PRXs) reduce alkyl hydroperoxides and H2O2 to their corresponding alcohol or H2O 
[35]. There is a crosstalk between GSH and thioredoxin systems, where the GSH system can also reduce 
TRX1 in the cytoplasm [38]. 
Both Trx and glutaredoxin (Grx) reduce protein disulphides and Grx also catalyses protein 
deglutathionylation [39]. Adapted from Nogueira and Hay [36], Marengo and colleagues [35], Castaldo 
el al. [40] and Lu et al. [38]. IMS - inter mitochondrial space. 
 
The nonenzymatic antioxidants include metabolic and nutrient antioxidants. The 
metabolic ones belong to endogenous antioxidants, result from body’s metabolism and the 
most relevant are lipoid acid, L-arginine, coenzyme Q10, melatonin, uric acid, bilirubin, 
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metal-chelating proteins, transferrin and GSH [33]. Importantly, GSH is a thiol present in 
almost all animal cells [41], that can function as a reducing agent, an antioxidant, a free-
radical scavenger and is also involved in the metabolism of xenobiotics and other cell 
molecules [42]. The nutrient antioxidants belong to exogenous antioxidants being provided 
through diet, including vitamin E, vitamin C, carotenoids, trace metals (selenium, manganese, 
zinc), flavonoids, omega-3 and omega-6 fatty acids [33].  
The transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor 2 (Nrf2) is 
a pivotal player in cellular redox homeostasis regulation, strongly influencing intrinsic 
resistance to oxidative stress and controlling adaptive responses to several stressful 
environmental conditions [43]. Nrf2 is not only involved in the regulation of the GSH-based 
antioxidant system, but also regulates the expression of cytosolic thioredoxin (TRX1), TrxR1 
and sulphiredoxin1 [43].  
In order to counteract oxidative stress, cancer cells present enhanced antioxidant defence 
systems [44,45] that actively upregulate and contribute to tumour progression [44–47]. For 
instance, increased levels of both GSH and glutamate cysteine ligase (GCL) were reported in 
several human cancer tissues (reviewed in [48]). TrxR expression was also found to be 
upregulated in several human cancers, including breast, thyroid, liver, prostate carcinomas 
and melanoma (reviewed in [31]). In human colorectal carcinomas, both increased TrxR 
activity and expression were found (reviewed in [31]). Moreover, the increased expression of 
PRXs was also found in several cancer cell types and experimental evidence have shown that 
the silencing of several PRXs sensitises cancer cells to ROS-induced apoptosis [49]. 
Strikingly, Roh et al. reported that the inhibition of both GSH and TRX systems presented a 
synergistic effect on head and neck cancer cells death, but the effect was suboptimal due to 
the activation of Nrf2-antioxidant response element pathway in resistant cells [45]. However, 
with the simultaneously blocking of GSH, Trx and the Nrf2-ARE pathways, the authors were 
able to eliminate the resistant head and neck cancers [45]. These results strongly support a 
key role of the antioxidant defence systems in cancer biology, thus suggesting that targeting 
multiple antioxidant pathways simultaneously could be a successful strategy to fight several 
types of cancer.  
Importantly, hypoxia is known to activate HIF signalling within tumours. Besides the 
enhanced antioxidant defence systems, intratumoural hypoxia activates HIF-1 and HIF-2, 
with HIF-1α overexpression being strongly associated with increased metastasis and 
mortality in several cancer types [50,51]. HIF-1α targets includes genes involved in 
angiogenesis, glucose metabolism, cell proliferation/viability, invasion and migration, thus, 
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the upregulation of HIF-1α activates several hallmarks of cancer [51]. Benita and colleagues 
have shown that the cellular response to hypoxia differs between cell types and reported over 
6000 differentially expressed genes under hypoxia [52], thus showing the complexity of the 
cellular hypoxia response via HIF-1. Moreover, Malec and colleagues have reported a role of 
NADPH oxidase subunit NOX1 in the activation of Nrf2 by protein stabilization, which 
subsequently induced TRX1 expression, resulting in enhanced HIF-1α signalling under 
intermittent hypoxia conditions in adenocarcinoma A549 cells [53]. The authors have 
provided, therefore, a link between Nrf2 and HIF-1α pathways in cancer cells [53]. 
Finally, hypoxia can also drive and maintain genetic instability and a mutator phenotype 
[54], increasing the levels of genetic variation among cells, thus accelerating the rate of 
somatic evolution in carcinogenesis [8]. In fact, increased mutagenesis was observed in cells 
exposed to in vitro and in vivo hypoxic conditions, confirming the hypothesis that the 
hypoxic environment drives a mutator phenotype [54–56]. Importantly, the deregulation of 
HIF-1α was reported to promote the malignant phenotype and genomic instability through 
interplay with oncoproteins like c-MYC [57]. Koshiji and colleagues also reported a role of 
HIF-1α in hypoxia-induced genetic instability through the inhibition of MutSα expression, a 
DNA mismatch repair gene [58]. 
With this section, we intended to clearer the key role of hypoxia in driving and 
maintaining malignant and aggressive phenotypes. In the next section we will focus on how 
cancer cells scape from drugs-induced death, a feature that is also intimately related with 
hypoxia. 
 
 
1.1.2 ESCAPING FROM DRUGS-INDUCED DEATH: THERAPY, A POWERFUL 
SELECTIVE PRESSURE ON CANCER CELLS EVOLUTION  
 
Besides hypoxia, cytotoxic cancer therapies also impose intense evolutionary selection 
pressures on cancer cells [26] that evolve mechanisms enabling drug-induced death 
avoidance. Drug resistance can be intrinsic (exists prior to treatment) or acquired during 
treatment [59] and two general causes of drug resistance exist: host factors and specific 
genetic or epigenetic alterations in the cancer cells [60]. Importantly, tumours present a high 
molecular heterogeneity [61], allowing therapy-induced selection of a resistant subpopulation 
of cells, thus leading to drug resistance emergence [59]. 
Several mechanisms were already associated with drug resistance, including the 
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increased drug efflux and decreased drug influx, drug inactivation, alterations in drug target, 
increased DNA damage repair, deregulation of apoptosis, autophagy, activation of 
prosurvival signalling, oncogenic bypass and pathway redundancy and epithelial–
mesenchymal transition [59]. The tumour microenvironment has been implicated not only in 
tumour growth, invasion, and metastasis but also in acquired drug resistance, mediated by 
myeloid cells, cancer-associated fibroblasts, mesenchymal stem cells and the interaction with 
the extracellular matrix [62]. Moreover, hypoxia is a common tumour microenvironmental 
condition that is intimately related to chemoresistance driven by the cellular responses 
described previously and also by other factors such as decreased drug activity in the absence 
of O2; decreased drug effect in hypoxic cells with low proliferation rates or with altered pH 
gradients; induction of gene amplification; and a generallly insuficient drug delivery to cells 
that are far from functional vasculature [54]. 
Because this thesis is focused on ovarian cancer, which is conventional treated with 
surgery combined with carboplatin-paclitaxel chemotherapy [63], we will focus on the 
resistance mechanisms described to these drugs.  
It is well known that platinum-based therapy involves ROS-mediated apoptosis [64–66]. 
Cisplatin and carboplatin are highly reactive molecules that bind to RNA, DNA and proteins, 
leading to the formation of adducts [63,66]. The nuclear DNA adducts are thought to be 
mainly responsible for cisplatin cytotoxicity, inducing cell death as a result of DNA damage 
and inhibition of replication and transcription [63,66]. Marullo et al. reported a role of 
cisplatin also in ROS production driven by protein synthesis impairment [66]. Strikingly, 
cisplatin and carboplatin resistance can be achieved by several different mechanisms such as 
decreased drug uptake, increased efflux, intracellular inactivation, mismatch repair 
deficiency, increased DNA repair, defective apoptosis, anti-apoptotic factors effects of 
several signalling pathways or extracellular matrix factors, showing the high complexity 
involved in platinum-drug resistance [67,68]. Importantly, GSH is known to mediate 
resistance both to cisplatin and carboplatin through several mechanisms, such as drug uptake 
reduction and increased intracellular drug detoxification/ inactivation, increased DNA repair 
and inhibition of apoptosis drug-induced oxidative stress [67,69–71]. Moreover, Champa and 
colleagues have selected multiple carboplatin resistant clones derived from a single cell that, 
while presenting no significant genetic alterations, each resistant clone activated different 
resistance mechanisms, leading to transcriptional heterogeneity [72]. These results strengthen 
again the complexity involved in the platinum acquired resistance.  
Paclitaxel cytotoxicity is associated with its binding to intracellular β-tubulin, which 
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leads to microtubule stabilization, G2-M arrest and apoptosis [63,73]. However, Alexandre et 
al. reported that paclitaxel exposure also induces ROS production, as H2O2 accumulation 
showed to be an early and crucial step in paclitaxel cytotoxicity [65]. Concerning paclitaxel 
resistance, also several different mechanism have been reported including over-expression of 
transmembrane efflux transporters, tubulin mutations or alterations in the microtubules 
stability and decreased function of apoptotic proteins [74]. Interestingly, Datta and colleagues 
reported increased activity of antioxidant systems during paclitaxel resistance development. 
The authors have shown a gradual increase in GSH content and in the activities of catalase 
and glutathione peroxidase (GPX) along with paclitaxel resistance development in A549 
human lung adenocarcinoma cells [75], thus linking GSH also with paclitaxel resistance. 
Recently, Vaidyanathan and colleagues, using the ovarian cancer cell line A2780 have 
developed several drug-resistant cell lines, and reported that A2780 resistant to both 
carboplatin and paclitaxel (A2780cpR) cells presented a distinct phenotype, that differed 
from both A2780 carboplatin resistant and A2780 paclitaxel resistant cells. Importantly, they 
have identified significant increases in the expression of targetable phosphoproteins 
important in cell signalling, such as pATM, pAKT, pCHK1 and pGSK3b in A2780cpR cells. 
The authors also compared the expression of 377 miRNAs in their cell line panel, and have 
identified several differentially expressed miRNAs, common to all resistant cells and 
exclusive to each drug-resistant phenotypes [76]. 
It is crucial to emphasize that conventional cancer therapies, which administer cytotoxic 
drugs at maximum tolerated doses until progression, strongly select for resistant phenotypes 
and, by eliminating all the competitors, allow a rapid proliferation of the resistant populations 
even in the absence of drugs - an evolutionary phenomenon designated “competitive release” 
[77–79]. However, as more and more evidence accumulates highlighting cancer as an 
evolutionary disease, in 2011, Atkipis et al. analysed 6228 publications concerning 
therapeutic resistance and/or cancer relapse and reported that in abstracts, evolution terms 
were present in only about 1% since the 1980s [80]. Moreover, Darwinian dynamics are still 
rarely integrated into anti-cancer protocols in clinical contexts [79]. 
In 2009, Gatenby and colleagues have explored the conceptual model of adaptive therapy 
that defends that, since the tumour populations that are exposed to treatment are dynamic, the 
treatment should be also dynamic with continuous adjustment of drugs, dose, and timing 
[81], thus employing a therapeutic strategy that evolves along with cancer cells. The authors 
have developed mathematical models that predicted that an optimal treatment strategy adjust 
therapy in order to maintain a stable population of chemosensitive cells that are more fitted in 
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the absence of therapy, being able to inhibit the growth of resistant populations due to fitness 
costs of resistance [81]. The same authors confirmed the benefits of the adaptive therapy in in 
vivo experiments with OVCAR3 xenografts treated with carboplatin, showing that this 
strategy was able to maintain a stable tumour population for a prolonged period of time, 
allowing a long-term survival [81]. Enriquez-Navas and colleagues reported similar findings 
in different preclinical models of breast cancer [78]. Gallaher et al. went furthered and 
identified two different adaptive strategies that are able to control heterogeneous tumours, a 
dose modulation strategy that controls the majority of tumours with fewer drug, and a more 
vacation-oriented strategy that is able to control more invasive tumours [82]. Interestingly, by 
using single-cell DNA sequencing, Xue and colleagues found that parallel evolution lead to 
the selection and spread of different BRAF-amplified subclones, allowing the tumours to 
adapt to ERK inhibitor treatment while maintaining intratumoral heterogeneity [83]. They 
proposed the fitness threshold model to explain their findings, being the fitness threshold the 
barrier that subclonal populations have to overcome in order to recover fitness during drug 
treatment. The model predicted that sequential treatment was not effective, prediction that 
was supported by their results showing that treatment with a RAF inhibitor followed by an 
ERK inhibitor induced a gradual increase in BRAF copy number, allowing a fitness 
advantage in the presence of the drugs [83]. Moreover, the same authors reported that an 
intermittent three-drug treatment combination was able to inhibit tumour growth in 
BRAFV600E patient-derived tumour xenografts models for lung cancer and melanoma, hence 
being able to increase the fitness threshold and counteracting the spread of subclones with 
BRAF-amplification [83]. 
Recently, Zhang and colleagues have integrated evolutionary dynamics into a pilot 
clinical trial of patients with metastatic castrate-resistant prostate cancer in order to avoid the 
evolution of resistance to abiraterone (that inhibits CYP17A, an enzyme responsible for 
testosterone auto-production). The authors reported that the adaptive therapy treatment 
increased time to progression and reduced the cumulative drug dose to less than a half 
compared to the standard strategy [79]. 
As Gallaher and colleagues argued, the future of precision medicine should not be (only) 
in the development of new drugs. Instead, evolutionary principles should be applied (also) in 
the pre-existing ones [82]. 
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 1.2 EPITHELIAL OVARIAN CANCER  
 
This thesis is focused on ovarian cancer, in particular epithelial ovarian cancer (EOC, 
ovarian carcinoma), hence, in this section, we will emphasise on the diverse histopathology 
and molecular/genetic features of this disease. 
Ovarian cancer includes a group of distinct diseases that present a common anatomical 
location [84], corresponding to the major cause of death from gynaecological cancer and the 
third most common gynaecological malignancy worldwide [85]. The risk factors for this 
disease currently include genetic, physiological, socioeconomic and environmental aspects 
[86]. Despite the overall survival of ovarian cancer patients has been improved in the last 30 
years, the cure rate did not [87]. This is mainly due to late diagnosis and resistance to therapy 
[88,89], barring ovarian cancer cure. 
EOC includes most ovarian malignancies [88,90] that can be classified based on 
histopathology and molecular/genetic features, being the ovarian carcinomas mainly 
classified as serous low grade (LG-OSC, <5%) and high-grade (HG-OSC, 70%), 
endometrioid (OEC, 10%), clear cell (OCCC, 10%) and mucinous (OMC, 3%) [91,92]. 
Recently, the histological types seromucinous carcinomas and Brenner tumours were also 
included [93]. Each of the main histological subtypes were already associated to a specific 
genetic and transcriptional signature: LG-OSC generally comprising proto-oncogene 
serine/threonine-protein kinase variant B (BRAF), Kirsten RAS oncogene (KRAS), 
neuroblastoma RAS viral oncogene homolog (NRAS), Erb-B2 receptor tyrosine kinase 2 
(ERBB2) mutations; HG-OSC comprising mutations in Tumour Protein P53 (TP53), 
BRCA1/2, Neurofibromin 1 (NF1), RB transcriptional corepressor 1 (RB1), Cyclin Dependent 
Kinase 12 (CDK12), homologous recombination repair of DNA damage defective in 
approximately 50% of HG-OSC and alterations in signalling pathways such as 
PI3K/Ras/Notch/FoxM1. The OEC subtype involve mutations in AT-Rich Interaction 
Domain 1A (ARID1A), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 
Alpha (PI3KCA), Phosphatase and Tensin homolog (PTEN), Protein Phosphatase 2 Scaffold 
Subunit Alpha (PPP2R1α), and mismatch repair deficiency. The OCCC subtype comprises 
de novo expression of HNF1β [94,95] and ARID1A, PI3KCA, PTEN, Catenin Beta 1 
(CTNNB1) and PPP2R1α mutations. The OMC subtype comprises tumours with mutations in 
KRAS and high frequency of ERBB2 amplification with overexpression of mucin coding 
genes [96,97]. 
	   	  
	   13	  
HG-OSC is the most prevalent histological type [89] with diagnosis at an advanced stage 
in approximately 70% of patients [84]. In contrast, OCCC, is a rather uncommon histological 
type of ovarian cancer that is frequently diagnosed at an initial stage [98]. However, OCCC 
tumours present markedly different clinical behaviours compared to other EOC subtypes 
presenting, generally, poor prognosis given intrinsic chemoresistance to conventional 
platinum or taxane-based therapy [98] which, together with surgery, constitute the standard 
care for ovarian cancer [63]. 
Despite initial response to treatment, 85% of advanced ovarian cancer patients suffer 
from disease recurrence [99], being of extremely importance to deepen our knowledge on this 
group of diseases in order to gain insight in novel possible strategies to fight them. 
 
 
1.3 CYSTEINE IN CANCER 
 
L-cysteine is a semi-essential amino acid [100,101] present extracellularly mainly in its 
oxidised form cystine, and intracellularly mainly in the form of cysteine due to the highly 
intracellular reducing conditions [102]. This amino acid plays an essential role in cellular 
homeostasis, as cysteine is a precursor of protein synthesis, GSH, taurine, hydrogen sulphide 
(H2S) [103,104], pyruvate and coenzyme A [103]. L-cysteine sources are the absorption from 
diet, the transsulphuration pathway from L-methionine degradation, endogenous proteins and 
GSH degradation [100]. Several systems were already associated with L-cysteine and L-
cystine transport, such as A, ASC, L, Xc-, Bo,+, and X-AG systems [101]. 
The intracellular free cysteine pool is tightly regulated in the mammalian liver [103]. L-
cysteine synthesis occurs through condensation of serine and methionine-derived 
homocysteine to form L-cystathionine, being this reaction catalysed by cystathionine-β-
synthase (CBS). Subsequently, L-cystathionine is converted into cysteine, α-ketobutyrate and 
ammonia by cystathionine-γ-lyase (CSE) [100]. 
In the next sections we will focus on the role of cysteine in cancer, mediated by both 
GSH and H2S generation. Interestingly, Visscher et al. reported that many oncogenic 
mutations consist in an insertion of a novel cysteine in the protein sequence [105]. They also 
reported that acquired cysteines account for at least 12% of all activating mutations found in 
KRAS in cancer, and 88% of mutations in fibroblast growth factor receptor (FGFR). They 
suggested that when acquired cysteines are found that often, they should play a role in 
tumorigenesis [105] probably by contributing for tumour suppressor genes inactivation and 
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oncogenes activation. 
 
 
1.3.1 CYSTEINE ROLE IN CANCER AS A PRECURSOR OF THE ANTIOXIDANT 
GSH 
 
Rey-Pailhade's described Philothion in 1888, as a molecule that reacted spontaneously 
with sulphur, producing hydrogen sulphide [106,107]. Years later, Hopkins' concluded that 
Philothion and GSH were identical and in 1935, its’ structure was established as a tripeptide, 
composed by glutamic acid, cysteine, and glycine [106,108]. Since then, a countless number 
of papers have been published regarding GSH role in health and disease.  
GSH is mainly found in Gram-negative bacteria and eukaryotes, being rare in Gram-
positive bacteria. In Archaea or in amitochondrial eukaryotes, GSH is not generally found, 
leading Copley and Dhillon to suggest that bacteria transferred the genes for GSH 
biosynthesis to eukaryotes via the progenitor of mitochondria [109]. However, the 
evolutionary history of GSH biosynthesis genes showed to be more complex, as data 
suggested that these genes evolved separately and their spread possibly involved events of 
horizontal gene transfer, including a transfer from an alpha-proteobacterium to a plant and 
also convergent evolution [109], as bacterial and eukaryotic proteins share a common 
structural fold, but with very divergent sequences. 
The built blocks of GSH are glutamic acid, cysteine and glycine, which biosynthesis 
involves two ATP-requiring enzymes: glutamate cysteine ligase (GCL) and GSH synthetase. 
The first enzyme catalyses the formation of a dipeptide bond between the γ -carboxylate of 
glutamic acid and the amino group of cysteine and the latter catalyses the subsequent 
formation of a peptide bond between the cysteinyl carboxylate of γ-Glu-Cys and the amino 
group of glycine. Besides substrate availability, GCL is the rate-limiting enzyme in GSH 
synthesis, which presents two different subunits: the catalytic subunit (GCLC), containing the 
active site responsible for the bond formation between the amino group of cysteine and the γ-
carboxyl group of glutamic acid, and the modifier subunit (GCLM) that interacts with GCLC, 
increasing the catalytic efficiency of GCLC [110]. 
It is well known that GSH not only plays a main role in intracellular redox balance [108] 
but it is also pivotal in cellular processes such as cell differentiation, proliferation, and 
apoptosis [42,111,112]. Moreover, GSH was associated to resistance to ionizing radiation and 
drug-induced cytotoxicity [41,42,112–114]. 
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As already mentioned, GSH is known to mediate resistance both to cisplatin and 
carboplatin through several mechanisms [67,69–71]. Specifically in ovarian cancer, although 
with some controversy [115,116], several reports already associated high GSH levels or 
glutathione S-transferase P1 (GSTP1) activity with cisplatin or carboplatin resistance [117–
124]. More recently, Sawers et al. [125] have shown that the stable deletion of GSTP1 
significantly and selectively increased sensitivity both to cisplatin and carboplatin in A2780 
ovarian cancer cells [125]. Crawford and Weerapana, reported a dichlorotriazine-containing 
compound (LAS17) that selectively and irreversibly inhibited GSTP1 activity, thus providing 
a promising cancer therapeutic target [126]. In addition, Chen et al. have shown that the 
overexpression of the microRNA miR- 133b increased ovarian cancer cell sensitivity to both 
cisplatin and paclitaxel by decreasing GSTP1 and Multi-Drug Resistance protein 1 (MDR1) 
expression [127]. Okuno et al. [128] reported that the transport system xc- (xCT), involved in 
cystine and glutamate transport, was associated with intracellular GSH level and with 
cisplatin resistance in human ovarian cancer cell lines. Wang and colleagues explored the 
role of ovarian cancer cells microenvironment and showed that fibroblasts decreased the 
nuclear accumulation of platinum in cancer cells, through GSH and cysteine release. On the 
other hand, they demonstrated that CD8+T cells counteracted this resistance by changing 
GSH and cystine metabolism in fibroblasts [129]. Moreover, Moheel and colleagues reported 
an active methylene quinuclidinone compound derived from the prodrug APR-246 (PRIMA-
1MET), that not only binds to cysteine residues in mutant p53, restoring its wild-type 
conformation, but also binds to cysteine from GSH, leading to decreased intracellular free 
GSH concentrations [130]. This compound was able to restore the sensitivity to both cisplatin 
and doxorubicin of p53-mutant drug-resistant ovarian cancer cells [130]. 
Importantly, our team [131] found differences among ovarian cancer histotypes in what 
concerns to carboplatin resistance and GSH levels. We have found that OCCC cells were 
more resistant to carboplatin than HG-OSC cells, and that the inhibition of GSH production 
by L-Buthionine Sulfoximine (BSO) sensitised these cells to carboplatin, both in vitro and in 
vivo [131]. Those results highlight that ovarian cancer is a complex disease in which, each 
histotype presents unique features in what concerns to thiols metabolism and response to 
chemotherapeutic agents that should be taken into account in the clinical context.  
Paradoxically, concerning the role of GSH in paclitaxel resistance, Liebmann et al. have 
shown that the depletion of cellular GSH by BSO resulted in increased resistance to taxol in 
MCF-7 and A549 cells [132]. However, Medeiros et al. reported that patients with ovarian 
cancer, who are carriers of glutathione-S-transferase class µ (GSTM1)-null genotype or 
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carriers of non-GSTM1-wt/ GSTT1-wt genotypes- when treated with both paclitaxel and 
cisplatin, presented higher mean survival time [133], suggesting a role for GSH also in 
paclitaxel resistance. As already mentioned, Datta and colleagues have shown a gradual 
increase in GSH content and in the activities of catalase and glutathione peroxidase (GPX) 
along with paclitaxel resistance development in A549 human lung adenocarcinoma cells [75], 
linking GSH with paclitaxel resistance once again. 
Therefore, evidence suggests a critical role of GSH in mediating resistance especially to 
platinum-based drugs. Moreover, cysteine is the thiol component of GSH and the reversible 
thiolation of proteins was already associated with the regulation of several metabolic 
processes such as enzyme activity, transport activity, signal transduction and gene expression 
[112]. Several proteins - such as Rat Sarcoma vírus (Ras) protein, Jun N-terminal Kinase 
(JNK)- 2, Activator Protein 1 (AP-1), Nuclear Factor-kappaB (NFkB), Protein Kinase C 
(PKC), caspases, thioredoxin and p53 [112,134], which are known to have important roles in 
ovarian cancer [135–146], are regulated by thiol oxidation [134]. Interestingly the oxidation 
of cysteine residues of p53 induces the protein inactivation, which accounts for 
carcinogenesis [134].  
 
 
1.3.2 CYSTEINE ROLE IN CANCER AS A SOURCE OF H2S 
 
In 2002, Wang proposed H2S as another gasotransmitter, along with nitric oxide and 
carbon monoxide [147]. H2S is involved in several biological processes such as autophagy, 
cellular metabolism, stem cells fate regulation, inflammation, cell cycle and cell death, being 
crucial both in health and disease [148]. This signalling molecule interacts and modifies 
target proteins through reaction with metal cores and through cysteine persulfidation, leading 
to protein structure and function changes [149]. 
In mammalian cells, H2S is generated mainly via enzymatic pathways and from the 
metabolism of L-cysteine by the catalysis of three key enzymes: cystathionine β-synthase 
(CBS), cystathionine γ-lyase (CSE) and by 3-mercapto-pyruvate sulphurtransferase (MpST) 
accompanied by cysteine aminotransferase (CAT) [150], enzymes that were already reported 
to be altered in several types of cancer (reviewed in [151]). Importantly, H2S exhibits both 
pro-cancer (through bioenergetics and angiogenesis stimulation, inhibiting apoptosis and 
promoting cell cycle progression) and anti-cancer (by inducing uncontrolled cellular 
acidification, suppressing cell survival and inducing cell cycle arrest) activities (reviewed in 
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[151]). 
H2S is the only inorganic compound presenting a bioenergetic role in mammalian cells 
mitochondria [152]. At low concentrations (nM), H2S is known to stimulate mitochondrial 
bioenergetics through different mechanisms: through donation of electron equivalents to the 
quinol pool via sulphide:quinone oxidoreductase; by the glycolytic enzyme glyceraldehyde 3-
phosphate dehydrogenase activation, and by persulfidation of ATP synthase (reviewed in 
[149]). Módis and colleagues, using isolated mitochondria from rat liver and murine 
hepatoma cells observed that an endogenous intramitochondrial H2S-producing pathway, 
governed by MpST complemented and balanced the bioenergetic role of Krebs cycle-derived 
electron donors [153]. In addition, Li and Yang reported a role of CSE/H2S system in 
enhancing mtDNA replication and cellular bioenergetics both in smooth muscle cells and 
mouse aorta tissues [154]. In human cancers, there is also evidence that H2S inside 
mitochondria is able to sustain mitochondrial ATP production [155,156]. Specifically in the 
context of ovarian cancer, Bhattacharyya et al. found a role of CBS in promoting ovarian 
tumour growth, cisplatin resistance and cellular bioenergetics [155]. More recently, 
Chakraborty and colleagues reported a new role of CBS in the regulation of mitochondria 
morphogenesis, promoting tumour progression in ovarian cancer [157].  
In particular under hypoxia conditions, H2S was reported to induce ATP synthesis, 
mediated by CSE translocation to the mitochondria in vascular smooth muscle cells [158] and 
to decrease ROS levels, mediated by CBS accumulation in human hepatoma Hep3B cells 
[159]. In the kidney, especially in the medulla, experimental evidence supports a role of H2S 
as an O2 sensor, as a higher content of H2S was found in renal medulla (that presents a lower 
O2 availability) compared with the renal cortex [160]. If H2S is a direct source of energy in 
renal medulla is still unclear [160]. A role of H2S as an O2 sensor was also already suggested 
in cardiovascular system, respiratory system and gastrointestinal tract [160]. 
H2S was also found to be associated with malignancy and resistance to treatment in 
different types of cancer. Gai et al. observed a correlation between the increased protein 
levels and catalytic activities of CBS, CSE, and MpST and the increase of malignant degrees 
in human bladder tissues and human urothelial cell carcinoma of bladder cell lines [161]. Pan 
et al. explored the role of endogenous H2S in hepatocellular carcinoma cells radiotherapy 
response. They observed that radiation treatment promoted the invasion capability of cells 
through epithelial-mesenchymal transition mediated by endogenous H2S/CSE signalling via 
the p38MAPK pathway [162]. Sen and colleagues found a role for CBS in human breast 
cancer cells in the protection against oxidative stress induced by activated macrophages 
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[163]. Moreover, data have been supporting a role of H2S as a pro-proliferative factor in 
human cancer cells by accelerating cell cycle progression [148]. 
However, as already mentioned, H2S can be also disadvantageous for cancer cells. While, 
in general, endogenous or low exogenous H2S levels are advantageous for cancer cells, the 
exposure to high levels is disadvantageous [151,164], exhibiting a bell-shaped curve effect 
[164]. Lee and colleagues reported that a slow-releasing H2S donor, GYY4137, lead to cell 
death in a concentration-dependent manner in several human cancer cell lines, while it did 
not impair the survival of normal human lung fibroblasts [165]. Moreover, Panza and 
colleagues reported that CSE-derived H2S leads to cell cycle arrest and induce apoptosis in 
human melanoma cells to a larger extent compared to CBS and MpST overexpression [166]. 
The same authors confirmed the role of CSE-derived H2S in inhibiting melanoma tumour 
growth also in an in vivo mice model, since the protective effect of L-cysteine was lost when 
a selective CSE inhibitor was co-administrated to mice [166]. Interestingly, Takano et al. 
reported that decreased CBS expression in glioma induced HIF2α protein levels and HIF2 
target gene expression, promoting glioma tumour formation [167].  
Together, evidence supports that cysteine is a pivotal player not only in ovarian cancer 
progression and resistance to treatment but also in several types of cancer, as it provides a 
dual role of cellular protection: GSH-mediated and H2S-mediated chemoresistance, redox 
balance maintenance, and allows the regulation of several metabolic processes central to 
cancer cells, thus supporting their survival and adaptation to changing microenvironments. 
 
 
1.4 HYPOTHESIS, AIMS AND THESIS OUTLINE 
 
Ovarian cancer is the third most common gynaecological malignancy worldwide [85] and 
the major cause of death from gynaecological cancer, mainly due to late diagnosis and 
resistance to therapy [85,88,89]. 
Cysteine role in cancer cells survival was already associated with its role as a precursor 
of the antioxidant glutathione (GSH) [48,131,168] and due to hydrogen sulphide (H2S) 
generation [113,114,119,120,122,121,125], leading us to hypothesise that cysteine 
metabolism plays an essential role in cancer cells selection and tumour progression on one 
hand, as a thiol, contributing for the dynamics of thiol synthesis and degradation that are 
determinant to cancer chemoresistance and adaptation to hypoxia; and on the other hand, as a 
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sulphur source mediated by H2S generation able to sustain ATP production under hypoxic 
conditions.  
Hence, our main focus is to clarify the relevance of cysteine metabolism in ovarian 
cancer cells selection and tumour progression. Thus, the major aims of this thesis are: 
1) to explore the effect of ovarian cancer cells selection under normoxia 
and hypoxia conditions on cells response to carboplatin, and the effect of cysteine 
supplementation in this response (Chapter 2); 
2) to address if cysteine has a widespread protective effect in ovarian 
cancer cells against hypoxia and carboplatin-induced death (Chapter 3); 
3) to explore if cysteine has a clinical role in ovarian cancer patients 
(Chapter 3); 
4) to disentangle the mechanism by which cysteine protects ovarian 
cancer cells from hypoxia-induced death (Chapter 4). 
This thesis includes 5 chapters. In the 1st chapter there is a presentation of a general 
theoretical framework concerning the issues approached in this thesis. The following chapters 
include the results obtained in this PhD project (Chapter 2-4). Each chapter contains an 
abstract, a short introduction, methods, results and discussion. In the final chapter (Chapter 
5), a global discussion on the relevance of the major findings of this thesis in ovarian cancer 
research is presented as well as future perspectives to follow some new research lines paved 
by this project. 
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CHAPTER 2 
 
 
CYSTEINE BOOSTERS THE EVOLUTIONARY ADAPTATION TO 
HYPOXIA, FAVOURING CARBOPLATIN RESISTANCE IN 
OVARIAN CANCER 
 
 
 
 
This chapter is based on the following publication: 
Nunes SC, Lopes-Coelho F, Gouveia-Fernandes S, Ramos C, Pereira SA, Serpa J. Cysteine 
boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring 
carboplatin resistance in ovarian cancer. BMC Evol. Biol. 2018;18:97–113. 
 
 
 
 “As humans spread around the world, so did their domesticated animals. Ten thousand years ago, not more 
than a few million sheep, cattle, goats, boars and chickens lived in restricted Afro-Asian niches. Today the 
world contains about a billion sheep, a billion pigs, more than a billion cattle, and more than 25 billion 
chickens. And they are all over the globe. The domesticated chicken is the most widespread fowl ever. 
Following Homo sapiens, domesticated cattle, pigs and sheep are the second, third and fourth most 
widespread large mammals in the world. From a narrow evolutionary perspective, which measures success 
by the number of DNA copies, the Agricultural Revolution was a wonderful boon for chickens, cattle, pigs 
and sheep. 
Unfortunately, the evolutionary perspective is an incomplete measure of success. It judges everything by the 
criteria of survival and reproduction, with no regard for individual suffering and happiness. Domesticated 
chickens and cattle may well be an evolutionary success story, but they are also among the most miserable 
creatures that ever lived. The domestication of animals was founded on a series of brutal practices that only 
became crueller with the passing of the centuries.” - Yuval Noah Harari 
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ABSTRACT 	  
Ovarian cancer is the third most common gynaecologic malignancy and the most 
common cause of death from gynaecologic cancer, especially due to diagnosis at an advanced 
stage together with resistance to therapy. As a solid tumour grows, such as an ovarian 
tumour, cancer cells are exposed to regions of hypoxia, known to be partially responsible for 
tumour progression, metastasis and resistance to therapies. This suggests that hypoxia entails 
a selective pressure in which the adapted cells not only have a fitness increase under the 
selective environment, but also in non-selective adverse environments. In here, we used two 
different ovarian cancer cell lines – OVCAR3, a serous carcinoma cell line and ES2, a clear 
cell carcinoma cell line– in order to address the effect of selection under normoxia and 
hypoxia on the evolutionary outcome of cancer cells. 
Our results showed that the adaptation to normoxia and hypoxia leads cells to display 
opposite strategies. Whereas cells adapted to hypoxia tend to proliferate less but present 
increased survival in adverse environments, cells adapted to normoxia proliferate rapidly but 
at the cost of increased mortality in adverse environments. Moreover, results also support that 
cysteine allows a quicker response and adaptation to hypoxic conditions that, in turn, are 
capable of driving chemoresistance.  
 
 
KEYWORDS 
Cancer, chemoresistance, cysteine, hypoxia, evolution, ovarian, tumour, selection. 
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INTRODUCTION 
 
Ovarian cancer is the third most common gynaecologic malignancy worldwide [1] and 
the major cause of death from gynaecologic disease especially due to late diagnosis and 
resistance to therapy [1–3]. Epithelial ovarian cancer (EOC) includes most malignant ovarian 
neoplasms [4], being the high-grade ovarian serous carcinoma (HG-OSC) the most prevalent 
histological type [3] with diagnosis at an advanced stage in approximately 70% of patients 
[5]. In contrast, ovarian clear cell carcinoma (OCCC) is a rather uncommon histological type 
of ovarian cancer in West countries that is frequently diagnosed at an initial stage [6]. 
However, OCCC tumours present noticeably different clinical behaviours compared to other 
ovarian carcinomas presenting, generally, poor prognosis given chemoresistance to 
conventional platinum-drugs and taxane-based chemotherapy [6]. The standard treatment for 
advanced ovarian cancer is a combination of surgery and paclitaxel–carboplatin 
chemotherapy [7], however, despite initial response, there is a recurrence of the disease in 
over 85% of advanced ovarian cancer patients [8]. Usually, HG-OSC shows an initial 
response to platinum based therapy with further progression to resistance [9] while OCCC is 
intrinsically resistant to platinum salts [6,10,11]. 
Serpa and Dias have suggested that the metabolic remodelling is determinant for tumour 
progression. They have proposed a model in which the selective pressure of the 
microenvironment involving metabolic pathways switching induces cell death in non-adapted 
cells and positively selects those cells with growth advantage, increased invasiveness and 
altered adhesiveness, allowing local and angio (vascular) invasion, and leading to cancer 
progression and distant metastasis [12]. Soon after this report, Hanahan and Weinberg had 
also included reprogramming of energy metabolism as an emerging hallmark of cancer [13].  
As a solid tumour grows, cancer cells are exposed to intermittent episodes of hypoxia. 
The effects of these episodes on cancer biology have been related to the aberrant blood 
circulation observed in solid tumours. This results in recurrent intra-tumoral episodic hypoxia 
and assaults metabolically less privileged cell niches. Studies showed that hypoxia is partially 
responsible for tumour progression, metastasis and resistance to therapies [14–17]. This 
evidence supports that hypoxia entails a selective pressure in which the adapted cells present 
a fitness increase not only under the selective environment, but also in non-selective 
environments. Interestingly, Cutter et al. [18] have recently reported that ovarian cancer cell 
lines subjected to hypoxia presented a more invasive, migratory and transformed epithelial–
mesenchymal transition (EMT) phenotype. Hence, ovarian cancer is a valuable model to 
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address the effects of hypoxia selection on the evolutionary outcome of several traits of 
ovarian cancer cells. 
The contribution of cysteine on cancer cells survival has been explored mainly due to 
hydrogen sulphide (H2S) generation [19–24] and as a precursor of the antioxidant glutathione 
(GSH) [25–27]. It was already showed that increased levels of cytoplasmic thiol-containing 
species, especially GSH or metallothioneins are associated with resistance to platinum-based 
chemotherapy [25,28,29]. Our group also showed that different ovarian cancer histological 
types presented different metabolic outcomes concerning thiols and chemoresistance [25]. 
Under normoxic conditions, the OCCC cells were more resistant to carboplatin than HG-OSC 
cells and the inhibition of GSH production by buthionine sulphoximine (BSO) sensitized 
OCCC cells to carboplatin, both in vitro and in vivo [25]. These results suggest that the 
ability to metabolise thiols by cancer cells is directly linked to poorer disease outcome. 
In here, we used two different ovarian cancer cell lines with different histological types, 
OCCC and HG-OSC, in order to address the effect of cancer cells selection under normoxia 
and hypoxia mimicked by cobalt chloride (CoCl2), on the evolutionary outcome of cancer 
cells. Cobalt is known as a hypoxia mimicking agent both in vivo [30] and in cell culture [31–
33], altering several systemic mechanisms related to hypoxia [31–33], namely the 
stabilization of hypoxia inducible factor 1 alpha (HIF-1α), thus preventing its degradation 
[34]. Chemically, CoCl2 reacts with oxygen avoiding its dissolution and oxygenation of 
aqueous solutions [35], thus impairing the availability of oxygen in culture media. 
Herein, we hypothesised that selection under hypoxia and normoxia leads cells to display 
different evolutionary outcomes, predicting that hypoxia selected cells would be more 
resistant to carboplatin than normoxia selected cells. Moreover, we hypothesised that 
selection under hypoxia is linked to a higher efficacy of cysteine metabolism, resulting in a 
poorer evolutionary outcome. 
 
 
MATERIAL AND METHODS 
 
Cell culture 
 
Cell lines from OCCC (ES2; CRL-1978) and HG-OSC (OVCAR-3; HTB-161) were 
obtained from American Type Culture Collection (ATCC). Cells were maintained at 37°C in 
a humidified 5% CO2 atmosphere. Cells were cultured in DMEM (41965-039, Gibco, Life 
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Technologies) containing 4.5 g/L of D-glucose and 0.58g/L of L-glutamine supplemented 
with 1% fetal bovine serum (FBS S 0615, Merck), 1% antibiotic-antimycotic (AA) (P06-
07300, PAN Biotech).  
Prior to any experiment, cells were synchronized under starvation (culture medium 
without FBS) for 8 h at 37°C and 5% CO2.  
After 24 h of experimental conditions, the medium was changed and fresh conditions 
were added, with the exception of proliferation curve and cell cycle analysis in which the 
medium was not changed. 
 
Immunofluorescence analysis 
 
Cells (4×104 cells/well) were seeded in 8-well Tek chamber slides (Thermo scientific 
177402) coated with Poly-L-Lysine (Biochrom AG L 7240) and cultured either in control 
condition or exposed to 0.1 mM CoCl2. Cells were collected after 8 hours of conditions and 
then cells were fixed with 2% paraformaldehyde for 15 min at 4 °C and permeabilized with 
PBS-BSA 0.1% with 0.1% Triton X-100 for 30 min. Cells were incubated with primary 
antibody (anti-HIF-1α; anti-mouse antibody from BD Biosciences 610959) overnight at 4ºC 
(diluted in PBA-BSA 0.1%, 1:100). Secondary antibody was the anti-mouse Alexa Fluor® 
488 (1:1000 in PBA-BSA 0.1%. Antibody from Jackson ImmunoResearch Laboratories 115-
545-003), 2 h at room temperature. The slides were mounted in VECTASHIELD media with 
DAPI (4′-6-diamidino-2-phenylindole) (Vector Labs) and examined by standard fluorescence 
microscopy using a Zeiss Imajer.Z1 AX10 microscope. Images were acquired and processed 
with CytoVision software.  
 
Cell lines selection 
 
ES2 and OVCAR3 cells (1×106 cells) were cultured in 25 cm2 tissue culture flasks and 
selected under normoxia and under hypoxia mimicked with 0.1 mM CoCl2. After reaching 
confluency (≈2x106 cells) cells were trypsinised and cultured in 75 cm2 tissue culture flasks, 
under selective conditions (hypoxia mimicked with 100µM CoCl2). Every 48 h, cells 
undergone passaging if confluency reached ~80% (~7.5x106) or culture media was only 
changed if this confluency was not achieved. As the proliferation and survival rates were 
different between cell lines, the assays were performed with different days of selection for 
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ES2 cells and for OVCAR3 cells. Within each cell line, selection in normoxia and hypoxia 
was performed simultaneously. Ancestral cell line was cultured in baseline conditions. 
Table I presents the selection and culture conditions for ES2 and OVCAR3 cell lines. 
 
Proliferation curve assay 
 
Cells selected under normoxia and hypoxia (5×104cells/well), were seeded in 24-well 
plates and cultured either in normoxia or exposed to 0.1 mM CoCl2. Cells were collected 
after 16 h, 32 h and 48 h of conditions. Cells were trypsinized and resuspended in 200 µL of 
PBS 1x. A total of 15 µL were collected and 5 µL of trypan blue were added. Cells were 
immediately counted. The remnant cells were used to cell cycle analysis. This assay was 
performed with 63 days of selection for ES2 cells and 35 days of selection for OVCAR3 
cells. 
 
Cell cycle analysis 
 
Cells were harvested by centrifugation at 153 g for 5 min and cells were fixed with 70% 
ethanol at 4ºC. Cells were then centrifuged at 153 g for 5 min, followed by the supernatant 
discharge. Cells were incubated with 100 µL of propidium iodide (PI) solution (50 µg/ml PI, 
0.1 mg/ml RNase A, 0.05% Triton X-100) for 40 min at 37ºC. After the incubation period, 
cells were washed with PBS 1x, centrifuged at 239 g for 10 min at 4ºC and the supernatant 
was discarded. Cell pellets were suspended in 200 µL of PBS-BSA 0.1%. The acquisition 
was performed in a FACScalibur (Becton Dickinson). Data were analysed with FlowJo 
software (www.flowjo.com).  
 
Cell death analysis 
 
Cells selected under normoxia and hypoxia (2×105 cells/well) were seeded in 12-well 
plates and cultured under normoxia and exposed to 0.402 mM L-cysteine and/or 0.1 mM 
CoCl2. In addition, cells were exposed to the previous conditions combined with carboplatin 
25 µg/mL. Cells were collected after 48 h of tested conditions. For the analysis of the 
response dynamics to carboplatin, the cells were collected after 16 h, 24 h and 48 h of 
conditions. The ancestral (not selected) cell lines were also tested. Half of the cells were used 
to cell death analysis and the other half was used for reactive oxygen species (ROS) 
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quantification. This assay was performed with 43 days of selection for ES2 cells and 84 days 
of selection for OVCAR3 cells. 
Cells were harvested by centrifugation at 153 g for 3 min, cells were incubated with 1µL 
FITC-annexin V (640906, BioLegend) in 100 µL annexin V binding buffer 1x (10 mM 
HEPES (pH 7.4), 140 mM sodium chloride (NaCl), 2.5 mM calcium chloride (CaCl2)) and 
incubated at room temperature and in the dark for 15 min. After incubation, samples were 
rinsed with 0.1% (w/v) BSA (A9647, Sigma) in PBS 1x and centrifuged at 153 g for 3 min. 
Cells were suspended in 200 µL of annexin V binding buffer 1x and 5 µL Propidium iodide 
(PI; 50 µg/mL). Acquisition was performed with a FACScalibur (Becton Dickinson). Data 
were analysed with FlowJo software (www.flowjo.com). 
 
Reactive oxygen species (ROS) quantification 
 
Cells selected under normoxia and hypoxia (2 × 105 cells/well) were seeded in 12-well 
plates and cultured in control condition and exposed to 0.402 mM L-cysteine and/or 0.1 mM 
CoCl2 and/or carboplatin 25 µg/mL. Cells were collected after 48 h of tested conditions. The 
ancestral cell lines were also tested. This assay was performed with 43 days of selection for 
ES2 cells and 84 days of selection for OVCAR3 cells. 
Cells were incubated for 15 min 37ºC with 2’, 7’-Dichlorofluorescin diacetate (D6883, 
Sigma) in a final concentration of 10 µM. The acquisition was performed with FACScalibur 
(Becton Dickinson). Data were analysed with FlowJo software (www.flowjo.com). 
 
Statistical analysis  
 
Data are presented as the mean ± SD and all the graphics were done using the PRISM 
software package (PRISM 6.0 for Mac OS X; GraphPad software, USA, 2013). Assays were 
performed with 3 replicates per treatment. For comparisons of two groups, two-tailed 
independent-samples T-test was used. For comparison of more than two groups, One-way 
analysis of variance (ANOVA) with Tukey’s multiple-comparisons post hoc test was used. 
To assess the existence of a linear relationship between two variables, two-tailed Pearson 
correlation was used. Statistical significance was established as p<0.05. All statistical 
analyses were performed using the IBM Corp. Released 2013. IBM SPSS Statistics for 
Macintosh, Version 22.0. Armonk, NY: IBM Corp. software. 
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RESULTS 
 
Adaptation to normoxia confers a highly proliferative ability to ES2 cells  
 
We started by confirming CoCl2 capacity of inducing HIF-1α expression in ovarian 
cancer cells. By immunofluorescence analysis, it was possible to verify that HIF-1α 
expression was increased upon CoCl2 exposure in both cell lines (figure 1).  
 
 Figure 1. CoCl2 induces HIF-1α expression in ES2 cells and OVCAR3 cells. 
Immunofluorescence analysis of Hif-1α expression (green) under normoxia and hypoxia for ES2 and 
OVCAR3 cells. Nuclei were stained with DAPI (blue). White bars scale mean 20 µm. 
 
We then addressed the effects of selection under normoxia (N) and hypoxia (H) in ES2 
and OVCAR3 cells proliferation. The codes of each cell line and culture condition are 
presented in supplement table I. 
The proliferation curves showed that ES2-N cells proliferated more than ES2-H, both 
under normoxia and hypoxia (supplement table II and figure 2 A). In addition, ES2-NN 
tended to proliferate more than ES2-NH, which was supported by cell cycle analysis that 
showed that ES2-NN presented a lower percentage of cells in G0/G1 compared to ES2-NH 
(figure 2 B).  
Regarding OVCAR3 cells, OVCAR3-NN proliferated more than OVCAR3-HH (figure 2 
C). In addition, the cell cycle analysis showed that OVCAR3-HH presented a higher 
percentage of cells in G0/G1 than both OVCAR3-NN and OVCAR3-NH (figure 2 D).  
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Figure 2. Proliferation rate of ES2 and OVCAR3 cells selected under normoxia and hypoxia. 
A. Proliferation curve for ES2 cells, B. Cell cycle analysis for ES2 cells for 48 h of assay, C. 
Proliferation curve for OVCAR3 cells, and D. Cell cycle analysis for OVCAR3 cells for 48 h of assay. 
NN – cells selected under normoxia and cultured under normoxia; NH – cells selected under normoxia 
and cultured under hypoxia; HN – cells selected under hypoxia and cultured under normoxia; HH – cells 
selected under hypoxia and cultured under hypoxia. Asterisks (*) represent statistical significance in 
comparison with cells selected under normoxia and cultured under normoxia (NN). Cardinals (#) 
represent statistical significance in comparison with cells selected under normoxia and cultured under 
hypoxia (NH). p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
 
Adaptation to normoxia is accompanied by an evolutionary trade-off that is suppressed 
by cysteine under hypoxia in ES2 cells  
 
Next, we assessed the effects of normoxia and hypoxia selection in ES2 and 
OVCAR3 cells death, exploring also the effect of cysteine supplementation in ovarian cancer 
cells response to hypoxia. The codes of each cell line and culture condition are presented in 
table I (supplement table 1). 
Cell death analysis showed that hypoxia was disadvantageous for both ES2-A and ES2-
N. Importantly, ES2-N cells were more sensitive to hypoxia than ES2-A thus indicating an 
evolutionary trade-off in the adaptation to normoxia. However, under hypoxia, cysteine was 
able to significantly decrease cell death both in ES2-AH and ES2-NH, indicating that 
cysteine was able to supress this trade-off in the adaptation to N (figure 3 A, B and 
supplement table III A, B). Under normoxia, cysteine did not present a significant effect in 
ES2-A, ES2-N and ES2-H cells death. For ES2-H, no differences were found among 
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conditions, thus suggesting that ES2-H performed equally in all environments (figure 3 A, B 
and supplement table III A, B).  
Regarding OVCAR3 cells, OVCAR3-N also showed to be more sensitive to hypoxia 
than OVCAR3-A, thus showing again an evolutionary trade-off in the adaptation to normoxia 
(figure 3 C, D and supplement table III C, D). Interestingly, only OVCAR3-A showed a 
benefit from cysteine under hypoxia, suggesting that selection under normoxia (OVCAR3-N) 
led to a decreased dependence on cysteine metabolism or to the loss of cellular efficacy in 
taking advantage from cysteine. Under normoxia, OVCAR3-A, OVCAR3-N and OVCAR3-
H showed no differences in the absence and presence of cysteine. 
Results also showed that OVCAR3-H was worse adapted to normoxia than both 
OVCAR3-A and OVCAR3-N. However, under H they performed better than OVCAR3-N 
(figure 3 C, D and supplement table III C, D), thus indicating that this cell line also present an 
evolutionary trade-off in the adaptation to hypoxia. However, like ES2-H, OVCAR3-H also 
performed equally in all environments (figure 3 C, D).  
 
Figure 3. Adaptation to normoxia is accompanied by an evolutionary trade-off, which is supressed 
by cysteine under hypoxia in ES2 cells. 
Cell death levels in a drug-free environment for A. and B. ES2 cells and C. and D. OVCAR3 cells. N 
selected – cells selected under normoxia; H selected – cells selected under hypoxia; N – Normoxia; NC – 
Normoxia supplemented with cysteine; H –Hypoxia; HC –Hypoxia supplemented with cysteine. Results 
are shown as mean ± SD. In A. and C. asterisks (*) represents statistical significance compared to cells 
cultured under normoxia within each cell line. The cardinals (#) represent statistical significance of cells 
cultured under hypoxia with cysteine compared to cells cultured under hypoxia without cysteine within 
each cell line. In B. and D. the asterisks (*) represent statistical significance among cell lines within each 
treatment. *p<0.05, **p<0.01, ***p<0.001 or #p<0.05, ##p<0.01, ###p<0.001 (One-way ANOVA with 
post hoc Tukey tests). 
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We must highlight that there was no difference in the response to hypoxia between 
OVCAR3 and the respective condition of ES2 cells. Nevertheless, OVCAR3 cells presented 
lower cell death levels in this treatment compared to the respective ES2 cells (figure 4 A and 
B and supplementary table IV). 
 
Figure 4. ES2 and OVCAR3 cells resistance to hypoxia. 
Comparison of ES2 and OVCAR3 cells resistance to hypoxia for 48 hours of assay for A. ES2 and 
OVCAR3 cells in which values were normalised to the respective control, and B. ES2 and OVCAR3 
cells with non-normalised to control values.  
N selected – cells selected under normoxia; H selected – cells selected under hypoxia. Results are shown 
as mean ± SD. Asterisks (*) represent statistical significance between ES2 and OVCAR3 cells. *p<0.05, 
**p<0.01, ***p<0.001 (Independent samples T tests). 
 
 
Metabolic evolution driven by hypoxia provides stronger resistance to carboplatin  
 
In here, we assessed the effects of selection under normoxia and hypoxia on cells 
capacity to survive upon carboplatin exposure. The codes of each cell line and culture 
condition are presented in supplement table I. 
Upon carboplatin exposure, cell death levels increased for ES2-A cells in all treatments 
when compared to a drug-free environment. ES2-N cells showed a similar trend to ES2-A, in 
all conditions, with the exception of ES2-NH, in which there was a tendency for higher cell 
death levels upon carboplatin exposure, though not statistically significant (figure 5 A and 
supplement table V A). Nonetheless, cysteine was advantageous under H in the presence of 
carboplatin for both ES2-A and ES2-N (figure 6 and supplementary table VI A). 
Interestingly, for ES2-H cells, upon carboplatin exposure, only ES2-HH showed a slight 
increase in cell death levels (figure 5A and table V A), indicating that ES2-H cells present a 
higher survival capacity upon carboplatin exposure than ES2-A and ES2-N cells (figure 5 B 
and table V C). Interestingly, under H, no differences were observed among ES2-A, ES2-N 
and ES-H in carboplatin response, suggesting that 48 h of H exposure were sufficient to drive 
carboplatin response in ES2 cells, independent of the regime of selection. 
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Strikingly, when compared to the other selection regimes, cysteine was advantageous 
both under normoxia and hypoxia for the ES2 cells adapted to hypoxia (ES2-H) (figure 5 A, 
B and supplement table V A, C). On the contrary, ES2 cells selected under normoxia (ES2-
N) presented an increased ratio of cell death when cultured in hypoxia with cysteine (ES2-
NHC) versus without cysteine (ES2-NH), upon carboplatin exposure (figure 5). Together, 
results suggest that cysteine facilitates the adaptation to hypoxia, which, in turn, drives 
carboplatin resistance. On the contrary, long-term selection under normoxia drives the 
selection of cells that have less capacity of benefiting from cysteine protection under hypoxia 
and upon drug exposure. 
Regarding OVCAR3 cells, cell death analysis showed increased cell death levels upon 
carboplatin exposure in OVCAR3-A, OVCAR3-N and OVCAR3-H cells, when compared to 
a drug-free environment and in all treatments (figure 5 C, and supplement table IV D). 
Nonetheless, cysteine was advantageous under H in the presence of carboplatin for all 
selection regimes of OVCAR3 cells (figure 6 and supplement table VI B). Interestingly, 
OVCAR3-HN cells presented stronger survival ability upon carboplatin than OVCAR3-AN 
and OVCAR3-NN (figure 5 D and supplement table V F). Taken together, results suggest 
that H-selection can also be advantageous for OVCAR3 cells upon carboplatin exposure, 
however at a lesser extent than ES2 cells. 
 
Figure 5. Metabolic evolution driven by hypoxia provides stronger resistance to carboplatin 
cytotoxicity. 
Cells response to Carboplatin exposure for 48 hours of assay for A. ES2 cells with non-normalised to 
control values, B. ES2 cells in which values were normalised to the respective control, C. OVCAR3 cells 
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with non-normalised to control values and D. OVCAR3 cells in which values were normalised to the 
respective control. N selected – cells selected under normoxia; H selected – cells selected under hypoxia; 
N – Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented 
with cysteine. In A. and C. asterisks (*) represent statistical significance compared to the respective 
control (cells cultured in the same experimental condition but in a free-drug environment) within each 
cell line. In B. and D. Asterisks (*) represent statistical significance compared to ancestral cells. 
Cardinals (#) represent statistical significance compared to N-selected cells. Data were normalised to the 
respective control. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 or #p<0.05, 
##p<0.01, ###p<0.001 (A. and C. Independent samples T test and B. and D. One-way ANOVA with post 
hoc Tukey tests). 
 
 
Figure 6. Metabolic evolution driven by hypoxia provides stronger resistance to carboplatin. 
Cell death levels (non-normalised values) in the presence of carboplatin for 48 hours of assay for A. ES2 
cells and B. OVCAR3 cells. N selected – cells selected under normoxia; H selected – cells selected under 
hypoxia; N – Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia 
supplemented with cysteine. Results are shown as mean ± SD. Asterisks (*) represent statistical 
significance compared to cells cultured under normoxia within each cell line. Cardinals (#) represent 
statistical significance compared to cells cultured under hypoxia within each cell line. *p<0.05, 
**p<0.01, ***p<0.001 or #p<0.05, ##p<0.01, ###p<0.001 (One-way ANOVA with post hoc Tukey 
tests). 
 
 
Carboplatin resistance driven by hypoxia is stronger in ES2 cells 
 
We next compared ancestral and selected ES2 and OVCAR3 cells response dynamics to 
carboplatin exposure. Results showed that ES2-A cells presented a stronger resistance to 
carboplatin both under N and H than OVCAR3-A cells for 48 h of assay (figure 7 A and 
supplement table VII A). Similar results were observed for N selected cell lines, where ES2-
NN and ES2-NH presented a stronger carboplatin resistance compared both to OVCAR3-NN 
and OVCAR3-NH cells (figure 7 B and supplement table VII B). Interestingly, ES2-H cells 
presented a stronger resistance to carboplatin in all treatments when compared to OVCAR3-
H cells (figure 7 C and table VII C).  
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Figure 7. ES2 cells tend to present a stronger resistance to carboplatin than OVCAR3 cells. 
Comparison of ES2 and OVCAR3 cells response to carboplatin for 48 h of experimental conditions for 
A. ancestral ES2 and OVCAR3 cells. B. ES2 and OVCAR3 cells selected under normoxia and C. ES2 
and OVCAR3 cells selected under hypoxia. N – Normoxia; NC – Normoxia supplemented with cysteine; 
H – Hypoxia; HC – Hypoxia supplemented with cysteine. Data were normalised to the respective 
control. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (Independent samples T test). 
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slight increase in cell death levels with increasing time of exposure. In OVCAR3-H cells, 
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carboplatin induced cell death in a time-dependent manner in all treatments (figure 8 C and 
table VIII C). 
 
Figure 8. ES2 and OVCAR3 cells present different dynamics of response to carboplatin. 
Cells response to Carboplatin over time for A. ancestral ES2 cells and OVCAR3 cells, B. ES2 and 
OVCAR3 cells selected under normoxia, C. ES2 and OVCAR3 cells selected under hypoxia. N – 
Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented 
with cysteine. Data were normalised to the respective control. Results are shown as mean ± SD. *p<0.05, 
**p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
Taken together, results suggest that hypoxia drives carboplatin resistance in ES2 cells 
and, at a lower extent, in OVCAR3 cells, thus pointing a more aggressive phenotype in ES2-
H than in OVCAR3-H cells. Since ES2-A and ES2-N cells were able to take advantage from 
cysteine under hypoxia (ES2-AH and ES2-NH), we propose that cysteine allows a quicker 
response and adaptation to hypoxic conditions that, in turn, drive carboplatin resistance.  
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ES2 cells present metabolic diversity in adverse environments, favouring resistance to 
carboplatin  
 
The codes of each cell line and culture condition are presented in supplement table I. 
In a drug-free environment, the analysis of ROS levels allowed the observation of two 
distinct populations in ES2-NH (figure 9 A), indicating the existence of a glycolytic and an 
oxidative phosphorylative population of cells. Interestingly, hypoxia was especially 
disadvantageous for the later cells, presenting the higher cell death levels in this condition 
(figure 3 A). This suggests that metabolic diversity among ES2-N cells could be a strategy to 
cope with new adverse environments. 
In ES2-HH, we only observed one population, thus revelling a higher metabolic adaptive 
capacity to hypoxia (figure 9 B). Interestingly, in OVCAR3-NH we were not able to 
distinguish two different populations of cells as in ES2-NH (figure 9 C). Also, we observed a 
trend to higher ROS levels in both ES2-N and ES2-H than in OVCAR3-N and OVCAR3-H, 
especially in conditions with cysteine supplementation (Figure 10 A to D and supplementary 
table IX A to D). This might indicate that cysteine allows higher metabolic activity in ES2 
cells, even under hypoxia. Moreover, the detection of ROS, using 2’, 7’-Dichlorofluorescin 
diacetate, never showed a correlation between higher ROS levels and higher cell death levels 
in any cell line. On the contrary, ROS showed a negative correlation with cell death.   
Upon carboplatin exposure, different populations were also observed for ES2-N cells 
under hypoxia (figure 9 E), thus showing again that this cell line present different cell 
populations with different metabolic states in an adverse environment. In addition, ES2-HH 
with cysteine showed a notable increase in ROS levels upon carboplatin exposure (figure 9 F 
and 10 E and F and supplement table IX E and F). Upon carboplatin exposure, OVCAR3-A, 
OVCAR3-N and OVCAR3-H cells did not show different populations in any treatment 
(figure 9 G and H). Interestingly, OVCAR3-H selected cells showed no differences in ROS 
dynamics, thus suggesting that cells do not present metabolic diversity (figure 9 H). 
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Figure 9. ES2 cells present metabolic diversity in adverse environments. 
ROS histogram for A. ES2-N cells, B. ES2-H cells, C. OVCAR3-N cells, D. OVCAR3-H cells in a free 
drug environment for 48 h of experimental conditions, and ROS histogram for E. ES2-N cells, F. ES2-H 
cells, G. OVCAR3-N cells and H. OVCAR3-H in the presence of carboplatin. NN – cells selected under 
normoxia and cultured under normoxia (grey line); NNC – cells selected under normoxia and cultured 
under normoxia supplemented with cysteine (blue line); NH – cells selected under normoxia and cultured 
under hypoxia (red line); NHC – cells selected under normoxia and cultured under hypoxia 
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supplemented with cysteine (green line); HN – cells selected under hypoxia and cultured under normoxia 
(grey line); HNC – cells selected under hypoxia and cultured under normoxia supplemented with 
cysteine (blue line); HH – cells selected under hypoxia and cultured under hypoxia (red line); HHC – 
cells selected under hypoxia and cultured under hypoxia supplemented with cysteine (green line). 
 
 
Figure 10. ROS levels in ES2 and OVCAR3 ancestral cells, cells selected under normoxia and 
under hypoxia. 
ROS levels in a drug-free environment for 48 h of assay for A. and B. ES2 cells and C. and D. OVCAR3 
cells and ROS levels in the presence of Carboplatin for 48 h of assay for E. and F. ES2 cells and G. and 
H. OVCAR3. N selected – cells selected under normoxia; H selected – cells selected under hypoxia; N – 
Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented 
with cysteine. Results are shown as mean ± SD. Asterisks (*) represent statistical significance compared 
to cells cultured under normoxia within each cell line. Cardinals (#) represent statistical significance 
compared to cells cultured under hypoxia within each cell line. *p<0.05, **p<0.01, ***p<0.001 or 
#p<0.05, ##p<0.01, ###p<0.001 (One-way ANOVA with post hoc Tukey tests). 
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Taken together, results support that ES2 cells present higher metabolic diversity under 
adverse environments when compared to OVCAR3 cells. This diversity possibly explains the 
increased response capacity of ES2 cells to the more stressful environments (hypoxia and 
carboplatin), whereas, in general, OVCAR3 cells failed to respond to it.  
 
DISCUSSION 
 
Although the outcome prognosis of OCCC and other histological subtypes has been a matter 
of controversy, it was shown that patients with OCCC present a significantly worse prognosis 
than patients with ovarian serous carcinomas when matched for age, stage, and level of 
primary surgical cytoreduction [36,37]. Moreover, while OCCC shows primary resistance to 
conventional platinum-based chemotherapy [10,11], in HG-OSC both initial sensitiveness 
with the development of progressive resistance [9,38] and primary resistance exists [38]. 
Interestingly, Beaufort and colleagues have explored the associations between the cellular 
and molecular features of 39 ovarian cancer cell lines and their clinical features [39]. They 
reported an association of the spindle-like tumours with metastasis, advanced stage, 
suboptimal debulking and poor prognosis [39]. Importantly, ES2 cells were included in this 
group whereas OVCAR3 cells were not [39]. In here, we used these two different cancer cell 
lines derived from these two histological types of ovarian cancer and addressed the effect of 
cells selection under normoxia and CoCl2 mimicked hypoxia on the evolutionary outcome of 
cancer cells, exploring also the role of cysteine in this adaptive process.  
The adaptation to a specific environment is widely associated to deterioration in other 
non-selective environments, being accompanied by an evolutionary trade-off [40–43]. Our 
results supported an evolutionary trade-off in ovarian cancer cells adaptation to normoxic 
conditions in which, cells adapted under normoxia duplicated rapidly but at the cost of 
increased mortality in adverse environments. Notably, in ES2 cells, cysteine was able to 
suppress this trade-off under hypoxia (ES2-NH versus ES2-NHC). It was already reported 
that intracellular cysteine directly induces the HIF prolyl-hydroxylases, leading to HIF-1α 
degradation [44,45], thus indicating that cysteine is able to convert a hypoxic cellular 
metabolism into a normoxic one. In addition, our data showed that ES2 ancestral cells present 
both higher intracellular cysteine and GSH degradation levels under hypoxia supplemented 
with cysteine compared to hypoxia without cysteine supplementation (chapter 3). Those 
observations could explain the protective effect of cysteine under hypoxia in both ancestral 
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and normoxia selected ES2 cells, thus allowing counteracting the disadvantage under 
hypoxia. Moreover, those results also support that ES2 cells selected under normoxia (ES2-
N) still present metabolic diversity concerning cysteine metabolism under hypoxic conditions 
(ES2-NH). Interestingly, OVCAR3-N cells showed less plasticity.  
ES2-H presented increased survival in non-selective environments compared to cells 
selected under normoxia (ES2-N), suggesting a generalist, more adaptive and more 
aggressive phenotype. Remarkably, results showed that the increased survival was 
accompanied by lower proliferation rates. Life history theory proposes that cancer cells may 
be subjected to trade-offs between maximizing cell survival and cell growth, and that both 
strategies can be successful depending on the environmental conditions [46]. We observed 
that ES2–H proliferated more slowly than ES2-N, but, nevertheless, presented increased 
survival in the presence of carboplatin, a cytotoxic agent used in ovarian cancer treatment, 
thus showing that life-history trade-offs may have clinical implications for cancer patients. 
These results are in accordance with the observations that hypoxia promote tumour 
progression and resistance to therapy (reviewed in [47]), having a complex role in the 
hallmarks of human cancers [13,48,49]. Importantly, hypoxia is known to induce 
mitochondrial ROS levels [50,51]. ROS levels are widely associated with tumour initiation, 
progression and chemoresistance [51–53]. Our results showed increased ROS levels in ES2-
H cells under hypoxia and cysteine supplementation upon carboplatin exposure. Interestingly, 
in the same conditions, ES2 cells showed a higher ability to survive upon carboplatin 
exposure. Nevertheless, it remains unclear if the increased ROS levels are responsible for 
carboplatin resistance or, on the contrary, if the higher cells adaptability to this environment 
leads cells to increased metabolic activity, thus increasing ROS levels. 
Notably, OVCAR3-A and OVCAR-N cells showed to be less sensitive to hypoxia than 
ES2-A and ES2-N cells, suggesting that these cells would be more prone to chemoresistance 
than ES2 cells. However, OVCAR3 cells presented a poorer response capacity to carboplatin, 
thus indicating that resistance to hypoxia alone cannot explain the more aggressive 
phenotypes. OVCAR3 cells also presented decreased cellular diversity concerning ROS 
levels in adverse environments. Our results highlight the role of hypoxia-induced 
chemoresistance in combination with metabolic diversity in cancer cells coping with adverse 
conditions. Whereas ES2 cells showed metabolic diversity, indicative of metabolism 
reprogramming in adverse conditions, OVCAR3 cells seemed to be ineffective in this 
process, thus preventing an increased survival upon carboplatin cytotoxicity. These results 
also reinforce that the metabolic adaptive capacity of cancer cells to cope with new adverse 
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environments is more important to cancer progression than the size of the cancer cell 
population, as OVCAR3 cells showed to be less sensitive to hypoxia, nonetheless presenting 
poor response to carboplatin exposure. In the natural course of cancer disease it is a low 
number of cells that are capable of resisting to adverse and toxic environments during 
treatment, that are further responsible for recurrent disease. 
We must highlight that ES2 and OVCAR3 cells were selected during different times, due 
to a lower proliferation rate of OVCAR3 cells under hypoxia compared to ES2, which could 
explain, in part, the lower diversity observed in OVCAR3 selected cells, as these cells were 
selected during more time than ES2 cells. However, in what concerns carboplatin resistance, 
we would expect an association between higher selection time and higher levels of resistance. 
However, in a general way, OVCAR3 selected cells showed to be less resistant than ES2 
selected cells. Moreover, our main propose was to compare the effect of selection under 
normoxia and hypoxia and cysteine supplementation in the dynamics of adaptation to 
carboplatin within each cell line (ES2/OVCAR3) and the time of selection was the same in 
these situations. Also, the ancestral OVCAR3 (OVCAR3-A) cells showed similar dynamics 
of response to carboplatin as selected cells, corroborating the results. The proliferation 
curves/cell cycle analysis and cell death analysis /ROS quantification were also performed 
with different selection times within each cell line but we did not aim to compare 
proliferation with cell death. The only speculation done was regarding ES2 cells selected 
under hypoxia and increased survival accompanied by lower proliferation rates. However, 
since proliferation curves were performed with increased selection time, it would be expected 
that the same selection time as cell death analysis, would lead to a more pronounced effect on 
decreased cell proliferation, given less time for adaptation. 
Our second hypothesis that selection under hypoxia in ES2 (ES2-H) cells would favour a 
stronger ability of cells to benefit from cysteine under hypoxia showed to be false in a drug-
free environment. Strikingly, in the presence of carboplatin, cysteine was especially 
advantageous to ES2-H, thus suggesting that they evolved mechanisms to a better usage of 
this amino acid in new adverse environments. In this study, we only focused on the role of 
cysteine supplementation in response to hypoxia and further response to carboplatin 
cytotoxicity. We did not address other amino acids since we were interested in cysteine as a 
sulphur source in hypoxia and carboplatin resistance. However, in another study we showed 
that glutamine also played a role in GSH synthesis, as glutamine is a source of glutamate and 
glycine [25], supporting again a role of thiols in chemoresistance. 
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Taken together, results have shown that the adaptation to normoxia and hypoxia leads 
ovarian cancer cells to display opposite strategies. Whereas cells adapted to hypoxia tended 
to proliferate less but show increased survival in adverse environments, cells adapted to 
normoxia present the opposite strategy, proliferating rapidly but at the cost of increased 
mortality in adverse environments. Albeit the limited number of cell lines, those different 
evolutionary courses should be taken into account in the clinical context, as therapy protocols 
could be more effective dependent on the evolutionary strategy of cancer cells. Moreover, 
results highlighted that the ability of ovarian cancer cells to use cysteine has an impact in 
cancer cells adaptation to hypoxic environment and, ultimately, to platinum-based 
chemotherapeutic agents, allowing the selection of resistant phenotypes that are more 
aggressive, being able to carry out cancer progression and recurrence (figure 11).  
Finally, our study supports that experimental evolution in cancer is a valuable tool to 
predict metabolic adaptation underlying drugs resistance, which can further contribute to the 
improvement of anti-cancer treatment strategies. 
            A.                                                               B. 
 
Figure 11. ES2 and OVCAR3 present different adaptive capacities in a drug free environment, 
impacting the response to carboplatin. 
A. Non-selected ancestral and Normoxia selected ES2 cell lines showed disadvantageous under hypoxia 
that cysteine was able to revert, protecting cells from hypoxia-induced death. Importantly, Normoxia 
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selected ES2 cell lines present an evolutionary trade-off when exposed to hypoxia, reverted by cysteine. 
Hypoxia selected cells behave equally in all environments. Upon carboplatin exposure, cysteine 
protected all ES2 cells variants, decreasing carboplatin cytotoxicity under hypoxia. Thus, ES2 cells 
exhibited a high adaptive capacity to hypoxia and cysteine, which reflects in a higher fitness upon 
carboplatin exposure, being hypoxia selected the best fitted. B. Non-selected ancestral and Normoxia 
selected OVCAR3 cell lines also showed disadvantageous under hypoxia. Normoxia selected OVCAR3 
cell lines also showed an evolutionary trade-off when exposed to hypoxia, but cysteine only reverted this 
disadvantage under hypoxia in Non-selected ancestral cells. Upon carboplatin exposure, cysteine protects 
all OVCAR3 cells, decreasing carboplatin cytotoxicity under hypoxia. OVCAR3 cells variants benefit 
from different grades of cysteine protection: Non-selected ancestral> hypoxia selected>Normoxia 
selected. Overall, OVCAR3 cells exhibited a lower adaptive capacity to hypoxia and cysteine, which 
reflects in a loss of fitness upon carboplatin exposure. Overall, ES2 cells present a higher metabolic 
plasticity than OVCAR3 cells. This fact might underlie the intrinsic resistance to carboplatin exhibited 
by OCCC histology in the clinical context. White ellipses in ES2 cells represent vacuoles characteristic 
of clear cell carcinoma. 
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SUPPLEMENTS 	  
Supplement table I: Ovarian cancer cell lines, selection and culture conditions. 
Cell line- histological type Cell line code Selection condition Culture condition 
Ovarian clear cell carcinoma (OCCC; ES2) 
ES2-AN Non selected ancestral cell line Normoxia 
ES2-ANC Non selected ancestral cell line Normoxia + 
cysteine 
ES2-AH Non selected ancestral cell line Hypoxia 
ES2-AHC Non selected ancestral cell line Hypoxia + cysteine 
ES2-NN Selected under Normoxia Normoxia 
ES2-NNC Selected under Normoxia Normoxia + 
cysteine 
ES2-NH Selected under Normoxia Hypoxia 
ES2-NHC Selected under Normoxia Hypoxia + cysteine 
ES2-HN Selected under Hypoxia Normoxia 
ES2-HNC Selected under Hypoxia Normoxia + 
cysteine 
ES2-HH Selected under Hypoxia Hypoxia 
ES2-HHC Selected under Hypoxia Hypoxia + cysteine 
Serous carcinoma (HG-OSC; OVCAR3) 
OVCAR3-AN Non selected ancestral cell line Normoxia 
OVCAR3-ANC Non selected ancestral cell line Normoxia + 
cysteine 
OVCAR3-AH Non selected ancestral cell line Hypoxia 
OVCAR3-AHC Non selected ancestral cell line Hypoxia + cysteine 
OVCAR3-NN Selected under Normoxia Normoxia 
OVCAR3-NNC Selected under Normoxia Normoxia + 
cysteine 
OVCAR3-NH Selected under Normoxia Hypoxia 
OVCAR3-NHC Selected under Normoxia Hypoxia + cysteine 
OVCAR3-HN Selected under Hypoxia Normoxia 
OVCAR3-HNC Selected under Hypoxia Normoxia + 
cysteine 
OVCAR3-HH Selected under Hypoxia Hypoxia 
OVCAR3-HHC Selected under Hypoxia Hypoxia + cysteine 
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Supplement table II: Adaptation to normoxia confers a highly proliferative ability to ES2 
cells.  
A. 
Treatments – proliferation curve (48 h) Tukey test sig.  
ES2-NN vs ES2-HN 0.000 
ES2-NN vs ES2-HH 0.000 
ES2-NH vs ES2-HN 0.000 
ES2-NH vs ES2-HH 0.001 
 
B. 
Treatments – cell cycle analysis Tukey test sig. 
G0/G1 ES2-NN vs ES2-NH 0.02 
 
C. 
Treatments – proliferation curve (48 h) Tukey test sig. 
OVCAR3-NN vs OVCAR3-HH 0.036 
 
D. 
Treatments – cell cycle analysis Tukey test sig. 
G0/G1 OVCAR3-NN vs OVCAR3-HH 0.006 
G0/G1 OVCAR3-NH vs OVCAR3-HN 0.033 
G0/G1 OVCAR3-NH vs OVCAR3-HH 0.001 
G2/M OVCAR3-NH vs OVCAR3-HH 0.027 
 
Supplement table III. Adaptation to normoxia is accompanied by an evolutionary trade-off 
that is suppressed by cysteine under hypoxia in ES2 cells.  
A. 
Treatments – cell death analysis (48 h) Tukey test sig. 
ES2-AN vs ES2-AH 0.008 
ES2-ANC vs ES2-AH 0.001 
ES2-AHC vs ES2-AH 0.001 
ES2-NN vs ES2-NH 0.000 
ES2-NNC vs ES2-NH 0.000 
ES2-NHC vs ES2-NH 0.000 
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B. 
Treatments – cell death analysis (48 h) Tukey test sig. 
ES2-NNC vs ES2-HNC 0.030 
ES2-NH vs ES2-AH 0.034 
ES2-NH vs ES2-HH 0.001 
ES2-HH vs ES2-AH 0.016 
 
C. 
Treatments – cell death analysis (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-AH 0.000 
OVCAR3-ANC vs OVCAR3-AH 0.000 
OVCAR3-AHC vs OVCAR3-AH 0.003 
OVCAR3-NH vs OVCAR3-NN 0.003 
OVCAR3-NH vs OVCAR3-NNC 0.004 
 
D. 
Treatments – cell death analysis (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-HN 0.002 
OVCAR3-NN vs OVCAR3-HN 0.009 
OVCAR3-ANC vs OVCAR3-NNC 0.004 
OVCAR3-ANC vs OVCAR3-HNC 0.000 
OVCAR3-NNC vs OVCAR3-HNC 0.001 
OVCAR3-AH vs OVCAR3-NH 0.036 
OVCAR3-HH vs OVCAR3-NH 0.008 
 
Supplement table IV. ES2 and OVCAR3 cells resistance to hypoxia.  
Treatments – cell death analysis (48 h) Independent samples T test sig. 
ES2-AH vs OVCAR3-AH 0.009 
ES2-NH vs OVCAR3-NH 0.009 
ES2-HH vs OVCAR3-HH 0.004 
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Supplement table V. Hypoxia provides stronger resistance to carboplatin. 
A. 
Treatments – cell death analysis (48 h) Tukey test sig. 
ES2-AN Ctr vs Carboplatin 0.008 
ES2-ANC Ctr vs Carboplatin 0.000 
ES2-AH Ctr vs Carboplatin 0.019 
ES2-AHC Ctr vs Carboplatin 0.0000 
ES2-NN Ctr vs Carboplatin 0.008 
ES2-NNC Ctr vs Carboplatin 0.002 
ES2-NH Ctr vs Carboplatin 0.069 
ES2-NHC Ctr vs Carboplatin 0.006 
ES2-HN Ctr vs Carboplatin 0.412 
ES2-HNC Ctr vs Carboplatin 0.175 
ES2-HH Ctr vs Carboplatin 0.016 
ES2-HHC Ctr vs Carboplatin 0.706 
 
B. 
Treatments – cell death analysis (48 h) Tukey test sig. 
ES2-HN vs ES2-AN 0.001 
ES2-HN vs ES2-NN 0.000 
ES2-HNC vs ES2-ANC 0.000 
ES2-HNC vs ES2-NNC 0.001 
ES2-HHC vs ES2-AHC 0.000 
ES2-HHC vs ES2-NHC 0.001 
 
C. 
Treatments – cell death analysis (48 h) Tukey test sig. 
OVCAR3-AN Ctr vs Carboplatin 0.000 
OVCAR3-ANC Ctr vs Carboplatin 0.000 
OVCAR3-AH Ctr vs Carboplatin 0.000 
OVCAR3-AHC Ctr vs Carboplatin 0.000 
OVCAR3-NN Ctr vs Carboplatin 0.000 
OVCAR3-NNC Ctr vs Carboplatin 0.000 
OVCAR3-NH Ctr vs Carboplatin 0.026 
OVCAR3-NHC Ctr vs Carboplatin 0.000 
OVCAR3-HN Ctr vs Carboplatin 0.000 
OVCAR3-HNC Ctr vs Carboplatin 0.000 
OVCAR3-HH Ctr vs Carboplatin 0.000 
OVCAR3-HHC Ctr vs Carboplatin 0.001 
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D. 
Treatments – cell death analysis (48 h) Tukey test sig. 
OVCAR3-HN vs OVCAR3-AN 0.002 
OVCAR3-HN vs OVCAR3-NN 0.001 
OVCAR3-HHC vs OVCAR3-NHC 0.013 
 
Supplement table VI. Metabolic evolution driven by hypoxia provides stronger resistance to 
carboplatin. 
A. 
Treatments – cell death analysis (48 h) Tukey test sig. 
ES2-AN vs ES2-ANC 0.006 
ES2-AN vs ES2-AH 0.003 
ES2-ANC vs ES2-AH 0.000 
ES2-AH vs ES2-AHC 0.000 
ES2-NN vs ES2-NH 0.002 
ES2-NNC vs ES2-NH 0.000 
ES2-NHC vs ES2-NH 0.001 
ES2-HN vs ES2-HH 0.006 
ES2-HNC vs ES2-HH 0.001 
ES2-HHC vs ES2-HH 0.001 
 
B. 
Treatments – cell death analysis (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-ANC 0.000 
OVCAR3-AN vs OVCAR3-AH 0.001 
OVCAR3-AN vs OVCAR3-AHC 0.006 
OVCAR3-AH vs OVCAR3-AHC 0.000 
OVCAR3-ANC vs OVCAR3-AH 0.000 
OVCAR3-NNC vs OVCAR3-NH 0.002 
OVCAR3-NHC vs OVCAR3-NH 0.018 
OVCAR3-HN vs OVCAR3-HH 0.013 
OVCAR3-HNC vs OVCAR3-HH 0.000 
OVCAR3-HHC vs OVCAR3-HH 0.003 
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Supplement table VII. ES2 cells tend to present a stronger resistance to carboplatin than 
OVCAR3 cells. 
A. 
Treatments – cell death analysis (48 h) T test sig.  
ES2-AN vs OVCAR3-AN 0.001 
ES2-ANC vs OVCAR3-ANC 0.347 
ES2-AH vs E OVCAR3-AH 0.000 
ES2-AHC vs OVCAR3-AHC 0.179 
 
B. 
Treatments – cell death analysis (48 h) T test sig.  
ES2-NN vs OVCAR3-NN 0.003 
ES2-NNC vs OVCAR3-NNC 0.085 
ES2-NH vs E OVCAR3-NH 0.007 
ES2-NHC vs OVCAR3-NHC 0.092 
 
C. 
Treatments – cell death analysis (48 h) T test sig.  
ES2-HN vs OVCAR3-HN 0.000 
ES2-HNC vs OVCAR3-HNC 0.000 
ES2-HH vs E OVCAR3-HH 0.000 
ES2-HHC vs OVCAR3-HHC 0.000 
 
Supplement Table VIII. ES2 and OVCAR3 cells dynamics of response to carboplatin. 
A. 
Treatments – cell death analysis – 16 h vs 
24 h vs 48 h 
Tukey test sig. 
ES2-AN 16 h vs 48 h 0.014 
ES2-ANC 16 h vs 48 h 0.000 
ES2-ANC 24 h vs 48 h 0.000 
ES2-AH 16 h vs 24 h 0.006 
ES2-AH 24 h vs 48 h 0.001 
ES2-AHC 16 h vs 24 h 0.007 
ES2-AHC 16 h vs 48 h 0.000 
ES2-AHC 24 h vs 48 h 0.000 
OVCAR3-AN 16 h vs 48 h 0.000 
OVCAR3-AN 24 h vs 48 h 0.000 
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OVCAR3-ANC 16 h vs 48 h 0.000 
OVCAR3-ANC 24 h vs 48 h 0.000 
OVCAR3-AH 16 h vs 48 h 0.000 
OVCAR3-AH 24 h vs 48 h 0.000 
OVCAR3-AHC 16 h vs 48 h 0.000 
OVCAR3-AHC 24 h vs 48 h 0.000 
 
B. 
Treatments – cell death analysis – 16 h vs 
24 h vs 48 h 
Tukey test sig. 
ES2-NN 16 h vs 48 h 0.000 
ES2-NN 24 h vs 48 h 0.001 
ES2-NNC 16 h vs 48 h 0.000 
ES2-NNC 24 h vs 48 h 0.000 
ES2-NHC 16 h vs 48 h 0.001 
ES2-NHC 24 h vs 48 h 0.002 
OVCAR3-NN 16 h vs 48 h 0.000 
OVCAR3-NN 24 h vs 48 h 0.000 
OVCAR3-NNC 16 h vs 24 h 0.041 
OVCAR3-NNC 16 h vs 48 h 0.001 
OVCAR3-NNC 24 h vs 48 h 0.01 
OVCAR3-NH 16 h vs 48 h 0.002 
OVCAR3-NH 24 h vs 48 h 0.006 
OVCAR3-NHC 16 h vs 48 h 0.000 
OVCAR3-NHC 24 h vs 48 h 0.001 
 
C. 
Treatments – cell death analysis – 16 h vs 
24 h vs 48 h 
Tukey test sig. 
ES2-HH 16 h vs 48 h 0.048 
ES2-HH 24 h vs 48 h 0.043 
OVCAR3-HN 16 h vs 48 h 0.000 
OVCAR3-HN 24 h vs 48 h 0.000 
OVCAR3-HNC 16 h vs 48 h 0.000 
OVCAR3-HNC 24 h vs 48 h 0.000 
OVCAR3-HH 16 h vs 48 h 0.000 
OVCAR3-HH 24 h vs 48 h 0.000 
OVCAR3-HHC 16 h vs 48 h 0.001 
OVCAR3-HHC 24 h vs 48 h 0.002 
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Supplement table IX. ROS levels in ES2 and OVCAR3 ancestral cells, cells selected under 
normoxia and under hypoxia. 
A. 
Treatments – ROS quantification (48 h) Tukey test sig. 
ES2-AN vs ES2-ANC 0.021 
ES2-AHC vs ES2-ANC 0.016 
ES2-HN vs ES2-HNC 0.003 
ES2-HN vs ES2-HHC 0.001 
ES2-HH vs ES2-HNC 0.001 
ES2-HH vs ES2-HHC 0.001 
 
B. 
Treatments – ROS quantification (48 h) Tukey test sig. 
ES2-AN vs ES2-NN 0.006 
ES2-ANC vs ES2-NNC 0.000 
ES2-ANC vs ES2-HNC 0.000 
ES2-HNC vs ES2-NNC 0.000 
ES2-AH vs ES2-NH 0.000 
ES2-AH vs ES2-HH 0.013 
ES2-HH vs ES2-NH 0.000 
ES2-AHC vs ES2-HHC 0.006 
 
C. 
Treatments – ROS quantification (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-AH 0.001 
OVCAR3-ANC vs OVCAR3-AH 0.004 
OVCAR3-AN vs OVCAR3-AHC 0.015 
OVCAR3-NN vs OVCAR3-NH 0.006 
OVCAR3-NN vs OVCAR3-NHC 0.013 
OVCAR3-HN vs OVCAR3-HHC 0.003 
OVCAR3-HNC vs OVCAR3-HHC 0.001 
OVCAR3-HH vs OVCAR3-HHC 0.001 
 
D. 
Treatments – ROS quantification (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-HN 0.001 
OVCAR3-NN vs OVCAR3-HN 0.021 
OVCAR3-ANC vs OVCAR3-NNC 0.017 
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OVCAR3-ANC vs OVCAR3-HNC 0.002 
OVCAR3-AH vs OVCAR3-HH 0.035 
OVCAR3-AHC vs OVCAR3-NHC 0.007 
OVCAR3-HHC vs OVCAR3-NHC 0.01 
 
E. 
Treatments – ROS quantification (48 h) Tukey test sig. 
ES2-AN vs ES2-AH 0.015 
ES2-ANC vs ES2-AH 0.001 
ES2-AHC vs ES2-AH 0.000 
ES2-NN vs ES2-NNC 0.026 
ES2-NN vs ES2-NH 0.008 
ES2-HN vs ES2-HHC 0.000 
ES2-HH vs ES2-HHC 0.000 
ES2-HNC vs ES2-HHC 0.000 
 
F. 
Treatments – ROS quantification (48 h) Tukey test sig. 
ES2-AN vs ES2-NN 0.022 
ES2-ANC vs ES2-NNC 0.000 
ES2-ANC vs ES2-HNC 0.000 
ES2-NNC vs ES2-HNC 0.000 
ES2-AH vs ES2-HH 0.026 
ES2-AHC vs ES2-NHC 0.019 
ES2-AHC vs ES2-HHC 0.000 
ES2-NHC vs ES2-HHC 0.000 
 
G. 
Treatments – ROS quantification (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-AH 0.022 
 
H. 
Treatments – ROS quantification (48 h) Tukey test sig. 
OVCAR3-AN vs OVCAR3-NN 0.025 
OVCAR3-AN vs OVCAR3-HN 0.016 
OVCAR3-ANC vs OVCAR3-NNC 0.044 
OVCAR3-AH vs OVCAR3-NH 0.043 
OVCAR3-AHC vs OVCAR3-NHC 0.03 
	   
 
 
CHAPTER 3 
 
 
CYSTEINE ALLOWS OVARIAN CANCER CELLS TO ADAPT TO 
HYPOXIA AND TO ESCAPE FROM CARBOPLATIN 
CYTOTOXICITY 
 
 
 
 
This chapter is based on the following publication: 
Nunes, S.C.; Ramos, C.; Lopes-Coelho, F.; Sequeira, C.O.; Silva, F.; Gouveia-Fernandes, S.; 
Rodrigues, A.; Guimarães, A.; Silveira, M.; Abreu, S.; et al. Cysteine allows ovarian cancer 
cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Sci Rep. 2018;8:9513–
29. 
 
“And who by fire, who by water, 
Who in the sunshine, who in the night time, 
Who by high ordeal, who by common trial, 
Who in your merry merry month of may, 
Who by very slow decay, 
And who shall I say is calling? 
And who in her lonely slip, who by barbiturate, 
Who in these realms of love, who by something blunt, 
And who by avalanche, who by powder, 
Who for his greed, who for his hunger, 
And who shall I say is calling? 
And who by brave assent, who by accident, 
Who in solitude, who in this mirror, 
Who by his lady's command, who by his own hand, 
Who in mortal chains, who in power, 
And who shall I say is calling?” 
  Leonard Cohen 
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ABSTRACT 
 
In the last 30 years, an improvement of the overall survival of ovarian cancer patients has 
been observed. However, an increased cure rate was not, and ovarian cancer is still the third 
most common gynaecologic malignancy and the main cause of death from gynaecologic 
cancer. The high mortality associated with ovarian cancer is mainly due to late diagnosis and 
resistance to treatment, barring ovarian cancer cure. Several studies have reported a role of 
cysteine in cancer by contributing for hydrogen sulphide (H2S) generation and as a precursor 
of the antioxidant glutathione (GSH). In the chapter two, our results supported a role of 
cysteine in a fast response and adaptation to hypoxic conditions that, in turn, were capable of 
driving chemoresistance. 
 In here, we aimed to deepen the role of cysteine in hypoxia and anti-cancer drugs 
response, by addressing if cysteine has a widespread protective effect in ovarian cancer cells. 
We also explored cysteine role in a clinical context of ovarian cancer patients. Hence, we 
used several ovarian cancer cell lines: ES2, OVCAR3, OVCAR8, A2780 and A2780cisR (a 
cisplatin resistant variant). In addition, we also quantified cysteine in peripheral blood serum 
from patients with ovarian tumours (benign and malignant) and healthy individuals, in 
samples from ovarian tumours with different histologies and in ascitic fluid derived from 
patients with advanced ovarian cancer, an important component of disseminated ovarian 
cancer cells microenvironment.  
Results have shown that cysteine presents a widespread protective effect against hypoxia 
and carboplatin-induced death among ovarian cancer cell lines. Interestingly, while cysteine 
was able to protect A2780 cisR cell line from carboplatin-induced death, it was not able to 
protect A2780 parental cells, supporting that cysteine is crucial for chemoresistance. 
Importantly, our data regarding peripheral blood serum and ascitic fluid from patients also 
pointed to a role of cysteine in a clinical context of ovarian cancer. Hence, data have shown 
that GSH degradation and subsequent cysteine recycling pathway were associated with 
ovarian cancer. Moreover, the levels of S-cysteinylated proteins together with the free levels 
of cysteine in serum were capable of distinguishing serum from patients with malignant 
tumours from patients with benign tumours and healthy individuals. Cysteine was also the 
prevalent thiol found in ascitic fluid from patients with advanced disease. 
Herein, this chapter strongly reinforces that cysteine contributes for a worse disease 
prognosis, allowing a faster adaptation to hypoxia and protecting ovarian cancer cells from 
carboplatin-induced death. Moreover, data also support a clinical relevance of cysteine, 
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where serum cysteine levels could be an effective tool for screening, early diagnosis, 
outcome prediction and follow up of disease progression. 
 
KEYWORDS 	  
Cancer, chemoresistance, cysteine, hypoxia, metabolism, ovarian, tumour, ascitic fluid, 
protein-S-cysteinylation, thiols. 
 
 
INTRODUCTION 
 
Ovarian cancer includes different diseases [1] and constitute the main cause of death 
from gynaecologic cancer, being the third most common gynaecologic malignancy 
worldwide [2]. The diagnosis at an advanced stage together with resistance to conventional 
therapy, are the main causes of ovarian cancer poor prognosis [3]. Epithelial ovarian cancer 
(EOC) is classified based on histopathology and molecular genetic features, being the high-
grade serous (HG-OSC) the most prevalent histotype [3,4,5,6]. The OCCC is a rather 
uncommon histotype that is highly chemoresistant [7]. Surgery and a combined paclitaxel-
carboplatin chemotherapy is the standard care for ovarian cancer [8]. However, despite an 
initial response, the disease recurs in over 85% of cases with advanced ovarian cancer [9]. 
The development of ascites is a common characteristic of these carcinomas [10], containing 
growth factors secreted by both cancer and stromal cells [10] that are mitogenic to cancer 
cells, contributing for an ideal microenvironment for tumour growth [11,12]. 
Metabolism reprogramming, already considered as an emerging hallmark of cancer [13], 
provides enough sources of energy and biomass to support cancer cell survival and 
proliferation [14].  
Expanding evidence exists on the dependence of these processes on cysteine and its 
metabolism, as cysteine not only contributes to hydrogen sulphide (H2S) generation [15–20], 
as it is the rate-limiting precursor for glutathione (GSH) synthesis [21–23]. It is known that 
tumours are subjected to intermittent hypoxia [24,25] and that hypoxia-inducible factors 
(HIFs) mediate adaptive pathophysiological responses underlying resistance to radiation 
therapy and chemotherapy [26]. In the context of ovarian cancer, Cutter et al., have recently 
reported that cancer cell lines subject to hypoxia exhibit a more aggressive phenotype [27]. 
Additionally, higher levels of cytoplasmic thiol-containing species, including GSH or 
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metallothioneins have been associated with resistance to platinum-based chemotherapy 
[23,28]. These species are rich in cysteine and result in decreased drug availability and 
increased intracellular drug detoxification/inactivation, since platinum binds readily to 
sulphydryl groups [29].  
In the previous chapter, our results supported a role of cysteine in ovarian cancer cells 
fast response and adaptation to hypoxic conditions that, in turn, were capable to drive 
chemoresistance. In here, we aimed to deepen the role of cysteine in hypoxia and anti-cancer 
drugs response, by addressing if cysteine has a widespread protective effect in ovarian cancer 
cells. Hence, we used several ovarian cancer cell lines, including high grade serous 
carcinoma (OVCAR3 and OVCAR8, HG-OSC), sensitive and resistant to Cisplatin A2780, 
unspecified histotype ovarian carcinoma cells (A2780 parental and A2780 cisR) and clear 
cell carcinoma cells (OCCC- ES2). In addition, we also explored the role of cysteine and 
other thiols in a clinical context of ovarian cancer, by analysing their levels in peripheral 
blood serum from patients with benign and malignant tumours, from healthy individuals, in 
samples from ovarian carcinomas and in ascitic fluid from ovarian cancer patients.  
 
MATERIAL AND METHODS 
 
Cell culture 
 
Cell lines ES2 (CRL-1978), OVCAR-3 (HTB-161) and OVCAR-8 (CVCL-1629) were 
obtained from American Type Culture Collection (ATCC). Cell line A2780 sensitive 
(93112519) and A2780 cisplatin resistant (93112517) were obtained from Sigma Aldrich. 
Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. ES2, OVCAR3 and 
OVCAR8 cell lines were cultured in DMEM (41965-039, Gibco, Life Technologies) 
supplemented with 1% FBS (S 0615, Merck), 1% antibiotic-antimycotic (AA) (P06-07300, 
PAN Biotech). A2780 parental and A2780 cisR cells were cultured in RPMI 1640 (BE12-
167F, Lonza) supplemented with 0.58 g/L of L-glutamine, 1% FBS (S 0615, Merck) and 1% 
antibiotic-antimycotic (AA) (P06-07300, PAN Biotech).  
Cells were exposed to 0.402 mM L-Cysteine (102839, Merck) and/or exposed to 
hypoxia-induced conditions with 0.1 mM cobalt chloride (CoCl2) (C8661, Sigma-Aldrich). 
Cobalt is a hypoxia mimicking agent used in in vivo [30] and in vitro [31–33] studies. 
Chemically, CoCl2 reacts with oxygen impairing its dissolution and oxygenation of aqueous 
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solutions [34] and is a way of impairing the availability of oxygen in culture media. 
Prior to any experiment, cells were synchronized under starvation (culture medium 
without FBS) for 8 h at 37°C and 5% CO2. 
 
Peripheral blood serum, tumour samples and ascitic fluid 
 
After collection, the blood was allowed to clot at room temperature, during 15–30 min. 
The clot was removed by centrifuging at 956 g for 5 min at 4°C. Serum is the resulting 
supernatant, which were preserved at -80°C. 
The tumours samples were frozen with isopentane and preserved at -80°C. 
After collection of the ascitic fluid, it was centrifuged at 153 g for 2 min at room 
temperature, to remove the cells, avoiding cell lysis. The supernatant was preserved at -80°C. 
The serum and ascitic fluid samples were collected from different individuals, with the 
exception of four serum and ascitic fluid samples, in which the patients were the same. The 
levels of thiols were determined in these biological samples, as described below. 
 
Cell death analysis 
 
Cells (5×105 cells/well) were seeded in 6-well plates and cultured in control condition 
and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.1 mM (CoCl2). Cells 
were collected at 16 h and 24 h after stimulation. 
To test whether the protective effect of cysteine in ES2 and OVCAR3 cells is dose-
dependent, cells (5×105 cells/well) were seeded in 6-well plates and cultured in control 
condition and exposed to 0.1 mM, 0.2 mM, 0.4 mM, 0.8 mM and 1.0 mM L-cysteine and/or 
hypoxia induced with 0.1 mM CoCl2. Cells were collected at 16 h after stimulation. 
To test whether the protective effect of cysteine under hypoxia was dependent on initial 
cell density, 5×103, 2.5×104, 5×104 and 1×105 cells/cm2 were seeded in 24-well plates and 
cultured in control condition and exposed to 0.402 mM L-cysteine and/or hypoxia induced 
with 0.1 mM CoCl2. Cells were collected at 16 h after stimulation. 
Cells were harvested and centrifuged at 153 g for 3 min, followed by incubation with 
1µL FITC-annexin V (640906, BioLegend) in 100 µL annexin V binding buffer 1× (10 mM 
HEPES (pH 7.4), 0.14 M sodium chloride (NaCl), 2.5 mM calcium chloride (CaCl2) and 
incubated at room temperature in the dark for 15min. After incubation, samples were rinsed 
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with 0.1% (w/v) BSA (A9647, Sigma) in PBS 1× and centrifuged at 153 g for 3 min. Cells 
were suspended in 200 µL of annexin V binding buffer 1× and 5 µL propidium iodide (PI) 
(50 µg/mL). Acquisition was performed with a FACScalibur (Becton Dickinson). Data were 
analysed with FlowJo software. 
 
Mitochondrial membrane potential (MMP) 
 
The MMP was measured in ES2 and OVCAR3 cell lines using JC-1 (M34152, Molecular 
Probes, Life Technologies) [35], a specific mitochondrial probe, which becomes red when it 
enters polarized mitochondria and it is green in cytoplasm when mitochondrial potential is 
lost avoiding its entrance. 
Cells (5×105 cells/well) were seeded in 6-well plates and cultured in control condition 
and exposed to 0.402 mM L-cysteine and/or 0.1 mM CoCl2 and were collected at 16 h after 
stimulation. Live cells were then washed with phosphate-buffered saline (PBS) 1x, incubated 
for 30 min with 5 µM JC-1 (37°C, 5% CO2), washed with PBS 1x, trypsinized, and recovered 
in a final volume of 300 µL of PBS 1x. A positive depolarized control was used, in which 
cells were previously incubated with 50 µM CCCP for 5 min (37°C, 5% CO2) and then 
incubated with JC-1. Acquisition was performed in a FACScalibur (Becton Dickinson). Data 
were analysed with FlowJo software. 
 
Cells response to paclitaxel and carboplatin  
 
Cells (1×105cells/well) were seeded in 24-well plates and cultured in control condition 
and exposed to 0.402 mM L-cysteine and/or 0.1 mM CoCl2. Cells were also exposed to the 
previous conditions combined with carboplatin 25 µg/mL, paclitaxel (10 µg/mL) or the 
combination of both. Cells were collected after one cycle of stimulation (16 h per cycle) and 
two cycles of stimulation (which was preceded by a period without drugs of proximately 32 h 
between cycles). Cell death analysis was performed. 
 
CD133 quantification 
 
Cells (2×105cells/well) were seeded in 12-well plates (ES2, OVCAR3 and OVCAR8) or 
24-well plates (1 × 105 cells/well) (A2780 and A2780 cisR) and cultured in control condition 
and exposed to 0.402 mM L-cysteine and/or 0.1 mM CoCl2. Cells were also exposed to the 
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previous conditions combined with carboplatin 25 µg/mL. Cells were collected after one 
cycle of stimulation (16 h per cycle) and two cycles of stimulation (which was preceded by a 
period without drugs of proximately 32 h between cycles). Cells were collected with PBS 1x-
EDTA 2 mM, centrifuged at 153 g for 3 min, re-suspended and incubated with 1 µL of anti-
CD133 (AC133-PE human, Miltenyi Biotec) and 99 µL PBS-BSA 0.1% for 20 min in the 
dark 4°C. Acquisition was performed in a FACScalibur (Becton Dickinson). Data were 
analysed with FlowJo software. 
 
Thiols quantification 
 
Because thiols can impact protein function by the formation of intra- and inter-molecular 
disulfide bond(s) with proteins [36], or may exist as free thiols, we measured both total and 
free thiol levels. 
Thiols quantification was performed by high-performance liquid chromatography 
(HPLC). Cells (4×106) were cultured in 75 cm2 tissue culture flasks in control conditions and 
exposed either to 0.402 mM L-cysteine and/or 0.1 mM CoCl2 for 16 h. The supernatants and 
the lysates were stored at −80°C. The assessment of the levels of cysteine (Cys), 
homocysteine (HCys), glutamylcysteine (GluCys), glutathione (GSH) and cysteinylglycine 
(CysGly) was performed according to Grilo and co-authors [37] and adapted to cell culture. 
The detector was set at excitation and emission wavelengths of 385 and 515 nm, respectively. 
The mobile phase consisted of 100 mM acetate buffer (pH 4.5) and methanol [98:2 (v/v)]. 
The analytes were separated in an isocratic elution mode for 20 min, at a flow rate of 0.6 
mL/min. The thiolomic profile was also quantified in peripheral blood serum from healthy 
individuals and patients with malignant and benign ovarian tumours and in ascitic fluid from 
patients with ovarian cancer, according to Grilo et al. [37].  
Serum samples from 12 healthy donors, 25 from patients with benign ovarian tumours 
and 30 from patients with malignant ovarian tumours were analysed. 
Primary ovarian tumours were also analysed in a total of 12 samples, including high 
grade serous ovarian carcinomas before (n=3) and after chemotherapy (n=3), clear cell 
carcinomas (n=3) and endometrioid carcinomas (n=3). 
Finally we also collected ascitic fluid samples and 41 samples were analysed, with 
patients diagnosed with ovarian cancer: serous, (n=32), mucinous (n=3), endometrioid (n=1) 
and without further histotype characterization (n=5). 
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Statistical analysis  
 
Data are presented as the mean ± SD and all the graphics were done using the PRISM 
software package (PRISM 6.0 for Mac OS X; GraphPad software, USA, 2013). Assays were 
performed with, at least, 3 replicates per experimental condition. For comparisons of two 
groups, two-tailed independent-samples T-test was used. For comparison of more than two 
groups, One-way analysis of variance (ANOVA) with Tukey’s multiple-comparisons post 
hoc test was used. To assess the existence of a linear relationship between two variables, two-
tailed Pearson correlation was used. To assess differences in cysteine and GSH levels in 
peripheral blood, in samples from ovarian tumours and in ascitic fluid, 2-sided independent 
samples Kruskal-Wallis 1-way ANOVA with pairwise comparisons was performed, where 
the adjusted significance was considered. Statistical significance was established as p<0.05. 
All statistical analyses were performed using the IBM Corp. Released 2013. IBM SPSS 
Statistics for Macintosh, Version 22.0. Armonk, NY: IBM Corp. software. 
 
Study approval 
 
All the experiments were developed according to relevant guidelines and regulations.  
The human samples were collected under informed consent of patients and blood donors 
from Instituto Português de Oncologia de Lisboa, Francisco Gentil, EPE. The study protocol 
was approved by the Ethical Committee IPOLFG (references: UIC/1080 and UIC/1082).  
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RESULTS 
 
Cysteine has a widespread protective effect under hypoxia in ovarian cancer cells  
 
We started by addressing if the protective effect of cysteine against hypoxia-induced 
death is widespread in several ovarian cancer cell lines.  
Results have shown that cysteine protected ES2 cells from death under hypoxia after 16 h 
(p=0.026) (figure 1A), but the effect was not maintained after 24 h (figure 1 A). Regarding 
OVCAR3 cells, no differences were found in total cell death levels in both time-points 
(figure 1 B).  
The effect of normoxia with cysteine and hypoxia without cysteine in total cell death was 
similar between cell lines. However, there was no similarity for the effect of hypoxia plus 
cysteine on cell death in ES2 and OVCAR3 cells (p=0.049). As observed, ES2 cells 
presented lower death levels compared to its control than OVCAR3 cells (figures 1 A and B). 
With 24 h of incubation under normoxia, cysteine induced higher levels of cell death in 
OVCAR3 cells compared to ES2 cells (p=0.001). However under hypoxia, there were no 
significant differences among cell lines.  
Next, we addressed the long-term effect of cysteine in ovarian cancer cells, also 
clarifying if the absence of protection by cysteine under hypoxia with 24 h of assay in ES2 
was due to cysteine consumption or CoCl2 exhaustion. The exposure of ES2 cells to two 
experimental cycles revealed a significant decrease in total cell death levels in all conditions 
from the first to the second cycle (p=0.000 for N, NC and HC), with the exception of hypoxia 
without cysteine (figure 1 C). No major alterations were registered from the first to the 
second cycle in total cell death for OVCAR3 cell line with the exception of total cell death 
under hypoxia without cysteine, in which cell death levels increased from the first to the 
second cycle (p<0.001; figure 1 D).  
We also investigated the effect of cysteine in the adaptation to hypoxia in other ovarian 
cancer cell lines. In OVCAR8 cell line, total cell death levels increased from the first to the 
second cycle under hypoxia, especially without cysteine, with no differences under normoxia 
conditions (under H p<0.001, under HC p=0.020) (figure 1 E). Nonetheless, in the second 
cycle, cysteine revealed to be also advantageous for this cell line (H vs HC p<0.001). 
We also addressed if cysteine impacts differently the adaptive potential to hypoxia in 
sensitive and cisplatin resistant A2780 cells. Under hypoxia, both A2780 and A2780 cisR cell 
lines presented increased cell death levels in the second cycle of culture without cysteine and 
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A2780 cisR with cysteine (A2780 cells p<0.001; A2780 cisR cells p<0.001under H and HC). 
Nevertheless, cysteine revealed to be advantageous under hypoxia in the second cycle for 
both cell lines (H vs HC for A2780 parental cells p<0.001, for A2780 cisR cells p<0.001) 
(figure 1 F and G). 
These results support that different ovarian cancer cells present different abilities to 
metabolise cysteine. Moreover, results have shown a widespread protective effect of cysteine 
upon hypoxic stress in ovarian cancer cells from different histological types. 
 
Figure 1. Cysteine has a widespread protective effect under hypoxia in ovarian cancer cells. 
Total cell death normalised to control for 16 and 24 h of assay for A. ES2 cells and B. OVCAR3 cells 
and total cell death in the first cycle (C1) and in the second cycle (C2) of treatments in C. ES2, D. 
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OVCAR3, E. OVCAR8, F. A2780 parental cells and G. A2780 cisR cells. N - Normoxia; NC - 
Normoxia supplemented with cysteine; H - Hypoxia; HC - Hypoxia supplemented with cysteine. Results 
are shown as mean ± SD. Cardinals (#) represent statistical significance among hypoxia with and without 
cysteine supplementation within the same cycle of treatments.*p<0.05, **p<0.01, ***p<0.001 (One-way 
ANOVA with post hoc Tukey tests). 
 
 
The protective effect of cysteine under hypoxia in ES2 is dose-dependent and cell 
density-dependent 
 
Because so far results have pointed to a strong protective effect of cysteine under 
hypoxia for ES2 cells, we further asked if this protection was cysteine dose-dependent or cell 
density-dependent.  
To test if the protection provided by cysteine under hypoxia was dose-dependent, we 
performed an assay under normoxia and hypoxia without cysteine and with increasing 
cysteine concentrations and compared the cell death levels with OVCAR3 cells.  
Results have shown that while there were no dose-dependence effects in ES2 under 
normoxia (figure 2 A), cell death decreased under hypoxia with increasing cysteine 
concentrations (Pearson r=-0.777, p<0.001) (figure 2 B).  
Regarding OVCAR3 cells, there was no correlation between cell death and cysteine 
concentration neither under normoxia nor under hypoxia (figure 2 C and D). 
To test if this protective effect of cysteine under hypoxia in ES2 cells was dependent on 
cell density, several initial cell densities were tested. In a general way, results showed a 
decreased cell death trend with increased cell density (p<0.001 for all conditions) (figure 2 
E). Moreover, results suggested that the protective effect of cysteine under hypoxia was 
dependent on cell density, as demonstrated by the decreased cell death ratio HC/H with the 
increase of cell density (Pearson r=-0.628, p=0.003) (figure 2F) whereas cell density did not 
impact on the cell death ratio NC/N (figure 2 F).   
Regarding OVCAR3 cells, the results also showed lower levels of cell death with higher 
cell densities in all conditions (p=0.004), with the exception of the control (figure 2 G). 
However, there was no impact of cell density neither on the NC/N nor on the HC/H ratios 
(figure 2 H). 
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Figure 2. The dose dependent and cell density dependent effects of cysteine in hypoxia adaptation 
in ES2 and OVCAR3 cells. 
A. Pearson correlation under normoxia for ES2 cell line, B. Pearson correlation under hypoxia for ES2 
cell line, C. Pearson correlation under normoxia for OVCAR3 cell line and D. Pearson correlation under 
hypoxia for OVCAR3 cell line for 16 h of assay. Treatments were normalised to the control values 
(normoxia without cysteine supplementation). E. Percentage of total cell death for ES2 cells for 16 h of 
assay for different initial cell densities, F. Pearson correlation for NC/N and HC/H ratios for ES2 cells, 
G. Percentage of total cell death for OVCAR3 cells for 16 h of assay for different initial cell densities 
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and H. Pearson correlation for NC/N and HC/H ratios for OVCAR3 cells. N – Normoxia; NC – 
Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented with cysteine. 5×103, 
2.5×104, 5×104 and 1×105 refers to initial cell densities expressed as cells/cm2. Results are shown as 
mean ± SD. 
 
 
Cysteine increases mitochondrial membrane potential in ES2 under normoxia and in 
OVCAR3 under normoxia and hypoxia 
 
Mitochondrial membrane potential (Δψm) is associated with ATP production by 
oxidative phosphorylation, being a good indicator of cells health and functional status[38]. 
Δψm changes can be measured by red/green fluorescence intensity ratio using JC-1 probe, in 
which Δψm loss can be detected by a decrease in this ratio. 
For ES2 cells, the Δψm loss was lower under N plus cysteine (NC) compared to the other 
conditions (p=0.005 compared to N, p<0.001 compared to H and p=0.001 compared to HC) 
(figure 3). However, there were no differences among hypoxia with and without cysteine.  
Regarding OVCAR3 cells, the Δψm loss was always lower in the presence of cysteine 
(NC vs N p=0.002, NC vs H p=0.024, HC vs N p<0.001 and HC vs H p=0.002) (figure 3). 
Together, results suggest that cysteine allows mitochondrial function and cell health, 
especially under normoxia for ES2 cells and both under normoxia and hypoxia for OVCAR3 
cells. 
 
Figure 3. Mitochondrial membrane potential under normoxia and hypoxia with and without 
cysteine in ES2 and OVCAR3 cells. 
Quantification of Δψm expressed as a ratio of red/green fluorescence intensity ratio in the different 
treatments (ratio of geometrical means) for ES2 and OVCAR3 cell lines for 16 h of assay. CCCP is a 
positive control for depolarization. N – Normoxia; NC – Normoxia supplemented with cysteine; H – 
Hypoxia; HC – Hypoxia supplemented with cysteine. Results are shown as mean ± SD. *p<0.05, 
**p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
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ES2 cells adaptation to hypoxia relies on free intracellular cysteine availability  
 
We then asked if ES2 and OVCAR3 cells presented different capacities to uptake 
cysteine and whether the dynamics of GSH synthesis and degradation could explain the 
protective effect of cysteine under hypoxia. For this, the free fraction and the protein-bound 
fraction of several thiols were measured. 
Results have shown that ES2 cells present higher free intracellular levels of cysteine in 
all treatments than OVCAR3 cells (p=0.001 in N, p<0.001 in NC, p=0.003 in H, p<0.001 in 
HC) (figure 4 A). Also, cysteine supplementation induced higher free intracellular levels of 
cysteine both under normoxia (p=0.001) and hypoxia (p=0.008) in ES2 cells. This result 
supports that hypoxia did not impair ES2 cells capacity to uptake this amino acid or that in 
these cells cysteine is not channelled for protein-S-cysteinylation pool or to de novo GSH 
synthesis. 
Thus, we asked how S-cysteinylated proteins (CysSSP) were comparable between the 
two cell lines. We observed that hypoxia reduced CysSSP in ES2 cells (p=0.02, for N vs H, 
p=0.037 for N vs HC, p=0.009 for NC vs H and p=0.016 for NC vs HC) (figure 4 B). This 
might suggest that this intracellular pool of cysteine is reduced to supply free cysteine for 
cells adaptation to hypoxia. In fact, CysSSP was not increased by cysteine under hypoxia, 
indicating the need of free cysteine availability and that the supplemented cysteine is not 
targeting proteins by S-cysteinylation.  
We then tried to clarify if the protection provided by cysteine under hypoxia was 
associated with GSH synthesis or degradation. In ES2 cells, no changes were observed 
neither for GSH intracellular levels among the experimental conditions (figure 4 C), nor for 
GluCys, the first product of GSH synthesis, even with supplementation of cysteine (figure 
4D), indicating that ES2 cells maintain high levels of available cysteine that are not being 
canalized to GSH synthesis. Moreover, in hypoxia conditions, the supplementation of 
cysteine increased GSH catabolism and cysteine recycling, as seen by the increased ratio 
CysGly/GSH, being CysGly the first product of GSH degradation. Thus, hypoxia decreased 
CysSSP levels supplying free Cys levels (figure 4 B). Cysteine supplementation under 
hypoxia led to increased intracellular pool of free Cys (figure 4 A) and the recycling of 
cysteine through GSH catabolism (figure 4 F). In accordance, the protective effect of cysteine 
under hypoxia was dependent on its concentration, indicating that intracellular pool of free 
cysteine in ES2 plays an important role in adaptation to hypoxia.  
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A different scenario was observed in OVCAR3. This cell line presented lower 
intracellular levels of cysteine than ES2 and the supplementation of cysteine did not have any 
effect on its free intracellular levels (figure 4 A). This might suggest an alteration in cysteine 
import or that imported cysteine is being channelled for CySSP pool or GSH synthesis. In 
fact, in this cell line, hypoxia did not change CysSSP but cells exposed to cysteine 
supplementation under hypoxia presented increased CysSSP levels (p=0.032 compared to N 
and p=0.038 compared to H) (figure 4 B). Also, under hypoxia with cysteine, ES2 cells 
presented lower levels of S-cysteinylated proteins (CysSSP) than OVCAR3 cells (p=0.030) 
(figure 4 B). Moreover, the recycling of cysteine through GSH catabolism is much lower in 
OVCAR3 cells compared to ES2, as evaluated by the ratio CysGly/GSH (p<0.001) (figure 4 
F). Together, results suggest that OVCAR3 are not so dependent on free cysteine levels as 
ES2 cells on coping with hypoxia.  
 
Figure 4. ES2 cells adaptation to hypoxia relies on free intracellular cysteine availability. 
Quantification of Δψm expressed as a ratio of red/green fluorescence intensity ratio in the different 
treatments (ratio of geometrical means) for ES2 and OVCAR3 cell lines for 16 h of assay. CCCP is a 
positive control for depolarization. N – Normoxia; NC – Normoxia supplemented with cysteine; H – 
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Hypoxia; HC – Hypoxia supplemented with cysteine. Results are shown as mean ± SD. *p<0.05, 
**p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
 
Cysteine and hypoxia have a role on the response of ovarian cancer cells to carboplatin  
 
Usually, ovarian cancer therapy protocols include platinum salts and taxanes [8]. 
However, we tested paclitaxel with and without carboplatin and no relevant alterations were 
found related to hypoxia (figure 5). Under normoxia, it was only observed an increased cell 
death due to paclitaxel in the presence of cysteine in the first cycle of ES2 cells exposure to 
drugs (figure 5). So, the experimental course was developed using only carboplatin, as 
chemically thiols react directly with platinum salts (oxidative compounds) and under hypoxia 
a protective effect was noticed mainly in ES2 cells. 
 
Figure 5. Effect of cysteine and hypoxia in ES2 and OVCAR3 cells response to paclitaxel alone or 
in combination with carboplatin. 
Percentage of cell death levels in the presence of paclitaxel for A. ES2 cells and B. OVCAR3 cells, and 
in the presence of paclitaxel in combination with carboplatin for C. ES2 cells and D. OVCAR3 cells. 
N – Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented 
with cysteine. Results are shown as mean ± SD. The asterisks (*) represent statistical significance among 
cycles of treatments and cardinals (#) represent statistical significance compared to the control 
(normoxia) within the same cycle of treatments..*p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA 
with post hoc Tukey tests). 
 
Herein, we addressed the role of hypoxia and cysteine in ovarian cancer cells response 
and adaptation to carboplatin, by exposing cells to two cycles of carboplatin and assessing the 
effects on cell death from the first to the second cycle of drug exposure. 
C1 C2 C1 C2 C1 C2 C1 C2
0
50
100
To
ta
l c
el
l d
ea
th
 (%
)
ES2 - paclitaxel
N H HCNC
*** *** *** ***
##
C1 C2 C1 C2 C1 C2 C1 C2
0
50
100
To
ta
l c
el
l d
ea
th
 (%
)
ES2 - carboplatin+paclitaxel
N H HCNC
*** *** *** ***
##
C1 C2 C1 C2 C1 C2 C1 C2
0
20
40
60
80
100
To
ta
l c
el
l d
ea
th
 (%
)
OVCAR3 - paclitaxel
N H HCNC
*** *** *** ***
C1 C2 C1 C2 C1 C2 C1 C2
0
20
40
60
80
100
To
ta
l c
el
l d
ea
th
 (%
)
OVCAR3 - carboplatin+paclitaxel
N H HCNC
*** *** *** ***
A. B.
C. D.
	   	  
	   84	  
With one cycle of carboplatin, no differences were found among treatments in ES2 cells 
(figure 6 A). Regarding the effect of two cycles of carboplatin, it was possible to observe 
differences among treatments (p=0.002). Results showed that cysteine protected cells from 
carboplatin-induced death both under hypoxia and normoxia (p=0.008 in H and p=0.015 in 
N) (figure 6 A). When analysing the alterations in ES2 total cell death in consecutive cycles, 
results showed that carboplatin induced higher cell death at the second cycle only in the 
absence of cysteine treatment (p<0.001 for N and H) (figure 6 A). This result suggests that 
for ES2 cells, cysteine is not advantageous under hypoxia but also allows faster adaptation to 
carboplatin both under normoxia and hypoxia. 
In OVCAR3 cells (figure 6 B), with one cycle of carboplatin there were no differences 
among treatments in cell death levels. However, with two cycles, there were differences 
among conditions (p=0.001), in which cell death levels were lower under H supplemented 
with cysteine compared to the other treatments (p=0.007 compared to N; p=0.003 compared 
to NC and p=0.001 compared to H). Regarding changes from the first to the second cycle of 
carboplatin in OVCAR3 cells, there was an increase in total cell death in all treatments in the 
second cycle (p<0.001) (figures 6 B). In this cell line, under hypoxia, cysteine protected cells 
from death in the second cycle of carboplatin (p=0.001). Nevertheless, total cell death was 
higher in this cycle compared to the first one (p<0.001). Under normoxia, cysteine did not 
confer any advantage for cells in the presence of carboplatin in the second cycle. 
We also asked the effect of hypoxia and cysteine in other ovarian cancer cell lines 
response to carboplatin. For OVCAR8 cells, no differences were observed with one cycle of 
carboplatin exposure among experimental conditions (figure 6 C). However, with two cycles, 
hypoxia was especially disadvantageous without cysteine for OVCAR8 cells (N vs H 
p<0.001, NC vs H p<0.001, N vs HC p=0.041, H vs HC p<0.001). When analysing the 
alterations in total cell death levels from the first to the second cycle in OVCAR8 cells, 
increased levels were observed under hypoxia with and without cysteine (under H and HC 
p<0.001), without significant differences under normoxia (figure 6 C). Nevertheless, cysteine 
was advantageous under hypoxia in the second cycle (H vs HC p<0.001). 
For A2780 parental cells, in the first cycle, no differences were observed among 
treatments in the presence of carboplatin. In the second cycle of experimental conditions, 
increased cell death levels were observed under hypoxia with cysteine (p=0.02) compared to 
normoxia with cysteine. When analysing the alterations in total cell death levels from the first 
to the second cycle, results showed an increased cell death between cycles in all the 
treatments (figure 6 D).  
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Regarding A2780 cisR cells, in the first cycle it was observed increased cell death levels 
under hypoxia with and without cysteine supplementation compared to the control and to 
normoxia with cysteine (N vs H p=0.001, N vs HC p=0.005, NC vs H p=0.007 and NC vs 
HC p=0.026), with no differences in the other conditions (figure 6 E). In the second cycle, 
hypoxia was disadvantageous for these cells, especially without cysteine (N/NC vs H/HC, 
p<0.001). When analysing the alterations in total cell death levels from the first to the second 
cycle, results showed increased cell death levels only under hypoxia, both with (p<0.001) and 
without (p<0.001) cysteine (figure 6 F). Nevertheless, cysteine was advantageous in the 
second cycle of experimental conditions for A2780 cisR under hypoxia also in the presence 
of carboplatin (H vs HC, p<0.001), in contrast to A2780, the parental cell line. 
Altogether, results revealed a protective effect of cysteine under hypoxia and in the 
presence of carboplatin in ovarian cancer cells from different histological types, thus 
suggesting a widespread role for cysteine in the selection of more aggressive phenotypes in 
ovarian cancer cells.  
 
Figure 6. Cysteine and hypoxia have a role on ovarian cancer cells response to carboplatin. 
Total cell death in the first (C1) and in the second (C2) cycles of treatments in the presence of 
Carboplatin for A. ES2, B. OVCAR3, C. OVCAR8, D. A2780 parental cells and E. A2780 cisR cells. N 
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– Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – Hypoxia supplemented 
with cysteine. Results are shown as mean ± SD. Cardinals (#) represent statistical significance among 
hypoxia with and without cysteine supplementation within the same cycle of treatments. *p<0.05, 
**p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
 
CD133 levels are induced upon hypoxia and carboplatin exposure in ES2, OVCAR8 
and A2780  
 
We next asked if cells resistant to hypoxia and carboplatin presented a cancer stem cell-
like phenotype.  
For that, we compared the changes in the levels of CD133 from the first cycle to the 
second cycle of treatments. 
In ES2 in a drug-free environment, the levels of CD133 were increased under hypoxia 
(figure 7) (p=0.013). Upon carboplatin exposure, from the first cycle to the second cycle, 
there was an increase in the levels of CD133 in all treatments (under N, NC, H and HC 
p<0.001) (figure 7 A).   
Interestingly, for OVCAR3 cells and in a drug-free environment, the CD133 levels 
decreased in treatments with cysteine (NC p=0.001; HC p=0.02). Upon carboplatin exposure, 
there was a decrease in CD133 levels in treatments under hypoxia (under H p=0.001; under 
HC p<0.001), with no differences among cycles in treatments under normoxic conditions 
(figure 7 B).  
Regarding OVCAR8 cells, in a drug-free environment, results showed that hypoxia 
without cysteine increased the levels of CD133 (p=0.001). Moreover, this effect was also 
observed under normoxia with cysteine supplementation (p<0.001) (figure 7 C). Upon 
carboplatin exposure, from the first cycle to the second cycle, there was an increase in CD133 
levels in all treatments (under N, NC, H and HC p<0.001) (figure 7 C).  
A2780 parental cells, in a drug-free environment, showed higher CD133 levels under 
hypoxia without cysteine (p<0.000), with no significant differences among cycles in the other 
conditions (figure 7 D). Upon carboplatin exposure, from the first cycle to the second cycle, 
an increase in CD133 levels was observed in all conditions (under N, NC, H and HC 
p<0.001) (figure 7 D). A different scenario was observed for A2780 cisR cells. In a drug-free 
environment, there was a decrease of CD133 levels from the first to the second cycle in all 
conditions (under N, NC and HC p<0.001) (figure 7 E) with the exception of hypoxia, in 
which there were no significant differences among cycles (figure 7 E). Upon carboplatin 
exposure, hypoxia without cysteine increased CD133 levels (p<0.001) from the first to the 
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second cycle. Under hypoxia with cysteine, there was a trend to increase CD133 levels 
among cycles (p=0.053) (figure 7 E).   
Together, results indicate that the levels of CD133 are not related to OVCAR3 cells 
resistance to neither hypoxia nor carboplatin, contrarily to what was observed in ES2, 
OVCAR8 and A2780 parental cells. Regarding the cisplatin resistant A2780 cisR cells, 
results point out that overall carboplatin resistance is not related to CD133 levels, only when 
combined with hypoxic stress. 
 
Figure 7. CD133 levels are induced upon hypoxia and carboplatin exposure in ES2, OVCAR8 and 
A2780. 
CD133 levels in a drug-free environment and upon carboplatin exposure for A. ES2 cells, B. OVCAR3 
cells, C. OVCAR8 cells, D. A2780 parental cells and E. A2780 cisR cells in the first and in the second 
cycles of treatments. N – Normoxia; NC – Normoxia supplemented with cysteine; H – Hypoxia; HC – 
Hypoxia supplemented with cysteine. Results are shown as mean ± SD. Asterisks (*) represent statistical 
significance among the first and the second cycle within the same treatment.*p<0.05, **p<0.01, 
***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
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All thiols but GSH are increased in patients with ovarian tumours- high GSH turnover 
 
Given the role of cysteine in the adaptation of ovarian cancer cell lines to hypoxic 
conditions and carboplatin exposure, we next assessed if higher serum levels of cysteine or 
other thiols were associated with ovarian tumours malignancy. Strikingly, total HCys levels 
were effective in distinguishing patients with malignant tumours from benign tumours and 
both of them from healthy individuals (figure 8 A). Results showed that increased total levels 
of Cys and GluCys (GSH precursor) were associated with ovarian tumours regardless 
malignancy (figure 8 B and C). Total GSH levels did not differ among groups (p>0.05) and 
CysGly (GSH degradation product) was increased in patients with malignant tumours 
compared only to healthy individuals (p=0.028) (figure 8 D and E).  
Regarding free thiol content in plasma, free HCys levels were able to distinguish patients 
with malignant tumours from benign tumours (p<0.001) and patients with benign tumours 
from healthy individuals (p=0.02) without significant differences between malignant tumours 
and healthy individuals (figure 9 A). Cys levels were increased in patients with malignant 
tumours compared to patients with benign tumours (p=0.005) but without significant 
differences compared to healthy individuals (figure 9 B). In addition, lower free GSH levels 
were associated with ovarian neoplasms regardless malignancy (p=0.006 donors vs benign 
tumours and p=0.005 donors vs malignant tumours) (figure 9 D). Free GluCys and free 
CysGly levels did not differ among groups (p>0.05) (figure 9 C and E).  
Regarding the thiol protein-bound fraction, higher levels of S-homocysteinylated proteins 
(HCysSSP) were associated with malignant ovarian tumours (p=0.019 benign vs malignant, 
p<0.001 donors vs malignant) (figure 10 A). Higher levels of S-cysteinylated, S-
glutamylcysteinylated, and S-cysteinylglycinylated proteins (CysSSP, GluCysSSP and 
CysGlySSP) were associated with ovarian neoplasms regardless malignancy (CysSSP: 
donors vs benign p<0.001, donors vs malignant p<0.001; GluCysSSP: donors vs benign 
p=0.001, donors vs malignant p<0.001; CysGlySSP: donors vs benign p=0.001, donors vs 
malignant p=0.001) (figure 10 B, C and E). No significant differences were found in the 
levels of S-glutathionylated proteins (GSSP) among groups (figure 10 D).  
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Figure 8. Total thiols in patients with ovarian tumours. 
Total thiols quantification in serum from healthy individuals (donors) and in serum from patients with 
benign and malignant ovarian tumours for A. HCys- Homocysteine, B. Cys – cysteine, C. GluCys – 
Glutamylcysteine, D. GSH – Glutathione, E. CysGly – Cysteinylglycine. Thiol concentration was 
normalised to protein concentration. Results are shown as median. The asterisks (*) represent the 
statistical significance among groups.*p<0.05, **p<0.01, ***p<0.001 (independent samples Kruskal 
Wallis One-way ANOVA with multiple comparisons). 
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Figure 9. Free total thiols in patients with ovarian tumours. 
Free total thiols quantification in serum from healthy individuals (donors) and in serum from patients 
with benign and malignant ovarian tumours for A. HCys- Homocysteine, B. Cys – cysteine, C. GluCys – 
Glutamylcysteine, D. GSH – Glutathione, E. CysGly – Cysteinylglycine. Thiol concentration was 
normalised to protein concentration. Results are shown as median. The asterisks (*) represent the 
statistical significance among groups.*p<0.05, **p<0.01, ***p<0.001 (independent samples Kruskal 
Wallis One-way ANOVA with multiple comparisons). 
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Figure 10. Thiol protein-bound fraction in patients with ovarian tumours. 
Thiols concentration bound to proteins (protein thiolation) quantification in serum from healthy 
individuals (donors) and in serum from patients with benign and malignant ovarian tumours for A. 
HCySSP – S-homocysteinylated proteins, B. CysSSP – S-cysteinylated proteins, C. GluCysSSPS – S-
Glutamylcysteinylated proteins, D. GSSP – S-glutathionylated proteins, E. CysGlySSP – S-
cysteinylglycinylated proteins. F. RSSP – total S-thiolated proteins. Thiol concentration was normalised 
to protein concentration. Results are shown as median. The asterisks (*) represent the statistical 
significance among groups.*p<0.05, **p<0.01, ***p<0.001 (independent samples Kruskal Wallis One-
way ANOVA with multiple comparisons). 
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with ovarian neoplasms, showing that patients with ovarian neoplasms present different thiol 
dynamics. Moreover, with the exception of GSH, thiols were mainly in the protein bound 
form and not free in serum from patients with ovarian tumours compared to healthy 
individuals.  
Noticeably, total CysSSP was capable of distinguishing serum of healthy blood donors 
from patients with ovarian tumours (benign and malignant) and total free Cys levels 
distinguished serum of patients with malignant tumours from patients with benign tumours. 
Together, data supports that cysteine, free levels together with the protein- bound fraction, 
are suitable markers for ovarian cancer allowing the development of a screening method to 
contribute for the screening and early diagnosis of this disease. 
 
 
Cysteine levels tend to be increased in clear cell carcinomas (OCCC) and endometroid 
carcinomas (OEC) and after chemotherapy in high grade serous carcinomas (HG-OSC) 	  
We have also measured thiols levels in tumour samples from different ovarian cancer 
types. No significant differences were observed among the different histological types of 
carcinomas in total thiols concentration (figure 11), nor in free total thiols (figure 12) nor in 
thiols concentration bound to proteins (figure 13). However, in HG-OSC, total and free total 
homocysteine and cysteine levels tended to increase after chemotherapy. Moreover, 
HCysSSP levels also tended to increase following chemotherapy, whereas CysSSP tended to 
decrease. Importantly, the total and free total levels of cysteine and CysGly tended to be 
higher OCCC and OEC compared to HG-OSC.  	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Figure 11. Total thiols in different ovarian carcinomas. 
Total thiols quantification in high grade serous carcinoma before chemotherapy (HG-OSC, n=3) and 
after chemotherapy (HG-OSC After CT, n=3), clear cell carcinoma (CCC, n=3) and endometrioid 
carcinoma (OEC, n=3) for A. HCys- Homocysteine, B. Cys – cysteine, C. GSH – Glutathione, and D. 
CysGly – Cysteinylglycine. Thiol concentration was normalised to protein concentration. Results are 
shown as median. Independent samples Kruskal Wallis One-way ANOVA with multiple comparisons 
were performed. 
 
	  
Figure 12. Free total thiols in different ovarian carcinomas. 
Free total thiols quantification in high grade serous carcinoma before chemotherapy (HG-OSC, n=3) and 
after chemotherapy (HG-OSC After CT, n=3), clear cell carcinoma (CCC, n=3) and endometrioid 
carcinoma (OEC, n=3) for A. HCys- Homocysteine, B. Cys – cysteine, C. GSH – Glutathione and D. 
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CysGly – Cysteinylglycine. Thiol concentration was normalised to protein concentration. Results are 
shown as median. Independent samples Kruskal Wallis One-way ANOVA with multiple comparisons 
were performed. 	  
	  
Figure 13. Thiol protein-bound fraction in different ovarian carcinomas. 
Thiols concentration bound to proteins (protein thiolation) quantification in high grade serous carcinoma 
before chemotherapy (HG-OSC, n=3) and after chemotherapy (HG-OSC After CT, n=3), clear cell 
carcinoma (CCC, n=3) and endometrioid carcinoma (OEC, n=3) for A. HcySSP – S-homocysteinylated 
proteins, B. CysSSP – S-cysteinylated proteins, C. GSSP – S-glutathionylated proteins, D. CysGlySSP – 
S-cysteinylglycinylated proteins and E. RSSP – total S-thiolated proteins. Thiol concentration was 
normalised to protein concentration. Results are shown as median. Independent samples Kruskal Wallis 
One-way ANOVA with multiple comparisons were performed. 	  
 
Cysteine is the prevalent thiol found in ascitic fluid from patients with advanced 
ovarian cancer  
 
As the ascitic fluid is an important component of ovarian tumour cells microenvironment, 
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patients with ovarian cancer. Results have shown that cysteine was the most prevalent thiol in 
the three pools, total (figure 14 A), free (figure 14 B) and S-cysteinylated proteins (figure 14 
C). HCys was mainly present bound to proteins, sequentially followed by Cys and CysGly, 
and then by GluCys and GSH (figure 14 D). 
As the prevalent thiol in the ascitic fluid, cysteine might promote an ideal tumour 
microenvironment for cancer cells, possibly acting both as a redox buffer and as a modifier of 
proteins, mediating the adaptation or abrogating the effect of platinum salts, such as 
carboplatin. 
 
Figure 14. Cysteine is the prevalent thiol in ascitic fluid from patients with ovarian cancer. 
Thiols quantification in ascitic fluid from patients with ovarian cancer. A. Total thiols concentration. B. 
Free total thiols concentration. C. Thiols concentration bound to proteins. D. Percentage of thiols 
concentration bound to proteins. Cys – cysteine, HCys- Homocysteine, CysGly – Cysteinylglycine, 
GluCys – Glutamylcystein, GSH – Glutathione, CysSSP – S-cysteinylated proteins, HcySSP – S-
homocysteinylated proteins, CysGlySSP – S-cysteinylglycinylated proteins, GluCysSSPS – 
Glutamylcysteinylated proteins, GSSP – S-glutathionylated proteins, RSSP – total S-thiolated proteins. 
Thiol concentration was normalised to protein concentration. Results are shown as median. The asterisks 
(*) represent the statistical significance in relation to Cysteine concentration. *p<0.05, **p<0.01, 
***p<0.001 (independent samples Kruskal Wallis One-way ANOVA with multiple comparisons). 
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DISCUSSION 
 
Although the outcome and prognosis of different histological types of ovarian cancer had 
been a matter of debate, it was shown that patients with OCCC present a significantly worse 
prognosis than patients with serous carcinoma when matched for age, stage, and level of 
primary cytoreduction [39]. In 2011, Lee et al. also shown that OCCC patients presented a 
poorer prognosis than those with other histological subtypes of carcinoma, especially in 
advanced stages [40]. Moreover, while OCCC show intrinsic resistance to conventional 
platinum-based chemotherapy, HG-OSC usually exhibit first sensitiveness to platinum-based 
chemotherapy, though the majority of cases develop chemoresistance during the course of 
treatment [41,42].  
The present work supports a widespread protective effect of cysteine both under 
carboplatin and hypoxia exposure, indicating that cysteine has a role in ovarian cancer cells 
survival in adverse environments. However, differences were found among cell lines on 
cysteine dependence on copping with hypoxia and carboplatin. Importantly, ES2 cells and 
OVCAR8 seemed to present a stronger dependence on cysteine metabolism in handling with 
hypoxic stress and carboplatin than OVCAR3. We must underline that OVCAR3 cells did 
not present increased levels of cell death under hypoxia than ES2 cells. Instead, our results 
supported that these cells manage hypoxic stress by different mechanisms, where ES2 cells 
present a metabolism that is more dependent on cysteine than OVCAR3 cells. This evidence, 
on the other hand, points that cysteine metabolism can be strongly related to a worse 
prognosis of ovarian cancer. It is plausible that the worse prognosis associated to the OCCC 
histological type is related to cysteine metabolism and or cysteine-dependent redox signalling 
process. However, we must test other OCCC cell lines in order to clarify the hypothesis that 
OCCC and HG-OSC tumours are a priori metabolically different. Interestingly, cysteine was 
advantageous for the cisplatin resistant A2780 cells but not for A2780 parental, sensitive 
cells, reinforcing that cysteine accounts for the selective process of platinum resistant ovarian 
cancer cells. Moreover, Beaufort and colleagues have explored the associations between the 
cellular and molecular features of 39 ovarian cancer cell lines and their clinical features [43]. 
They reported an association of the spindle-like tumours with metastasis, advanced stage, 
suboptimal debulking and poor prognosis [43]. Importantly, ES2 cells were included in this 
group whereas OVCAR3 cells were not [43], hence supporting that ES2 cells present a more 
aggressive phenotype.  
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Our data have shown increased levels of CD133, a cancer stem cell marker [44], in ES2, 
OVCAR8 and A2780 parental cells but not in OVCAR3 cells, upon cyclic exposure to 
hypoxia. Moreover, in these cells, carboplatin also increased the levels of CD133. This fact 
indicates that the activation of a pool of cancer stem cells underlies the adaptive capacity of 
these cells to hypoxia and drug resistance, where cysteine acts as a facilitator. Interestingly, 
upon carboplatin exposure, the CD133 levels did not increase in the already resistant A2780 
cisR cells in the majority of treatments, whereas in A2780 parental cells it happened. Those 
results support that CD133+ cells are involved in the process of adaptation to carboplatin but 
it is lost when cells become chemoresistant, thus suggesting a role for CD133+ cells in the 
adaptation to adverse environments. 
Lopes-Coelho et al. have shown that, under normoxia, ES2 cells are more resistant to 
carboplatin than OVCAR3 and that the inhibition of GSH production by buthionine 
sulphoximine (BSO), sensitizes ES2 cells to carboplatin [23]. Our results suggest that the 
protective effect against carboplatin under hypoxia is mediated by cysteine. However, it is 
still unclear if GSH is involved in this protection under hypoxia. Moreover, our team has 
described recently that under normoxia and in glucose free media ES2 present higher levels 
of thiols than OVCAR3 [23]. In the present study we cannot see that difference since we used 
different culture conditions, namely high glucose culture media. It is known that glucose can 
form adducts with GSH, which can in part explain the observed differences [45]. Despite we 
have detected lower or equal levels of GSH in ES2 than in OVCAR3 cells, we also detected 
higher degradation of GSH in ES2, pointing a faster thiols’ turnover in this cell line indicated 
by the levels of cysteinylglycine (Cys-Gly) [46]. 
In a general way, our results pointed to a tendency to decreased cell death levels with 
increased cell density. Recently, it was shown that cytosolic lipid droplets, which are known 
to protect cancer cells from starvation-induced death, increased in content with increased cell 
density in HeLa cells [47]. This observation could, in part, explain the protective effect of 
high initial cell densities observed in our cell models. However, in the initial cell density 
5x103 cells, we observed lower cell death levels than 2.5x104. This can be due to cells 
dormancy that ensure cells survival in a quiescent metabolic state, due to stressful conditions 
[48] that are imposed by such a decreased cell density. Moreover, the effect of cell density in 
the response to carboplatin is an issue that must be addressed in future studies using 3D 
models. One may expect that increased cell density will have an impact on cells capacity of 
adapting to carboplatin, since a larger cell population often present more heterogeneity, thus 
more adaptive potential. In fact, our preliminary results of spheroids models point out a 
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protective effect of cysteine in ES2 but not in OVCAR3 upon carboplatin exposure (Suppl. 
figure 1). Interestingly, Lavi and colleagues [49], through mathematical modelling, showed 
how cancer cell density and cells alteration rate impact the heterogeneity over time, and its 
consequences on multidrug resistance. Moreover, in the context of ovarian cancer, Greene et 
al. [50] have shown that local cell density and initial global cell density, are able to lead to 
significant differences in spatial growth, proliferation, and paclitaxel-induced apoptosis rates 
in OVCAR8 cells, thus having a role not only in cancer cells growth but also in drug 
response. 
Mitochondrial membrane potential (Δψm) has been considered a good indicator of cells’ 
health [38], as it is critical for maintaining the physiological function of the respiratory chain 
to generate ATP in mitochondria. A significant loss of ΔΨm will lead to energy depletion 
with subsequent cell death. Thus, in the present work, a lower loss of Δψm under hypoxia 
plus cysteine compared to cysteine absence was expected. The obtained results are apparently 
contradictory to the data obtained with annexin V/PI staining for cell death, in which, under 
hypoxia, cysteine was able to protect cells from death. However, annexin V labels apoptotic 
cells independently of the apoptotic pathways they underwent and as extrinsic apoptosis does 
not involve mitochondrial disruption it can be a plausible explanation for these results. On the 
other hand, to assess Δψm only adherent (putatively alive) cells were used. Hence, cells that 
were dying faster and detaching under hypoxia without cysteine were not used to assess 
Δψm. Additionally, Tang et al. found that cancer cells were able to survive even after the 
cells had undergone critical apoptotic events such as mitochondrial fragmentation and 
dysfunction, nuclear condensation, cell shrinkage and activation of caspases [51]. They 
observed this apoptosis reversibility in various cancer cell lines and after different apoptotic 
stimuli [51]. Therefore, another interesting possibility is that, under hypoxia, cysteine is able 
to reverse apoptosis in ES2 cells. 
With the exception of GSH, our results showed an overall increase of thiols 
concentration in serum from peripheral blood of patients with ovarian neoplasms, regardless 
malignancy, compared to healthy donors. Strikingly, total and free levels of HCys 
distinguished all the three groups of individuals and free levels of Cys showed to be effective 
in distinguishing malignant from benign neoplasms. In disease, the literature has already 
shown that increased levels of HCys, Cys and CysGly in peripheral blood serum were 
associated with ischemic heart disease [52] and increased levels of CysGly [53] and Cys [54] 
were associated with increased risk of breast cancer [53]. Moreover, higher HCys levels were 
associated with greater risk of breast cancer only when combined with higher levels of Cys 
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and with low levels of folate [54]. Differently, high plasma HCys levels were also associated 
with increased risk of colorectal cancer, whereas high Cys levels were associated with 
decreased risk for this disease [55]. Chiang and colleagues have confirmed the association 
between increased HCys levels and the risk of colorectal cancer adding that this increased 
risk was independent of oxidative stress indicators and antioxidant capacities [56]. In 
contrast, higher serum concentrations of Cys were associated with a significantly reduced risk 
of oesophageal squamous cell carcinomas and gastric/cardia adenocarcinomas [57]. The 
assessment of different thiol pools total, free and protein linked confers an innovative 
approach in our work. We observed that the contribution of protein-S-thiolation was 
augmented in patients with ovarian neoplasms compared to healthy individuals. The 
reversible thiolation of proteins was already associated with the regulation of several 
metabolic processes such as enzyme activity, transport activity, signal transduction and gene 
expression [58]. Several proteins - such as Ras, JNK- 2, AP-1, NF-kappaB, PKC, caspases, 
thioredoxin and p53 [58,59] - which are known to have important roles in cancer, are 
regulated by thiol oxidation [59]. Visscher et al. reported that many oncogenic mutations 
consist in an insertion of a novel cysteine in the protein sequence, as it happens in 12% of 
KRAS and 88% of FGFR mutations [60]. These facts suggest that newly introduced cysteines 
should play a role in tumourigenesis by contributing for tumour suppressor genes inactivation 
and oncogenes activation. Moreover, thiols can also interfere with epigenetic modulation of 
genes expression, which is pivotal in carcinogenesis [61].  
Importantly, our results have shown that cysteine levels are putative biomarkers for 
ovarian cancer early diagnosis. As seen, the total levels in peripheral blood of protein-S-
cysteinylation distinguished healthy blood donors from patients with ovarian neoplasms 
(benign and malignant) and free cysteine distinguishes patients with ovarian benign tumours 
from patients with malignant tumours. This is undoubtedly a step forward for ovarian cancer 
research, as the late diagnosis is one of the most important barriers accounting for the poor 
outcome and high mortality. 
We also observed that cysteine was the prevalent thiol in ascitic fluid from patients with 
ovarian cancer and that S-cysteinylation was the most abundant form of S-thiolated proteins 
showing, again, that cysteine is a relevant organic compound in ovarian cancer cells 
microenvironment. 
We must emphasize that most samples analysed from patients with ovarian cancer were 
from serous carcinoma histotype. It would be interesting to assess thiols levels also in 
patients with OCCC. Albeit the limitation of the in vitro studies with a single OCCC cell line, 
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we believe that the levels of cysteine and other thiols would be even higher in patients with 
this histological type compared to serous carcinomas, allowing faster disease progression and 
recurrence. Despite OCCC is frequently diagnosed at an initial stage [7], in an extraovarian 
advanced stage the disease has poor prognosis given intrinsic chemoresistance to 
conventional platinum drugs [7]. Our data supports that ovarian cancer cells that are more 
dependent on cysteine metabolism are more resistant to carboplatin effects mainly under 
hypoxia. The ability to take advantage from cysteine accounting for chemoresistance can be 
intrinsic, as OCCC, or acquired upon cyclic exposure to chemotherapy as happens with 
recurrent HG-OSC.   
Albeit we did not find any statistically significant difference concerning thiols content in 
the different histological types of ovarian tumours, it is important to highlight that a tendency 
for higher cysteine levels was observed in the OCCC histotype compared to HG-OSC 
histotype, hence supporting a more important role of cysteine metabolism also in primary 
OCCC tumours. Interestingly, we also observed a tendency for increased cysteine levels in 
HG-OSC after chemotherapy, hence supporting a role of cysteine in the process of acquired 
resistance, where the chemotherapy may select cancer cells with an increased cysteine 
metabolism that may further allows their adaptation in the presence of drugs. It is of extreme 
importance to increase the number of samples analysed in order to confirm these tendencies. 
Taken together, results strongly support that cysteine protects cells from the adverse 
hypoxic microenvironment and from platinum-based chemotherapy, thus having a role in 
cancer progression. Because of the high cysteine concentrations found in ascitic fluid and in 
serum from patients with ovarian malignant tumours, we propose that cysteine acts as a first 
protection barrier for neoplastic cells against hypoxia, having a role as a redox buffer, and 
against chemotherapy, as sulphur rapidly binds to platinum-based drugs, thus preventing their 
efficacy (figure 15). In metastatic peritoneal disease, cysteine rich ascites may contribute for 
the perpetual maintenance of resistance to therapy, as cancer cells proliferate directly 
embedded in ascitic fluid (figure 15).  
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Figure 15. Role of cysteine in cells response to carboplatin and hypoxia adaptation. 
In cancer cells, cysteine allows adaptation to adverse hypoxic microenvironments acting as a redox 
buffer, and to platinum-based chemotherapy as sulphur rapidly binds to carboplatin, avoiding DNA 
damage and evading apoptosis. Because of the presence of high cysteine concentrations in ascitic fluid 
from patients with ovarian cancer and also in serum from patients with ovarian malignant neoplasms, we 
propose that cysteine acts as a first protection barrier for malignant cells against hypoxia and against 
chemotherapy, thus contributing for disease progression and recurrence. 
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SUPPLEMENTS 	  
Supplement figure 1 
 
Supplement figure 1. ES2 and OVCAR3 spheroid exposure to chemotherapeutic treatment: 
protective effect of cysteine. 
Single cell suspension of OVCAR3 and ES2 cells (5x106 cell/mL) were inoculated in spinner vessels and 
maintained under 60-80 rpm agitation to induce aggregation, according to Santo et al. [62] Spheroid 
cultures were challenged with 2 cycles of exposure with 25 µg/mL carboplatin, with or without 
supplementation with 0.4 mM cysteine (on day 0 and 4), and compared to control cultures without 
chemotherapy treatment, with or without cysteine supplementation. A. Cell concentration, determined by 
detection of cellular DNA, and B. spheroid concentration, determined by phase contrast microscopy and 
automatic evaluation using ImageJ software (as described in [62]) were evaluated along drug exposure 
time. Data is presented as fold change relative to the respective control condition. 
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Will you follow and know 
Know me more than you do 
Track me down 
And try to win me?” 
 Morrissey 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	  
	   109	  
ABSTRACT 
 
Despite the observation of an improvement in the overall survival of ovarian cancer 
patients in the last 30 years, this improvement has been mainly achieved due to an increased 
life expectancy of women with recurrent ovarian cancer, instead of an increased cure rate. 
The late diagnosis together with resistance to treatment represent the major causes of this 
poor prognosis disease.  
As a solid tumour grows, cancer cells are exposed to regions of hypoxia, known to be a 
stimulus for tumour progression and resistance to therapy. Since our previous results 
supported that cysteine allows adaptation to hypoxia, in here, we aimed to investigate the 
mechanisms by which cysteine protects ovarian cancer cells from hypoxia-induced death, by 
addressing its role in cellular metabolism, namely through energy production.  
Our results strongly supported a role of the xc- system via cystine uptake (the oxidised 
form of cysteine) in energy production that requires cysteine metabolism instead of H2S per 
se. Interestingly, albeit CBS and CSE inhibition was not sufficient to impair ATP production, 
the inhibition of both enzymes affected ATP synthesis mainly under hypoxia in ovarian 
cancer cells, thus supporting a role of their activity in this environment. However, the specific 
contribution of CBS/CSE/MpST activities on cysteine-derived ATP synthesis under hypoxia 
remains unclear. Strikingly, NMR analysis strongly supported a role of cysteine in cellular 
metabolism rescue under hypoxia, especially in ES2 cells, hence strengthening that cysteine 
supports cells viability and proliferation in hypoxic environments. 
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Cysteine, hypoxia, ovarian cancer, hydrogen sulphide, xCT, CBS, CSE, MpST 
 
 
INTRODUCTION 
 
Despite all the progresses developed in prevention and new treatment approaches, cancer 
corresponds to the second leading cause of death worldwide [1]. In accordance with the 
International Agency for Research on Cancer, in 2012 14.1 million cancer cases [2] and 8.2 
million cancer deaths [3] were estimated worldwide. For 2020, 17.1 million incidences and 
10.05 million cancer deaths [2] are estimated. In one hand, these values are explained by the 
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increasing incidence of cancer cases due to aging and growth of the global population, 
together with exposition to risk factors such as smoking, obesity, and dietary patterns [1]. In 
another hand, the late diagnosis combined with resistance to the conventional anti-cancer 
drugs used, explain cancer poor prognosis. 
Ovarian cancer is not an exception to this scenario, being estimated, in 2020, 0.28 million 
new cases and 0.18 million ovarian cancer deaths worldwide [2]. The late diagnosis together 
with resistance to treatment represent the major causes of this poor prognosis disease [4].  
Epithelial ovarian cancer (EOC) includes most ovarian malignancies [5,6] that can be 
classified based on histopathology and molecular/genetic features, being the ovarian 
carcinomas mainly classified as high-grade serous (HG-OSC, 70%), low grade serous 
carcinomas (LG-OSC, <5%) endometrioid (OEC, 10%), clear cell (OCCC, 10%) and 
mucinous (OMC, 3%) [7,8]. 
As a solid tumour grows, cancer cells are exposed to regions of hypoxia, strictly linked to 
oxidative stress [9,10] and known to be responsible for tumour progression and resistance to 
therapy [11,12]. In ovarian cancer, oxidative stress was already associated with the 
pathogenesis of the disease [10,13], indicating that ovarian cancer cells present mechanisms 
that allow them to cope with the harmful oxidative conditions. Recently, it was proposed that 
cysteine facilitates the adaptation of ovarian cancer cells to hypoxic environments and also 
contribute to their escape from carboplatin-induced death [14,15]. The relevance of cysteine 
in ovarian cancer clinical context was also corroborated, since ascitic fluid from ovarian 
cancer patients - an important compartment of tumour microenvironment -, showed cysteine 
as the prevalent thiol and because cysteine levels were also altered in serum from patients 
with ovarian tumours [15]. Cysteine role in cancer cells survival was already associated with 
its role as a precursor of the antioxidant glutathione (GSH) [16–18] and due to hydrogen 
sulphide (H2S) generation [19–25] by cysteine catalybolism through the activity of the 
enzymes cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and/or 3-mercapto-
pyruvate sulfurtransferase (MpST) together with cysteine aminotransferase (CAT) [26–28]. 
In here, we aimed to address the mechanism by which cysteine protects ovarian cancer 
cells from hypoxia-induced death, hypothesising that besides GSH synthesis, cysteine has a 
role also in energy production under hypoxic conditions. To test this hypothesis, we used two 
different cancer cell lines derived from two different histological types of ovarian cancer, ES2 
cells, corresponding to an ovarian clear cell carcinoma (OCCC) cell line and OVCAR3 cells, 
corresponding to a ovarian serous carcinoma (HG-OSC) cell line. 
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MATERIALS AND METHODS 
 
Cell culture 
 
Cell lines from OCCC (ES2; CRL-1978) and HG-OSC (OVCAR-3; HTB-161) were 
obtained from American Type Culture Collection (ATCC). Cells were maintained at 37°C in 
a humidified 5% CO2 atmosphere. Cells were cultured in DMEM 1× (41965-039, Gibco, Life 
Technologies) containing 4.5 g/L of D-glucose and 0.58 g/L of L-glutamine supplemented 
with 1% FBS (S 0615, Merck), 1% antibiotic-antimycotic (P06-07300, PAN Biotech) and 0.1 
% gentamicin (15750-060, Gibco, Life Technologies) and exposed either to 0.402 mM L-
cysteine (102839, Merck) and/or exposed to hypoxia induced with 0.1 mM cobalt chloride 
(CoCl2) (C8661, Sigma-Aldrich). 
Prior to any experiment, cells were synchronized under starvation (culture medium 
without FBS) for 8 h at 37°C and 5% CO2. 
 
ATP quantification 
 
To test the effect of xCT inhibition on ATP levels, cells (5×105 or 2.5×105 cells/well) 
were seeded in 6-well white plates and exposed to hypoxia induced with 0.100 mM CoCl2 
combined with 0.250 mM sulphasalazine (S0883, Sigma), an xCT inhibitor. After 24 h, the 
medium was changed and fresh experimental conditions were added. Cells were collected at 
48 h after stimulation.  
To test the effect of the enzymes involved in cysteine metabolism on ATP synthesis, cells 
(5×105 or 2.5×105 cells/well) were seeded in 6-well plates and cultured in control condition 
and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.1 mM CoCl2. The 
previous conditions were combined with 1 mM O-(Carboxymethyl)hydroxylamine 
hemihydrochloride (AOAA, C13408, Sigma) and 3 mM DL-propargylglycine (PAG, P7888, 
Sigma), which are respectively inhibitors of CBS and CSE. After 24 h, the medium was 
changed and fresh experimental conditions were added. Cells were collected at 16 and 48 h 
after stimulation. This assay was also performed with cell collection after 2 h of experimental 
conditions. In this case, 5×105 cells were seeded in 6-well white plates for both ES2 and 
OVCAR3 cells. 
To investigate the effect of cysteine and NaHS upon xCT inhibition on ATP synthesis, 
cells (5×105 or 2.5×105 cells/well) were seeded in 6-well plates and exposed to hypoxia 
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induced with 0.100 mM CoCl2 with and without 0.402 mM L-cysteine combined with 0.250 
mM sulphasalazine, 30 µM NaHS (161527 Sigma-Aldrich) or both. After 24 h, the medium 
was changed and fresh experimental conditions were added. Cells were collected at 48 h after 
stimulation. This assay was also performed with cell collection after 1 h of experimental 
conditions. In this case, 5×105 cells were seeded in 6-well white plates for both ES2 and 
OVCAR3 cells. 
To ascertain the effect of the inhibition of fatty acids degradation (β-oxidation) and 
glucose degradation (glycolysis) on ATP production, cells (5×105 or 2.5×105 cells/well) were 
seeded in 6-well plates and exposed to hypoxia induced with 0.100 mM CoCl2 with and 
without 0.402 mM L-cysteine combined with 10 µΜ etomoxir (β-oxidation inhibitor), 20 µM 
bromopyruvic acid (glycolysis inhibitor) or both. After 24 h, the medium was changed and 
fresh experimental conditions were added. Cells were collected at 48 h after stimulation. 
Cells were scrapped with cold PBS 1x- EDTA 2 mM and homogenized in 1% Nonidet P-
40 (NP-40) lysis buffer (1% NP40 N-6507 Sigma, and 1x protease inhibitor, 
SIGMAFASTTM Protease inhibitor cocktail tablets S8830, Sigma) on ice for 30 minutes and 
centrifuged at 20000 g for 5 min at 4ºC. Protein was quantified and the same amount of total 
protein was used within each assay, in a range between 2.5 and 10 µg. ATP determination kit 
(A22066, Molecular probes) was used in accordance with the manufacturer. The 
measurements were performed using Luciferase protocol from VIKTOR3 instrument from 
PerkinElmer, using Wallac 1420 Software version 3.0 (Luminometry, Luciferase FIR 
protocol). The ATP concentration was determined against an ATP calibration curve, within 
the range of 0 µM and 30 µM. 
 
Immunofluorescence analysis 
 
Cells (1×105 cells/well) were seeded in 24-well plates and cultured in control condition. 
Cells were collected after 16 h of experimental conditions and fixed with 4% 
paraformaldehyde for 15 min at 4°C and permeabilised with PBS(1X)-BSA 0.5%-saponin 
0.1% for 15 min at room temperature. Cells were then incubated with Anti-xCT (ab175186, 
abcam) for 30 min (diluted in PBS(1X)-BSA 0.5%-saponin 0.1%; 1:100) and incubated with 
secondary antibody for 2 h at room temperature (Alexa Fluor® 488 anti-rabbit, A-11034, 
Invitrogen) (1:1000 in PBS(1X)-BSA 0.5%-saponin 0.1%). The slides were mounted in 
VECTASHIELD media with DAPI (4′-6-diamidino-2-phenylindole) (Vector Labs) and 
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examined by standard fluorescence microscopy using a Zeiss Imajer.Z1 AX10 microscope. 
Images were acquired and processed with CytoVision software. 
 
Western blotting analysis with isolated mitochondria 
 
Cells (7×106 cells/flask) were cultured in 150 cm2 culture flasks and exposed to control 
condition and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.100 mM 
CoCl2. Cells were collected after 16 h of experimental conditions, and mitochondria were 
isolated with Mitochondria Isolation Kit for profiling cultured cells (MITOISO2, Sigma). 
Briefly, cells were scraped, centrifuged for 5 min at 600 g and washed in ice cold PBS 1x. 
The cell pellet was resuspended in 650 µL of Lysis Buffer. A 5 min period of incubation was 
performed on ice and samples were suspended at 1 min intervals by pipetting up and down 
once. Two volumes of extraction buffer were added and the homogenate was centrifuged at 
600 g for 10 min at 4°C. The supernatant was transferred to a fresh tube and centrifuged at 
11000 g for 10 min at 4°C, this new supernatant was removed and the pellet suspended in 75 
µL of CelLytic M Cell Lysis Reagent. 
The lysates were centrifuged at 20817 g for 5 min at 4ºC and protein concentration was 
determined based on Bradford method (500-0006, Bio Rad). For western blotting for xCT 
and TOMM20 with isolated mitochondria, 15 µg of total protein from each sample was used. 
For MpST, 20 µg of total protein from each sample was used. 
Membranes were incubated with Anti-xCT (1:1000 in PBS 1x-Milk 5%; ab175186 from 
abcam) or Anti-MpST (1:250 in PBS 1x-Milk 5%; HPA001240 from sigma) at 4ºC with 
agitation, overnight. The membranes were then washed 3 times, for 5 min, with PBS 1x 0.1% 
(v/v) Tween 20. Posteriorly, the membranes were incubated with the secondary antibody 
(1:5000 in PBS 1x-Milk 5%; anti-rabbit, 31460 from Thermo Scientific) for 2 h at room 
temperature. For the membrane that was previously incubated with xCT, the protocol was 
repeated in the same membrane for anti-TOMM20 antibody (1:1000 in PBS 1x-Milk 5%; 
ab186734 from abcam).  
 
Measurement of basal H2S in cell homogenates 
 
Cells (5×105 cells/well) were seeded in 6-well black plates and cultured in control 
condition and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.1 mM CoCl2. 
After 24 h, the medium was changed and fresh experimental conditions were added. Cells 
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were collected at 48 h after stimulation. Cells were scrapped with PBS 1x and homogenized 
in NP40 lysis buffer (1% NP40, 150 mM NaCl, 50 mM Tris-Cl, pH 8.0) on ice for 30 min 
and centrifuged at 20000 g for 5 min at 4ºC. Cell homogenates (20 µl) were incubated in 
black 96-well plates with 80 µl of 10 µM 7-Azido-4- Methylcoumarin (AzMC, L511455, 
Sigma) with and without 1 mM AOAA, 3 mM PAG or the combination of both the inhibitors. 
The protein concentration was determined with Bradford method using protein assay dye 
reagent concentrate (500-0006, Bio Rad) and a BSA calibration curve. The H2S 
measurements were posteriorly normalised to total protein concentration and to a blank 
sample (cellular lysates with and without AOO, PAG or both without probe). 
H2S production was monitored following fluorescent signal of AzMC using Umbelliferone 
protocol from VIKTOR3 instrument from PerkinElmer and Wallac 1420 Software version 3.0 
every 30 min for 2 h (Prompt fluorometry, Umbelliferone – 355 nm/460 nm, 0.1 s - protocol). 
 
Cell death analysis 
 
To test whether the protective effect of cysteine under hypoxia was dependent on H2S 
production, cells (1×105 cells/well) were seeded in 24-well plates. Cells were cultured in 
control condition and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.1 mM 
CoCl2, combined to 1 mM O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOAA, 
C13408, Sigma), to 3 mM of DL-Propargylglycine (PAG, P7888, Sigma), or the combination 
of both. Cells were collected 16 h after stimulation. 
Cells were harvested by centrifugation at 153 g for 3 min, cells were incubated with 0.5 
µL FITC Annexin V (640906, BioLegend) in 100 µL annexin V binding buffer 1x (10 mM 
HEPES (pH 7.4), 0.14 M sodium chloride (NaCl), 2.5 mM calcium chloride (CaCl2) and 
incubated at room temperature and in the dark for 15 min. After incubation, samples were 
rinsed with 0.2% (w/v) BSA (A9647, Sigma) in PBS 1x and centrifuged at 153 g for 3 min. 
Cells were suspended in 200 µL of annexin V binding buffer 1x and 2.5 µL Propidium Iodide 
(50 µg/mL). Acquisition was performed in a FACScalibur (Becton Dickinson). Data were 
analysed with FlowJo software. 
 
Nuclear magnetic resonance (NMR) analysis 
 
Cells (6.5×106 cells) were seeded in 175 cm2 culture flasks and cultured in control 
condition and exposed to 0.402 mM L-cysteine and/or hypoxia induced with 0.1 mM CoCl2. 
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Cells and supernatants were collected at 48 h after stimulation and stored at −20°C. 
Cell extracts were performed with methanol and chloroform to separate organic and 
aqueous phases. After cold methanol mixture (4 mL methanol/ 1 g weight pellet), 2 volumes 
(vol) of water were added, mixed, and incubated for 5 min on ice. Chloroform (1 vol) was 
then added to the sample and mixed. Finally, 1 vol of water was added and samples were 
incubated for 10 min on ice, following centrifugation at 1699 g for 15 min at 4°C. Aqueous 
(upper) and organic (lower) phases were collected. After extraction of solvents by 
evaporation, using a Speed Vac Plus Scllon, the samples were suspended on KPi buffer (50 
mM, pH 7.4) in deuterated water (D2O) with 4% (v/v) sodium azide (NaN3) and 0.097 mM 
of 3-(trimethylsilyl)propionic-2,2,3,3-d4 (TSP). Culture supernatants were also diluted in this 
solution at 1:10 ratio. The 1H-NMR (noesypr1d) was obtained at 25°C in Avance 500 II+ 
(Bruker) operating at 500.133 MHz, equipped with a 5 mm TCI(F)-z H-C/N Prodigy cryo-
probe. The chemical shifts in aqueous sample were referred to the TSP. Topspin 3.2 (Bruker) 
was used for acquisition and spectra analysis. Compound identification was performed by 
resorting to the Human Metabolome database (HMDB) (http://www.hmdb.ca/) and Chenomx 
NMR suite software version 8.1 (Chenomx Inc.). Metabolites concentration was determined 
using Chenomx NMR suite software version 8.1 (Chenomx Inc.). 
 
Statistical analysis  
 
All data are presented as the mean ± SD with the exception of 1H-NMR data, which are 
presented as the median with 25th to 75th percentiles. All the graphics were done using the 
PRISM software package (PRISM 6.0 for Mac OS X; GraphPad software, USA, 2013). 
Assays were performed with at least 3 biological replicates per treatment. For comparisons of 
two groups, two-tailed independent-samples T-test was used. For comparison of more than 
two groups, One-way analysis of variance (ANOVA) with Tukey’s multiple-comparisons 
post hoc test was used. Statistical significance was established as p<0.05. All statistical 
analyses were performed using the IBM Corp. Released 2013. IBM SPSS Statistics for 
Macintosh, Version 22.0. Armonk, NY: IBM Corp. software, with the exception of metabolic 
pathway analysis that was performed with MetaboAnalyst 4.0 
(https://www.metaboanalyst.ca/faces/home.xhtml). 
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RESULTS 
 
Hypoxia is able to induce ATP synthesis 
 
Since our previous results have shown that cysteine was able to protect ovarian cancer 
cells from hypoxia-induced death, we further explored the ability of these cells to synthesize 
ATP under hypoxic conditions.  
Results have shown that in ES2 cells with 16 h of conditions, ATP levels did not differ 
among hypoxia with and without cysteine supplementation and were higher under hypoxia 
without cysteine compared to normoxia with cysteine supplementation (p=0.017) (figure 1A). 
With 48 h of experimental conditions, ATP levels were increased under hypoxia without 
cysteine compared both to hypoxia (p=0.018) and normoxia (p=0.033) with cysteine 
supplementation (figure 1 A). 
In OVCAR3 cells, with 16 h of conditions no differences were observed among 
treatments (figure 1B). However, with 48 h of experimental conditions, the results were 
identical to ES2 cells, where cells cultured under hypoxia without cysteine presented higher 
ATP levels compared both to normoxia (p=0.008) and hypoxia (p<0.001) with cysteine 
(figure 1 B).  
These results support that ovarian cancer cells exhibit alternative ways that allow 
sustaining energy production under hypoxic environments. Because cells cultured under 
hypoxia without cysteine supplementation also present cysteine in the medium (yet in lower 
concentrations), and also because cells cultured under hypoxia with cysteine reach higher 
cellular confluence levels compared to hypoxia without its supplementation, we cannot, 
nevertheless, rule out a role of cysteine in ATP production. 
 
Figure 1. Hypoxia induced ATP synthesis under hypoxia. 
ATP levels normalised to control values (normoxia without cysteine) for 16 h and 48 h of experimental 
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conditions for A. ES2 cells and B. OVCAR3 cells. N – normoxia; NC – normoxia with cysteine, H – 
hypoxia, HC – hypoxia with cysteine. The asterisks (*) represent the statistical significance compared to 
normoxia without cysteine and the cardinals (#) represent the statistical significance compared to hypoxia 
without cysteine within the same time-point. The differences among the different time-points are pointed 
in the figure. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with 
post hoc Tukey tests). 
 
 
xCT transporter localises in ovarian cancer cells’ mitochondria and its inhibition 
impairs ATP synthesis under hypoxia, which cysteine is able to revert 
 
Since no direct associations were found between cysteine and ATP production under 
hypoxia, we further explored the role of xCT, a member of the cystine-glutamate transporter 
xc- system, known to mediate the uptake of cystine [29] (the oxidised form of cysteine), on 
ATP production. Thus, we started by addressing if this transporter could localise in ovarian 
cancer cells’ mitochondria thus suggesting a role of cysteine metabolism in ATP production 
via xc- system. Immunofluorescence analysis suggested a mitochondrial localisation of xCT 
in both ES2 and OVCAR3 cells (figure 2A) that was further confirmed by western blotting 
analysis with isolated mitochondria (figure 2 A and B). Interestingly, by western blotting with 
anti-TOMM20 (a mitochondrial marker) results seem to indicate that ES2 cells present a 
higher content of mitochondria under hypoxia compared to the other experimental conditions, 
whereas OVCAR3 cells seem to present the opposite tendency. As a consequence, the ratio 
xCT/TOMM20 was decreased in ES2 cells and increased in OVCAR3 cells. Nonetheless, 
these resuts are preliminary and must be confirmed. 
We then explored the effect of xCT inhibition in the ability of ovarian cancer cells to 
produce ATP under hypoxia. Strikingly, xCT inhibition led to impaired ATP production 
under hypoxia in both cell lines (p=0.038 for ES2 and p=0.010 for OVCAR3 cells) (figure 
3A), which cysteine was able to revert, since the impact on ATP production was decreased 
under hypoxia with cysteine supplementation compared to hypoxia alone (p<0.001) (figure 
3B). 
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Figure 2. xCT localises in ovarian cancer cells mitochondria. 
A. Immunofluorescence analysis for the xCT transporter under control conditions (normoxia) for ES2 
and OVCAR3 cells and B. western blot analysis with isolated mitochondria for xCT and TOMM20 in 
ES2 and OVCAR3 cells. N – normoxia; NC – normoxia with cysteine, H – hypoxia, HC – hypoxia with 
cysteine. 
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Figure 3. Cysteine is able to rescue the impaired ATP synthesis triggered by xCT inhibition under 
hypoxia. 
ATP levels for 48 h of experimental conditions for ES2 and OVCAR3 cells. A. under hypoxia and in the 
presence of the xCT inhibitor, sulphasalazine, B. under hypoxia and in the presence of the xCT inhibitor, 
sulphasalazine and cysteine. In B. the values were normalised to the respective control and log(2) was 
calculated. H – hypoxia, HC – hypoxia with cysteine supplementation. Results are shown as mean ± SD. 
*p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test). 
 
 
H2S may correlate with ATP synthesis under hypoxia 
 
Since we observed a role of cysteine in ATP synthesis mediated by the xc- system, we 
next aimed to address if H2S production would be the source of ATP under hypoxia without 
cysteine. For that, basal cellular H2S levels were measured with and without the inhibition of 
two enzymes involved in cysteine degradation. Thus, AOAA was used to inhibit CBS activity 
and PAG was used to inhibit CSE activity. 
For ES2 cells, results have shown that hypoxia without cysteine (H) induced H2S 
production compared to the other treatments (p<0.001 compared both to NC and HC). With 
AOAA alone, PAG alone or the combination of both, similar results were observed (p<0.001 
compared to N, NC and HC) (figure 4 A-E). 
Interestingly, in all experimental conditions, PAG alone was not able to decrease H2S 
levels (figure 4E). On the contrary, AOAA alone or in combination with PAG was 
responsible for decreased H2S levels. 
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Figure 4. Hypoxia induces H2S production in ES2 cells. 
H2S levels in ES2 cells for 48 h of experimental conditions in A. Control (no inhibitors), B. With CBS 
inhibitor (AOAA), C. with CSE inhibitor (PAG), E. with both the inhibitors (AOAA+PAG) and E. in all 
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experimental conditions. N – normoxia; NC – normoxia with cysteine, H – hypoxia, HC – hypoxia with 
cysteine . In A-D the asterisks (*) represent the statistical significance compared to N, the section 
symbols (§) represents the statistical significance compared to NC and the cardinals (#) represent the 
statistical significance compared to HC. In E. the section symbols (§) represent the statistical significance 
compared to AOAA and the cardinals (#) represent the statistical significance compared to AOAA+PAG. 
Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc 
Tukey tests). 
 
Regarding OVCAR3 cells, results also supported that hypoxia without cysteine tends to 
induce H2S production compared to the other treatments, although some differences were not 
significant. Without the inhibitors (control), H2S levels were increased under hypoxia 
compared to normoxia with cysteine (NC) (p=0.006), without differences compared to 
hypoxia with cysteine (HC). With AOAA alone, hypoxia induced H2S levels compared to all 
conditions (p=0.008 compared to N, p=0.002 compared to NC and p=0.031 compared to HC). 
With PAG alone, hypoxia (H) induced H2S levels only when compared to normoxia with 
cysteine (NC) (p=0.02) and with both the inhibitors, hypoxia induced H2S levels compared to 
both treatments with cysteine (p=0.000 compared to NC and p=0.022 compared to HC) 
(figure 5 A-E). 
For this cell line, PAG alone was not able to decrease H2S levels (figure 5 E). However, 
AOAA in combination with PAG was responsible for decreased H2S levels in all 
experimental conditions. Interestingly, while AOAA alone was also able to decrease H2S 
levels under normoxia treatments (N and NC), under hypoxia AOAA failed to significantly 
decrease H2S levels (figure 5 E).  
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Figure 5. Hypoxia tends to induce H2S production also in OVCAR3 cells. 
H2S levels in OVCAR3 cells for 48 h of experimental conditions in A. Control (no inhibitors), B. With 
CBS inhibitor (AOAA), C. with CSE inhibitor (PAG), E. with both the inhibitors (AOAA+PAG) and E. 
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in all experimental conditions. N – normoxia; NC – normoxia with cysteine, H – hypoxia, HC – hypoxia 
with cysteine. In A-D the asterisks (*) represent the statistical significance compared to N, the section 
symbols (§) represents the statistical significance compared to NC and the cardinals (#) represent the 
statistical significance compared to HC. In E. the section symbols (§) represent the statistical significance 
compared to AOAA and the cardinals (#) represent the statistical significance compared to AOAA+PAG. 
Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc 
Tukey tests). 
 
Together, results support an association between H2S and ATP production under hypoxia, 
as both were increased in this experimental condition in ovarian cancer cells, especially in 
ES2 cells. 
 
 
CBS and CSE inhibition does not impair ATP synthesis but induce cell death in ES2 
cells 
 
Since results suggested that cysteine has a role in ATP synthesis mediated by the xCT 
transporter and that increased ATP levels were concomitant with increased H2S levels under 
hypoxia, we next measured ATP levels upon CBS and CSE inhibition. 
Results have shown that with 16 h of experimental conditions, no differences were found 
in ATP levels with or without CSE and CBS inhibitors (PAG and AOAA, respectively) for 
both ES2 and OVCAR3 cells in any other condition (figure 6 A-D). Moreover, 48 h with the 
inhibitors resulted in increased ATP levels in all experimental conditions for both ES2 (under 
N p=0.002, under NC p=0.001, under H p=0.004, under HC p=0.001) and OVCAR3 cells 
(under N, NC and HC p<0.000 and under H p=0.003) (figure 6 A-D). In what concerns ATP 
synthesis, interestingly, CBS and CSE inhibitors presented a more pronounced deleterious 
effect under hypoxia without cysteine (H) and normoxia with cysteine (NC) in ES2 cells and 
under hypoxia without cysteine (H) in OVCAR3 cells (figure 6 C and D), corroborating the 
relevance of these enzymes on ATP production under hypoxia. 
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Figure 6. CBS and CSE inhibition does not impair ATP synthesis in ovarian cancer cells. 
ATP levels in the presence of 1 mM AOOA and 3 mM PAG for 16 h and 48 h of experimental conditions 
for A. and B. ES2 cells and C. and D. OVCAR3 cells. In A. and C. the asterisks (*) represent the 
statistical significance compared to the respective control. Data were normalised to control (normoxia 
without cysteine and without inhibitors). *p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test). 
In B. and D. the asterisks (*) represent the statistical significance compared to N, the section symbols (§) 
represents the statistical significance compared to NC and the cardinals (#) represent statistical 
significance compared to HC. Data were normalised to the respective control and Log(2) was calculated. 
*p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). N – normoxia; NC – 
normoxia with cysteine, H – hypoxia, HC – hypoxia with cysteine. Results are shown as mean ± SD. 
 
Increased ATP levels under stressful conditions were already reported [30]. Thus, we 
next aimed to explore if increased cell death levels were able to explain the increased ATP 
levels observed in the presence of AOAA and PAG.  
Results have demonstrated that, for ES2 cells, under normoxia both with and without 
cysteine supplementation (N and NC), PAG alone was more responsible for cell death 
induction compared to AOAA alone (p=0.017) (figure 7 A and B). Under hypoxia (H), the 
combination of both inhibitors was more prone to induce cell death compared to the other 
treatments (p<0.001 compared to all treatments). Interestingly, under hypoxia with cysteine, 
PAG showed to be disadvantageous also alone (p=0.038 compared to the control) or in 
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combination with AOAA (p=0.002 compared to the control and p=0.01 compared to AOAA 
alone) (figure 7 C and D).  
 
 
Figure 7. CBS and CSE inhibition affect ES2 cells survival, mainly under hypoxia. 
Cell death levels for ES2 cells in the control condition, in the presence of CBS inhibitor (1 mM AOAA), 
CSE inhibitor (3 mM PAG) or both inhibitors under A. normoxia, B. normoxia with cysteine, C. hypoxia 
and D. hypoxia with cysteine. Data were normalised to control (normoxia without cysteine and without 
inhibitors). In A. and B. the cardinals (#) represent statistical significance between AOAA and PAG 
alone. In C. the asterisks (*) represent statistical significance between AOAA+PAG and its control, the 
cardinals (#) represent statistical significance between AOAA+PAG and AOAA alone and the section 
symbols (§) represent statistical significance between AOAA+PAG and PAG alone. In D. the asterisks (*) 
represent statistical significance between PAG alone/AOAA+PAG and its control and the cardinals (#) 
represent statistical significance between AOAA+PAG and AOAA alone. Results are shown as mean ± 
SD. *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
Regarding OVCAR3 cells, no differences were observed among treatments, with or 
without the inhibitors (figure 8 A-D). 
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Figure 8. CBS and CSE inhibition does not affect OVCAR3 cells survival. 
Cell death levels for OVCAR3 cells in the control condition, in the presence of CBS inhibitor (1 mM 
AOAA), CSE inhibitor (3 mM PAG) or both inhibitors under A. normoxia, B. normoxia with cysteine, C. 
hypoxia and D. hypoxia with cysteine. Data were normalised to control (normoxia without cysteine and 
without inhibitors). Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (One-way 
ANOVA with post hoc Tukey tests). 
 
Together, results indicate that CBS and CSE inhibition is not sufficient to impair ATP 
production but the inhibition of both enzymes affected ATP synthesis mainly under hypoxia 
for both cell lines.  
Moreover, since ES2 cells viability was reduced upon both CBS and CSE inhibition 
under hypoxia, this shows that ES2 cells are especially sensitive to the inhibition of these 
enzymes under hypoxia, hence indicating their role in hypoxia adaptation.  
 
 
Cysteine degradation is necessary to rescue the impaired ATP production triggered by 
xCT inhibition  
 
Since results have suggested that cysteine has a role in ATP production under hypoxia 
that can be in part related to H2S synthesis, we next aimed to explore if cysteine metabolism 
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was necessary or if H2S per se, was sufficient to counteract the ATP impairment triggered by 
xCT inhibition. 
Results have shown once again that cysteine was able to revert this ATP impairment 
upon xCT inhibition in both ES2 and OVCAR3 cells (p<0.001 for both cell lines), however, 
NaHS alone, an H2S donor, was not able to counteract this effect, as no differences were 
found among treatments with NaHS combined with sulphasalazine and sulphasalazine alone 
(p>0.05 for both cell lines), indicating that H2S alone might not be able to rescue ATP 
production and that cysteine degradation is required for both cell lines (figure 9 A and B). 
 
Figure 9. Cysteine, but not NaHS, is able to rescue ATP synthesis under hypoxia triggered by xCT 
inhibition. 
ATP levels for 48 h of experimental conditions for A. ES2 and B. OVCAR3 cells under hypoxia with and 
without cysteine and in the presence of the xCT inhibitor, sulphasalazine and the H2S donor, NaHS. Data 
were normalised to the respective control condition (the same environmental condition H/HC without 
NaHS or Sulphasalazine). H – hypoxia, HC – hypoxia with cysteine. Results are shown as mean ± SD. 
*p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with post hoc Tukey tests). 
 
Due to the unstable nature of NaHS that was reported to lead to an instant release of H2S 
in culture medium [31] that decays rapidly [32], and because Fu and colleagues have reported 
that in vascular smooth-muscle cells, 1 h of NaHS exposition was sufficient to increase 
mitochondrial ATP production under hypoxia [33], we quantified ATP levels upon NaHS 
exposure for 1 h of the experimental conditions tested before. 
Results have shown that, even with 1 h of experimental conditions, H2S alone was not 
sufficient to rescue ATP levels under hypoxia upon xCT inhibition. In fact, for ES2 cells 
under hypoxia without cysteine, NaHS led to decreased ATP levels (p=0.047). However, 
under hypoxia with cysteine supplementation, NaHS did not affect ATP production. For 
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OVCAR3 cells, NaHS led to decreased ATP levels both under hypoxia with (p=0.002) and 
without cysteine supplementation (p=0.003) (figure 10 A). Moreover, for ES2 cells, both 
NaHS alone or combined with sulphasalazine lead to decreased ATP levels under hypoxia 
with and without cysteine supplementation compared to sulphasalazine alone (H NaHS vs H 
sulphasalazine p<0.001; H NaHS+sulphasalazine vs H sulphasalazine p<0.001; HC NaHS vs 
HC sulphasalazine p=0.002; HC NaHS+sulphasalazine vs HC sulphasalazine p<0.001) 
(figure 10 B). For OVCAR3, no differences were observed among treatments (figure 10 C).  
Finally, while 1 h of sulphasalazine was not sufficient to inhibit ATP levels in ES2 cells, 
it was in OVCAR3 cells (figure 10 B and C), suggesting that the former could present higher 
basal levels of the xCT transporter or that these cells activate xCT transcription in a more 
efficient way compared to OVCAR3 cells. In fact, in basal conditions, ES2 cells express 
higher xCT levels compared to OVCAR3 cells (Suppl. figure 1), hence supporting that a 
more prolonged exposure to sulphasalazine is necessary for the effective blocking of xCT in 
ES2 cells. 
 
Figure 10. NaHS impairs ATP synthesis under hypoxia in ovarian cancer cells. 
ATP levels for 1 h of experimental conditions for A. ES2 and OVCAR3 cells under hypoxia with and 
without cysteine and in the presence of the H2S donor, NaHS (un-normalised data), and B ES2 and C. 
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OVCAR3 cells under hypoxia with and without cysteine supplementation and in the presence of the xCT 
inhibitor, sulphasalazine and NaHS. In B. and C. data were normalised to the respective control condition 
(the same environmental condition H/HC without NaHS or Sulphasalazine). H – hypoxia, HC – hypoxia 
with cysteine. Results are shown as mean ± SD. In A. the asterisks (*) represent the statistical 
significance among the indicated conditions. In B, the asterisks (*) represent the statistical significance 
compared to H+sulphasalazine, the cardinals (#) represent the statistical significance compared to 
HC+sulphasalazine and the section symbols (§) represent the statistical significance compared to 
HC+NaHS. *p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test for A. and One-way ANOVA 
with post hoc Tukey tests for B. and C.). 
 
 
Cysteine is not able to rescue ATP production upon β-oxidation and glycolysis inhibition 
 
Since β-oxidation and glycolysis are other important sources of ATP synthesis, we ended 
by investigating if cysteine was able to rescue ATP production upon the blockage of these 
pathways under hypoxia. 
For ES2 cells, cysteine was not able to rescue ATP synthesis and even presented a 
negative effect upon β-oxidation inhibition with etomoxir (p=0.019). 
With bromopyruvic acid, an inhibitor of glycolysis, cysteine also presented a trend to 
reduce ATP levels, although there was no statistical significance (p=0.054) (figure 11 A).  
Regarding OVCAR3 cells, cysteine did not affect ATP synthesis neither upon the β-
oxidation nor the glycolysis inhibition (figure 11 B). 
 
 
Figure 11. Cysteine is not able to rescue ATP production upon β-oxidation and glycolysis 
inhibition. 
ATP levels for 48 h of experimental conditions for A. ES2 and B. OVCAR3 cells under hypoxia with and 
without cysteine and in the presence of the β-oxidation inhibitor etomixir and glycolysis inhibitor, 
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bromopyruvic acid. Data were normalised to the respective control condition (the same environmental 
condition H/HC without etomoxir or bromopyruvic acid). H – hypoxia, HC – hypoxia with cysteine. 
Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test). 
 
Together, results support a role of cysteine metabolism in ATP synthesis under hypoxia 
mediated, dependent on xCT transporter for cysteine uptake. However, cysteine was not able 
to rescue ATP synthesis upon both β-oxidation and glycolysis inhibition, indicating that these 
metabolic pathways are also sources of ATP production. Furthermore, cysteine can also be 
canalised to other metabolic pathways that do not contribute directly for ATP production. 
Nevertheless, these inhibitors can also have off-target effects, affecting other metabolic 
pathways. 
 
 
Cysteine rescues cellular metabolism of hypoxic ES2 cells 
 
In order to address the metabolic effects of cysteine under normoxia and hypoxia in ES2 
and OVCAR3 cells, we also measured the levels of several metabolites by 1H-NMR (figures 
12 and 13). 
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Figure 12. 1H-NMR spectra of ES2 cells. 
Typical 1H-NMR spectra of the growth media (upper panel) and aqueous phase (bellow panel) of ES2 
cells under hypoxia with cysteine. 
Metabolites: 1- formate, 2- inosine, 3- hypoxanthine, 4- UDP-N-acetyglucosamine, 5- phenyalanine, 6- 
tyrosine, 7- glucose, 8- lactate, 9- creatine, 10- glutamate, 11-glycine, 12- O-phosphocholine, 13- choline, 
14- succinate, 15- acetate, 16- alanine, 17- valine, 18- isoleucine, 19- leucine, 20- nicotinurate, 21- 
histidine, 22- tryptophan, 23- fumarate, 24- threonine, 25- pyroglutamate, 26- methionine, 27- glutamine, 
28- isopropanol, 29- isobutyrate, 30- 2-hydroxybutyrate, 31- methanol. 
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Figure 13. 1H-NMR spectra of OVCAR3 cells. 
Typical 1H-NMR spectra of the growth media (upper panel) and aqueous phase (bellow panel) of 
OVCAR3 cells under normoxia with cysteine supplementation. 
Metabolites: 1- formate, 2- inosine, 3- hypoxanthine, 4- UDP-N-acetyglucosamine, 5- phenyalanine, 6- 
tyrosine, 7- glucose, 8- lactate, 9- creatine, 10- glutamate, 11-glycine, 12- O-phosphocholine, 13- choline, 
14- succinate, 15- acetate, 16- alanine, 17- valine, 18- isoleucine, 19- leucine, 20- nicotinurate, 21- 
histidine, 22- tryptophan, 23- fumarate, 24- threonine, 25- pyroglutamate, 26- methionine, 27- glutamine, 
28- isopropanol, 29- isobutyrate, 30- 2-hydroxybutyrate, 31- methanol. 
 
The intracellular metabolites were analysed comparing the effect of cysteine in the 
metabolic profile of cells cultured in hypoxia with cells cultured in normoxia, in order to 
determine the decrease and increase of organic compounds driven by the presence of cysteine 
in both environments.  
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Regarding ES2 intracellular metabolites, cysteine increased the intracellular levels of the 
amino acids alanine (p=0.009), glutamate (p=0.012), glycine (p=0.008) and threonine 
(p=0.016) under hypoxia (figure 14 A). Cysteine also led to increased intracellular levels of 
lactate (p=0.021) (figure 14 B), choline (p=0.005) and creatine (p=0.005) (figure 14 C) under 
hypoxia. In the extracellular media (supernatants), the only significant difference found was 
in fumarate levels (p=0.046), where cysteine under hypoxia decreased the release of this 
amino acid (figure 14 E). Regarding histidine, when comparing the levels of this amino acid 
in the control media (without cells) we observed that CoCl2 reacted with histidine, as seen by 
its decreased concentrations under hypoxia, especially without cysteine supplementation 
(figure 15). Therefore, we cannot state that cysteine decreased the uptake of histidine under 
hypoxia. Instead, results suggest that cysteine increases the release of this amino acid, 
especially under normoxia (p<0.001). 
Through metabolic pathway analysis, results predicted that 9 metabolic pathways are 
significantly and differently altered in ES2 cells by cysteine under hypoxia compared to 
normoxia.	   The	   analysis	   showed	   alteration in the pathways of biosynthesis of: 1) glycine, 
serine and/ threonine; 2) alanine, aspartate and glutamate; 3) glutamine and glutamate; 4) 
arginine and proline; 5) GSH; 6) primary bile acid; 7) glycerophospholipid; 8) aminoacyl-
tRNA; and 9) purine nitrogen bases (figure 16). 
Regarding OVCAR3 cells, the only significant difference found on the effect of cysteine 
under hypoxia and normoxia on intracellular metabolites concentration was on glucose levels, 
where cysteine decreased the intracellular levels of glucose under hypoxia compared to 
normoxia (p=0.021) (figure 17 B). However, cysteine in hypoxia also provided a general 
tendency for increased intracellular amino acids such as alanine, glutamate, tyrosine and 
valine (figure 17 A). 
When analysing the amino acids levels present in the cell media, results have shown that 
cysteine under hypoxia led to a decreased uptake of alanine (p=0.023) and proline (p=0.008) 
and to an increased uptake of glycine (p=0.013) and phenylalanine (p=0.049) (figure 17 D). 
Cysteine also decreased the release of 2-hydroxibutyrate (p<0.001), formate (p=0.002) and 
isobutyrate (p<0.001) under hypoxia compared to normoxia in OVCAR3 cells (figures 17 E). 
Regarding histidine levels, similar to ES2 cells, cysteine seemed to induce a release of this 
amino acid, especially under normoxia (p<0.001) (figure 18). 
The metabolite pathway analysis was not performed for OVCAR3 cells because cysteine 
only altered significantly one metabolite (glucose) under hypoxia, thus making this analysis 
inaccurate.  
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Figure 14. Cysteine rescues ES2 cellular metabolism under hypoxia. 
Metabolites levels for 48 h of experimental conditions for ES2 cells A. intracellular amino acids, B. 
intracellular sugars and organic acids, C. other intracellular compounds, D. amino acids in supernatants, 
B. sugars and organic acids in supernatants, C. other compounds in supernatants. Data were normalised 
to the respective control condition (the same environmental condition NC/N and HC/H). NC – Normoxia 
with cysteine and HC – hypoxia with cysteine. Results are shown as median with 25th to 75th 
percentiles. *p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test). 
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Figure 15. Cobalt chloride (CoCl2) affects histidine levels. 
Histidine levels in control media (without cells) and after 48 h of experimental conditions for ES2 cells. 
N – Normoxia; NC – Normoxia with cysteine; H – hypoxia and HC – hypoxia with cysteine. Results are 
shown as mean ± SD. 
 
 
Figure 16. Under hypoxia, cysteine impacts several metabolic pathways in ES2 cells. 
Metabolic pathway analysis for the effect of cysteine under normoxia and hypoxia in intracellular ES2 
metabolites. All the matched pathways are displayed as circles. The colour and size of each circle are 
based on p-value and pathway impact value, respectively. The most impacted pathways having statistical 
significance (p<0.05) are indicated.  
Source: https://www.metaboanalyst.ca/MetaboAnalyst/faces/home.xhtml. 
 
 
N media N NC media NC H media H HC media HC
0.00
0.05
0.10
0.15
C
on
ce
nt
ra
tio
n 
(m
M
)
Histidine - ES2
	   	  
	   136	  
	  
Figure 17. Effect of cysteine in OVCAR3 metabolites under normoxia and hypoxia. 
Metabolites levels for 48 h of experimental conditions for OVCAR3 cells A. intracellular amino acids, B. 
intracellular sugars and organic acids, C. other intracellular compounds, D. amino acids in supernatants, 
B. sugars and organic acids in supernatants, C. other compounds in supernatants. Data were normalised 
to the respective control condition (the same environmental condition NC/N and HC/H). NC – Normoxia 
with cysteine and HC – hypoxia with cysteine. Results are shown as median with 25th to 75th 
percentiles. *p<0.05, **p<0.01, ***p<0.001 (Independent-samples T test). 
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Figure 18. Cobalt chloride (CoCl2) affects histidine levels. 
Histidine levels in control media (without cells) and after 48 h of experimental conditions for OVCAR3 
cells. N – Normoxia; NC – Normoxia with cysteine; H – hypoxia and HC – hypoxia with cysteine. 
Results are shown as mean ± SD. 
 
Importantly, hypoxia did not alter the intracellular and extracellular levels of glucose and 
lactate in both cell lines. Interestingly, hypoxia led to a decreased uptake of glutamine 
(p=0.032) and to an increased release of fumarate (p=0.041) in OVCAR3 cells (figure 19 A 
and B). 
 
Figure 19. Effect of hypoxia in glucose, lactate, pyruvate, fumarate and glutamine levels in ovarian 
cancer cells. 
Metabolites levels for 48 h of experimental conditions for A. ES2 and B. OVCAR3 cells. N – Normoxia 
and H – hypoxia. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (Independent-
samples T test). 
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Taken together, results suggest that under hypoxia, cysteine allows to increase the rate of 
some metabolic pathways in ES2 cells, as increased intracellular levels of several amino acids 
and other compounds were observed. Regarding OVCAR3 cells, results support that cysteine 
impacts differently the cellular needs of amino acids under normoxia and hypoxia, as cysteine 
increased the uptake of glycine and phenylalanine under hypoxia, whereas under normoxia, 
cysteine increased the uptake of alanine and proline. Moreover, under hypoxia, cysteine 
impacted in a more pronounced way ES2 cells metabolism compared to OVCAR3 cells, as 
seen by the higher number of metabolic pathways that were significantly altered under 
hypoxia compared to normoxia in ES2 cells. 
DISCUSSION 
 
As a solid tumour grows, cancer cells are exposed to regions of hypoxia, known to be a 
stimulus for tumour progression and resistance to therapy [11,12]. Recently, we have 
proposed that cysteine allows adaptation to hypoxic environments and also contribute to 
escape from carboplatin-induced death in ovarian cancer cells [14,15]. In here, we aimed to 
explore the mechanisms by which cysteine protects ovarian cancer cells from hypoxia-
induced death, by addressing its role in cellular metabolism, namely through energy 
production.  
Cystine uptake, the oxidized form of cysteine, is mediated by xCT (solute carrier family 7 
member 11 - SLC7A11), a member of the cystine-glutamate transporter xc- system [29]. 
Intracellularly, cystine is reduced to cysteine, which is the rate-limiting substrate for 
glutathione (GSH) synthesis, making xCT pivotal in the cellular redox balance maintenance 
(reviewed in [34]). In here, we have shown a mitochondrial localization of the xCT 
transporter concomitant with an impaired ATP production triggered by its inhibition under 
hypoxia, thus indicating a role of the xc- system via cystine uptake also in energy production. 
These data are in accordance with recent findings supporting a role of Nrf2 in the regulation 
of mitochondrial ATP synthesis (reviewed in [35]), as Nrf2 was already reported to regulate 
the expression of xCT and the activity of the xc- system in response to oxidative stress in 
human breast cancer cells [36]. Therefore, Nrf2 role in ATP synthesis can be mediated by 
cysteine via xCT transporter. We have to highlight that albeit sulphasalazine has been 
reported as a potent inhibitor of xCT function [37–39], it was also reported to inhibit the 
cystine transporter solute carrier family 3, member 1 (SLC3A1) in breast cancer cells, where 
increased expression of this transporter was found to enhance cysteine uptake and GSH 
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accumulation, decreasing ROS levels [40]. It is important to emphasise that SLC7A11 is 
generally assumed to function at the plasma membrane [41–43], but, in here, a mitochondrial 
localization was also found in ES2 and OVCAR3 cells. Other cysteine transporter, SLC3A1, 
was reported to localise on the plasma membrane of breast cancer cells as well [40], however, 
its localisation in ovarian cancer cells should be investigated in order to exploit its possible 
role in mitochondrial ATP synthesis. Interestingly, it was reported an up-regulation of 
SLC3A1 in samples from ovarian clear cell carcinomas compared to non-clear cell samples 
of epithelial ovarian cancer patients [44], hence suggesting the possible role of cysteine 
uptake via this transporter especially in ES2 cells.  
Cysteine role in mitochondrial ATP synthesis can be due to its degradation into H2S. H2S 
is the only inorganic compound presenting a bioenergetic role in mammalian cells’ 
mitochondria [45], that was already reported to contribute to mitochondrial ATP production 
through the activity of the enzymes involved in cysteine metabolism: MpST in conjunction 
with CAT [46,47], CSE [33] and CBS [19,20]. At low concentrations (nM), H2S is known to 
stimulate mitochondrial bioenergetics by way of different mechanisms: through donation of 
electron equivalents to the quinol pool via sulfide:quinone oxidoreductase; by the glycolytic 
enzyme glyceraldehyde 3-phosphate dehydrogenase activation, and by persulfidation of ATP 
synthase (reviewed in [28]). In addition, Li and Yang reported a role of CSE/H2S system in 
enhancing mtDNA replication and cellular bioenergetics both in smooth muscle cells and 
mouse aorta tissues [48]. More recently, Chakraborty and colleagues reported a new role of 
CBS in the regulation of mitochondria morphogenesis, promoting tumour progression in 
ovarian cancer [49]. Our results pointed to higher ATP levels concomitant with higher H2S 
levels, supporting that H2S can be an important source of mitochondrial ATP under hypoxia. 
Specifically under hypoxia conditions, H2S was reported to decrease reactive oxygen species 
(ROS), mediated by CBS mitochondrial accumulation [50] and induce ATP synthesis, 
mediated by CSE translocation to the mitochondria [33].   
Interestingly, our data have shown that the inhibition of CSE alone was not sufficient to 
decrease H2S levels. Miyamoto et al., using peripheral neurons, reported that H2S synthesis 
was inhibited by AOAA but not by PAG [51]. Hellmich and colleagues have reported similar 
results using colon cancer cell lines [52]. These results could explain the high levels of H2S 
observed in the presence of PAG in both ES2 and OVCAR3 cells, which, in turn, can be 
explained by both CBS and MpST activities since they were not inhibited. In the presence of 
both CBS and CSE inhibitors, the H2S levels are due to MpST activity in conjunction with 
CAT. The decreased H2S levels compared to the control can be related to CAT inhibition, 
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since AOAA was reported to inhibit also this enzyme in peripheral neurons [51]. We have to 
highlight that, whereas PAG is a selective CSE inhibitor, AOAA selectivity for CBS activity 
over CSE or other PLP dependent enzymes is limited, since it leads to an irreversible binding 
to the prosthetic group PLP [52]. Unfortunately, there are no commercial selective MpST 
inhibitors available. Just recently, Hanaoka et al. reported the discovery of selective MpST 
inhibitors with promising applications for in vitro and in vivo studies [53]. Therefore, more 
selective CBS inhibitors together with MpST inhibitors would allow shedding light on their 
role in H2S generation and ATP synthesis. But the simultaneous inhibition of CBS and CSE 
should undoubtedly show that MpST plays a relevant role in ATP production driven by 
cysteine degradation.  
Since we observed that the inhibition of both CBS and CSE enzymes was sufficient to 
decrease H2S levels, an impaired ATP synthesis upon their inhibition was expected. 
Bhattacharyya et al. reported that CBS inhibition with both AOAA and CBS siRNA, led to 
decreased ATP synthesis in ovarian cancer cells [19]. Strikingly, Chakraborty and colleagues 
not only reported a role of CBS in the regulation of mitochondria morphogenesis [49] but 
also in lipid uptake in ovarian cancer cells [54], suggesting a role of CBS in ATP synthesis 
favouring β-oxidation, which is also a mitochondrial pathway. In our study, we measured 
ATP levels with both CBS and CSE inhibitors and we did not observe decreased ATP levels, 
thus indicating that the inhibition of both enzymes leads to compensatory or alternative 
mechanisms of energy production, namely through MpST activity. We have to highlight that 
H2S levels were determined in cellular lysates that were exposed to the inhibitors for only 2 h, 
while ATP was determined with cells that were exposed for 48 h to the inhibitors. Thus, cells 
may have adapted to the presence of these inhibitors with a longer exposure period, allowing 
to compensate the activity of these enzymes, being able to also increase H2S production. 
However, we also have analysed ATP levels with 2 h of exposure to CBS and PAG inhibitors 
and we did not observe significant differences in ATP levels with or without the inhibitors in 
both cells lines, with the exception of OVCAR3 cells under hypoxia with cysteine 
supplementation in which the inhibitors led to decreased ATP levels (Suppl. figure 2). Hence, 
OVCAR3 cells may canalise the extra cysteine available for H2S synthesis, enhancing ATP 
synthesis under hypoxia in a short-term exposition but in a long-term, results support the 
existence of alternative ATP sources besides H2S under hypoxia. 
Interestingly, albeit CBS and CSE inhibition was not sufficient to impair ATP 
production, the inhibition of both enzymes affected ATP synthesis mainly under hypoxia for 
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both ES2 and OVCAR3 cells, thus supporting a role of their activity in hypoxic environment. 
PAG alone was not able to decrease H2S, but AOAA alone or the combination of both 
inhibitors generally was, implicating CBS activity inhibition (or MpST/CAT or both) in the 
decreased ATP synthesis observed upon the exposure to both inhibitors under hypoxia. Teng 
and colleagues reported that ischemia/hypoxia resulted in the increased accumulation of CBS 
in liver mitochondria, increased H2S generation and decreased ROS [50]. These results, 
therefore, may explain the decreased ATP levels under hypoxia upon the exposure to both 
inhibitors, where CBS inhibition may lead to increased ROS levels, affecting mitochondria 
function, hence affecting ATP synthesis. Regarding CSE, in vascular smooth-muscle cells, Fu 
et al., showed that this enzyme translocate to mitochondria under hypoxia, promoting H2S 
generation and resulting in mitochondrial ATP sustainability [33]. The specific contribution 
of CSE in ATP synthesis in ovarian cancer cells and under hypoxia remains unclear, since 
PAG alone was not able to decrease H2S levels, at least with 2 h of exposure. MpST role in 
H2S mediated-ATP production under hypoxia remains also unclear. It was reported that 
oxidative stress suppresses MpST activity, effecting the bioenergetic role of the 3-
mercaptopyruvate/MPST/H2S pathway in murine hepatoma cells [55]. However, we did not 
observe differences in MpST protein levels in both cell lines (Suppl. figure 3) and H2S levels 
were even induced under hypoxia, hence supporting that the activity of this enzyme was not 
affected under hypoxia in ovarian cancer cells. Moreover, we also observed a mitochondrial 
MpST enrichment compared to the cytosolic content. These results must be, nonetheless 
confirmed (Suppl. figure 4). Interestingly, MpST homolog was reported to protect E. coli 
against oxidative stress via L-cysteine utilization [56]. 
The specific contribution of CBS/CSE/MpST activities on cysteine-derived ATP 
synthesis under hypoxia remains unclear. Nevertheless, our results pointed to a role of 
cysteine in energy production mediated by the xc- system that requires its metabolism instead 
of H2S per se. Remarkably, in vascular smooth-muscle cells, NaHS, an exogenous H2S 
source, was reported to be sufficient to increase mitochondrial ATP production under hypoxia 
[33]. In Fu and colleagues study, the ATP measurements were performed after 1 h of NaHS 
exposition, and Sun et al. reported that NaHS is unstable and leads to an instant release of 
H2S in culture medium [31], which decays rapidly [32], we also quantified ATP levels with 1 
h of NaHS and sulphasalazine exposure to address if H2S effect was transient, hence 
undetectable with 48 h of culture conditions. Our results have shown that H2S per se was not 
sufficient to counteract the impaired ATP production driven by sulphasalazine, leading even 
to an impaired ATP production under hypoxia for both ES2 and OVCAR3 cells, suggesting 
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that cysteine metabolism provides alternative sources for energy production in ovarian cancer 
cells. In addition to H2S, cysteine degradation is known to generate pyruvate as well [27], 
which can further supply substrates to the tricarboxylic acid cycle, sustaining mitochondrial 
ATP production in ovarian cancer cells. Furthermore, recently, it was shown a role of 
cysteine hydropersulphide (CysSSH) in the regulation of mitochondrial biogenesis and 
bioenergetics [57]. Using HEK293T cells, the authors found that CysSSH can be produced 
not only by CBS and CSE (from cystine) but also by the mitochondrial isoform cysteinyl-
tRNA synthetases (CARS2) plays also an important role in CysSSH generation (from 
cysteine) [57], hence making us hypothesise that this may be other source of ATP production 
upon the action of both the inhibitors. However, the authors have also shown that the 
persulphide synthase activity of CARS2 is also dependent on the presence of pyridoxal 
phosphate (PLP) [57] and AOAA inhibits several PLP-dependent enzymes [52], thus the 
possible CysSSH contribution in ATP production in hypoxic ovarian cancer cells remains 
unclear.  
Other possibility of cysteine role in ATP production upon xCT inhibition is through an 
indirect contribution by increasing GSH content. The extra cysteine available can be used in 
GSH synthesis, thus allowing cells to escape from oxidative stress and enabling increased cell 
viability and proliferation, therefore leading to increased ATP synthesis. In fact, our previous 
data have supported a role of a higher thiols turnover in hypoxia adaptation, especially in ES2 
cells [15]. Interestingly, H2S was also reported to increase the production of GSH by inducing 
the expression of cystine/cysteine transporters and by redistributing GSH to mitochondria in 
mouse brain neuroblastoma, Neuro2a cells and mouse hippocampal HT22 cells [58]. In here, 
1H-NMR results have also suggested a role of cysteine in cellular metabolism rescue under 
hypoxia, especially in ES2 cells. Therefore, our data have shown that under hypoxia, cysteine 
significantly increased the intracellular levels of several amino acids, including alanine, 
glutamate, glycine and threonine in ES2 cells. Interestingly, Jain and colleagues have 
reported that increased glycine consumption was associated with increased proliferation rate 
in 60 cancer cell lines, and that this effect was more evident in ovarian cancer, colon cancer, 
and melanoma cells [59]. The authors also demonstrated that glycine was used in part for de 
novo purine nucleotide biosynthesis and for GSH in rapidly proliferating cells, as they 
reported an incorporation of labelled glycine into this thiol [59]. Importantly, the same 
authors have also shown that this phenotype with increased dependence on glycine 
metabolism was specific of rapidly proliferating malignant cells [59]. Cysteine was found to 
increase glycine levels in ES2 cells under hypoxia, hence supporting its role in the putative 
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rescue of the proliferation of hypoxic ES2 cells. Furthermore, strengthening the proliferation 
rescue effect of cysteine in hypoxic ES2 cells, Hosios and colleagues have found that the 
majority of cellular carbon mass is not derived from glucose and glutamine (that contributed 
only for about 10% of cell mass each one) but from other amino acids that were consumed at 
lower rates, where glutamine contributed primarily to protein, and glucose contributed as a 
major source of de novo lipogenesis [60]. Valine and serine each contributed only for 2–4% 
of carbon cell mass but a pooled mixture of amino acids was able to label the majority of 
cellular carbon in proliferating mammalian cells, including alanine, arginine, asparagine, 
aspartate, cystine, glutamate, glycine, histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine [60], hence 
supporting a role for these amino acids in biomass building. Importantly, using two different 
non-small cell lung cancer cell lines, the same authors also reported that hypoxia did not alter 
glucose and glutamine incorporation in H1299 cells, but the incorporation of both was 
decreased in A549 cells, while serine and valine incorporation were relatively unaltered in 
both cell lines [60], hence showing metabolic diversity when coping with hypoxia. 
Under hypoxia, cysteine was also able to increase intracellular choline levels in ES2 cells. 
An activated choline metabolism was already considered as a metabolic hallmark of cancer, 
where increased levels of phosphocholine and total choline-containing compounds are 
features of the cholinic phenotype, and are not only important for cancer cells proliferation 
but also for the malignant transformation [61]. Phosphatidylcholine is the most prevalent 
phospholipid in eukaryotic cell membranes, contributing to cell growth and programed cell 
death [62]. Choline kinase catalyses choline to phosphocholine phosphorylation, which is the 
first step of phosphatidylcholine biosynthesis [62]. Hypoxia was shown to increase cellular 
phosphocholine levels and total choline levels by inducing choline kinase protein expression 
in prostate cancer cells [63]. Interestingly, choline was reported to protect the endothelial 
function against hypoxia in rats exposed to chronic intermittent hypoxia [64]. In our study, 
cysteine increased choline levels under hypoxia, supporting again its role in hypoxic ES2 
cells metabolic rescue. 
Our data supported that cysteine increased histidine release in both ES2 and OVCAR3 
cells under hypoxia. Recently, Kanarek and co-workers have reported that the histidine 
degradation pathway significantly augments the sensitivity of cancer cells to methotrexate, an 
anti-cancer drug that inhibits the enzyme dihydrofolate reductase, responsible for 
tetrahydrofolate generation, which is an essential cofactor in nucleotide synthesis, both in 
vitro and in vivo in leukaemia context [65]. The authors have reported that histidine 
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supplementation increased the efficacy of methotrexate in mice leukaemia xenograft models, 
through tetrahydrofolate depletion within tumour cells [65]. These results may suggest that 
histidine is disadvantageous in stressful environments, hence leading cells to avoid its 
consumption. However, in our study, CoCl2 was found to decrease histidine levels in media 
without cells. Torii and colleagues have reported that histidine was able to inhibit the cobalt-
induced HIF-1α expression in human breast cancer MCF-7 cells cultured in DMEM, possibly 
by sequestrating the free cobaltous ion in the medium [66]. In fact, cobalt (II) was reported to 
form tetrahedral complexes with L-histidine [67] and that oxygen interacts with the complex 
Cobalt(II)-Histidine in basic solutions [68], hence explaining the decreased levels of histidine 
under hypoxia mimicked with CoCl2. Because results suggested that cysteine increased the 
release of histidine under hypoxia, we hypothesise that histidine release is another way of 
cellular protection against the oxidative stress imposed by CoCl2. However, under normoxia, 
cysteine also increased the release of this amino acid both in ES2 and OVCAR3 cells, and 
under hypoxia without cysteine no release of histidine was observed. Thus the role of 
histidine in the response to hypoxia mimicked with CoCl2 remains unclear. We have to 
highlight that albeit histidine might decrease CoCl2 concentration, our previous results have 
shown that the CoCl2 concentration used was able to induce HIF-1α expression in our 
experimental setting. Interestingly, the pentose phosphate pathway supplies the biosynthesis 
of histidine [69], hence an altered glucose metabolism explains the higher levels of histidine 
release. In fact, our results supported that cysteine increased glucose metabolism under 
hypoxia for both ES2 (as seen by the increased intracelular lactate levels) and OVCAR3 cells 
(as seen by the decreased intracelular glucose levels) compared to normoxia, hence 
supporting that under hypoxia, histidine biosynthesis may be increased due to an increased 
glycolysis. Remarkably, it was reported that HIF-2α induces the hepatocyte release of the 
histidine rich glycoprotein [70]. If this mechanism is spread to other histidine rich proteins 
and if HIF-2α is up-regulated under hypoxia in our experimental setting is unknown, but we 
can speculate that hypoxia induces both HIF-1α and HIF-2α, inducing the release of histidine 
in the presence of cysteine. 
Strikingly, the metabolic impact of cysteine under hypoxia was much more pronounced 
in ES2 cells compared to OVCAR3 cells, as seen by the remarkable number of metabolic 
pathways that were significantly altered in these cells. Interestingly, hypoxia led to an 
increased release of fumarate in OVCAR3 cells. Importantly, Schito and colleagues have 
reported that fumarate accumulation was responsible for an increased antioxidant capacity of 
hypoxic cancer cells through upregulation of the pentose phosphate pathway. Moreover, the 
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authors also reported that this fumarate-dependent increase of antioxidants was able to 
counteract the hypoxic activation of the endoplasmic reticulum kinase (PERK), a possible 
signalling transducer of the unfolded protein response that inhibits mRNA translation via 
eIF2α phosphorylation. This enabled protein synthesis and proliferation, allowing an 
impaired hypoxia tolerance in cancer cells [71]. Hence, increased fumarate release may play a 
role in hypoxia tolerance in OVCAR3 cells. Interestingly, cysteine affected differently the uptake of 
several aminoacids under hypoxia, decreasing the uptake of alanine, histidine and proline and 
increasing the uptake of glycine and phenylalanine. Nevertheless, these results also support a 
possible role of cysteine in the rescue of the proliferation of hypoxic OVCAR3 cells, at least 
in part. In OVCAR3 cells, cysteine decreased the release of 2-hydroxibutyrate, which is a by-
product of the conversion of cystathione to cysteine in the methionine-to-glutathione 
pathway, being its generation directly related to the rate of glutathione synthesis [72]. 
Therefore, higher extracellular levels of this compound were expected under hypoxia in the 
presence of extra cysteine. This suggests that OVCAR3 cells show little reliance in GSH 
synthesis on coping with hypoxia, results supported by our previous observations [15]. 
Nevertheless, 2-hydroxibutyrate also results from the degradation of long and very long chain 
fatty acids through β-oxidation [73], and since cysteine decreased the release of this 
compound under hypoxia, this suggests that this pathway is also decreased. Moreover, 
isobutyrate, which is a precursor of hydroxybutirate [74], was also decreased by cysteine in 
hypoxic OVCAR3 cells.  
Cysteine also decreased the release of formate under hypoxia compared to normoxia in 
OVCAR3 cells. Formate is primarily produced in the mitochondria from serine and functions 
as a source of one-carbon groups for the synthesis of 10-formyl-tetrahydrofolate and for other 
one-carbon intermediates, which are mainly used for the synthesis of purine and thymidylate, 
and for the delivery of methyl groups for synthetic, regulatory, and epigenetic methylation 
reactions [75]. In cancer, results have strongly supported an enhanced mitochondrial 
production of formate [75]. Interestingly, Thomas and colleagues suggested formate as a 
potent reductive force opposing oxidative stress in Pseudomonas fluorescens, by contributing 
both to the synthesis of NADPH and to the reduction of fumarate to succinate [76]. Formate 
probably has a role also in cancer cells response to oxidative stress, as mitochondrial folate 
pathway generates excess of formate that cells secrete, suggesting that the folate pathway 
plays pivotal roles besides the one-carbon delivery, such as the maintenance of mitochondrial 
NADH and NADPH levels [77]. Importantly, evidence supports an important role of the 
folate pathway in ovarian cancer, as α-folate receptor (αFR) was found to be expressed in 
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over 70% of primary ovarian tumours and 80% of recurrent ovarian cancers, whereas the 
normal ovarian epithelium does not express this receptor [78]. Moreover, the receptor 
expression was also shown to be associated with the progression of the disease and with 
chemoresistance [78]. Given the relevance of folate pathway in ovarian cancer, different 
targeted therapies were already developed with promising results [79]. In OVCAR3 cells 
cysteine decreased the release of formate levels under hypoxia, hence suggesting that cysteine 
impairs folate pathway under hypoxia in these cells. However, since formate can also be 
produced from histidine catabolism and since cysteine significantly reduced histidine uptake 
or increased histidine release under hypoxia in OVCAR3 cells, this could explain the low 
levels of formate release in these conditions. Similar trends were found for ES2 cells also, 
albeit the differences were not statistical significant.  
Interestingly, while cysteine was able to rescue the impaired ATP synthesis triggered by 
xCT inhibition, it was not able to increase ATP synthesis upon β-oxidation and glycolysis 
inhibition, indicating that cysteine is not enough to replace the contribution of these pathways 
for ATP production. In fact, for ES2 cells, cysteine tended to decrease ATP synthesis in the 
presence of these inhibitors. Pike at al., using human glioblastoma cells, demonstrated that 
etomoxir, an inhibitor of β-oxidation, lead to decreased cellular ATP levels and viability, 
concomitant with decreased GSH content and increased ROS [80]. These results suggest that 
the extra cysteine available may be being canalised to GSH synthesis. However, the 
decreased ATP and GSH content were observed with very high doses of etomoxir (0.75 mM 
and 1 mM) [80]. Recently, Yao et al. reported that 200 µM lead to etomoxir off-targets 
effects in BT549 breast cancer cells, inhibiting not only the etomoxir target CPT1 but also the 
complex I of the electron transport chain, leading to decreased ATP production and cell 
proliferation independent of β-oxidation [81]. The authors also reported that BT549 cells 
treated with 10 µM of etomoxir (the same concentration used in here), while presented a 90% 
block of β-oxidation without off-target effects on respiration, did not present reduced 
proliferation, mitochondrial respiration and ATP production. Instead, the authors reported 
that cells adjusted their nutrients uptake and utilization to compensate for the inhibition of 
this pathway [81]. Weather this dose was sufficient to increase ROS levels and reduce GSH 
content in BT549 breast cancer cells is still unclear, since the authors did not address these 
effects. However, O’Connor and colleagues reported that etomoxir concentrations above 5 
µM presented off-targets effects, inhibiting the oxidative metabolism and inducing severe 
oxidative stress in T cells [82]. These results therefore support that oxidative stress is a 
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common off-target effect of etomoxir, even with low doses, indicating that the extra cysteine 
available is indeed canalised as a ROS scavenger for counteracting the harmful oxidative 
conditions. 
Bromopyruvic acid is an alkylating agent capable of inhibiting not only glycolysis, but 
also mitochondrial respiration [83], glutaminolysis and TCA cycle functions [84]. This 
compound, was also shown to induce oxidative stress through antioxidants depletion and 
inactivation of antioxidant enzymes in human breast cancer cell lines [85]. This decreased 
GSH content may be explained by the reaction of bromopyruvic acid with GSH, forming a S-
conjugate [86]. These results suggest that, in the presence of etomoxir and bromopyruvic 
acid, ES2 cells preferentially canalised the extra cysteine available for GSH synthesis instead 
of ATP production, thus allowing the cellular defence against oxidative stress. Nevertheless, 
cysteine can act by itself as an antioxidant and S-conjugates of bromopyruvic acid can also be 
established with cysteine instead of GSH. However, we may not have used the right 
experimental approach to inhibit these pathways without un-specifically interfering with other 
metabolic reactions. 
Together, the results support that ES2 and OVCAR3 cells use cysteine differently in order to 
cope with hypoxic environments, where cysteine especially impacts hypoxic ES2 cells metabolic 
features, hence providing a source for metabolism reprograming under hypoxia conditions. In the 
figure 20, the possible direct and indirect mechanisms by which cysteine allows ATP production in 
hypoxic ovarian cancer cells is presented. The profound metabolic impact that cysteine showed 
under hypoxia, suggesting a strong remodelling of the carbon metabolism is also presented. 
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Figure 20. Cysteine possible direct and indirect roles in ATP synthesis and in carbon metabolism 
reprogramming under hypoxia in ovarian cancer cells. 
A. Under hypoxia, cysteine degradation could contribute directly to ATP production via not only H2S generation, 
but also via pyruvate and α-ketobutyrate that could further supply the TCA cycle, leading to increased ATP 
synthesis. Cysteine could also present an indirect role in ATP synthesis mediated by increasing GSH content under 
hypoxia, hence counteracting oxidative stress and thereby increasing cellular metabolism. 
B. The axis cysteine-pyruvate-glucose is central in whole metabolic network of carbon. Cysteine degradation can 
originate pyruvate and glutamate. Pyruvate besides being a major supplier of tricarboxylic acids (TCA) cycle, it can 
be converted into valine, isoleucine, leucine, alanine, lactate and acetate. Alanine can be a source of glucose 
through gluconeogenesis. Glycolysis, produce intermediates to supply the TCA cycle (a hub for many precursors 
of organic compounds, such as threonine) and the pentose phosphate pathway (PPP). PPP intermediates can be 
converted into amino acids such as histidine and can be conjugated with glycolysis intermediates, originating 
tyrosine, phenylalanine and serine, which can be converted into glycine. PPP is also crucial in the nucleotides 
synthesis. The increased concentration of these compounds under hypoxia, suggests that cysteine is pushing the 
metabolic flow in order to supply the main carbon metabolic pathways. The direct incorporation of cysteine into 
this compounds is possible, however further studies are needed to clarify this. Based on information from 
www.bioinfo.org.cn. 
 
New experiments are needed to ascertain if cysteine is used as substrate to produce some of 
these organic metabolites. NMR analysis of cells exposed to 13C-cysteine would be very helpful to 
clearly determine which metabolic pathways are directly dependent on cysteine.  
Taken together, our data support that targeting cysteine uptake is a promising tool to fight 
ovarian cancer, as it allows not only hypoxia adaptation, but also platinum-based drugs 
resistance. The system xc- was already reported to be up-regulated in several cancer cell 
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types and it is associated with drug resistance [34] thus, inhibiting its function through 
sulphasalazine may constitute a valuable tool to fight several types of cancer. Sulphasalazine 
is already used in the context of other diseases, such as Crohn’s disease [87] and rheumatoid 
arthritis [88,89]. Interestingly, in patients with inflammatory bowel disease, Qiu and 
collegues through a systematic review with meta-analysis reported that 5-Aminosalicylic acid 
(the main metabolite of sulphasalazine and mesalazine) decreased the risk of colorectal 
cancer but not the risk of dysplasia [90]. However, the authors also reported that whereas 
mesalazine showed a protective role against colorectal cancer, sulphasalazine did not [90]. 
Nevertheless, a beneficial use of sulphasalazine in other cancer types was also reported. In the 
context of pancreatic cancer, Lo et al. reported that sulphasalazine was able to enhance 
gemcitabine efficacy, thus indicating that this combined therapy is more effective in 
refractory pancreatic cancer [91]. Balza and colleagues, in an experimental model of 3-
methylcholantrene induced mouse sarcoma, reported that sulphasalazine combined with the 
cyclooxygenase 2 inhibitor, ibuprofen, led to decreased sarcoma progression and tumour size 
as well as an increased survival of treated mice [92]. Later, Balza et al. also reported that 
sulphasalazine combined with esomeprazole (which inhibits membrane v-ATPases) 
decreased cellular growth and migration in melanoma and sarcoma cells [93]. Remarkably, 
Nagano et al. have already proposed the use of targeted therapy to cancer stem cells that 
express variant forms of CD44 (CD44v) that stabilize and interact with xCT [94]. This 
targeted CD44v-xCT system would possibly allow to abrogate cellular ROS defence and 
redox adaptation, therefore sensitizing cancer stem cells to the available anti-cancer drugs 
[94].  
Collectively, data support the use of cysteine metabolism and transport-targeted therapy, 
such as sulphasalazine, as a promising strategy in the context of ovarian cancer treatment. 
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SUPPLEMENTS 	  
Supplement figure 1 
 
Supplement figure 1. ES2 cells express higher basal mRNA levels of xCT than OVCAR3 cells. 
Basal relative xCT mRNA expression for ES2 and OVCAR3 cells. 
Briefly, ES2 and OVCAR3 cells were cultured in 6-well plates (5x105 cells/well) and cultured under 
basal conditions (normoxia without cysteine supplementation with 1% of FBS). Cell were collected and 
RNA was extracted with RNeasy Mini Extraction kit (74104, Qiagen), according to the manufacturer’s 
protocol. cDNA was synthesized from 1µg RNA and reversely transcribed by SuperScript II Reverse 
Transcriptase (18064-22, Invitrogen), according to the manufacturer’s protocol. Quantitative Real-Time 
PCR was performed using LightCycler 480 SYBR Green I master (04707516001, Roche), according to 
manufacturer’s protocol. Primers for xCT (For: 5’ GGTCCTGTCACTATTTGGAGC 3’; Rev: 5’ 
GAGGAGTTCCACCCAGACTC 3’) were used. Real-time PCR was carried out in LightCycler 480 
instrument (Roche). Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 (Independent-
samples T test). 
 
Supplement figure 2 
 
Supplement figure 2. Effect of CBS and CSE inhibition in ATP synthesis in ovarian cancer cells. 
ATP levels in control conditions and in the presence of 1 mM AOOA and 3 mM PAG for 2 h of 
experimental conditions for ES2 and OVCAR3 cells. The asterisks (*) represent the statistical 
significance compared to the respective control. *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA 
with post hoc Tukey tests). N – normoxia; NC – normoxia with cysteine, H – hypoxia, HC – hypoxia 
with cysteine. Results are shown as mean ± SD. 
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Supplement figure 3 
 
Supplement figure 3. MpST protein levels in ES2 and OVCAR3 cells. 
Quantification of anti-MpST western blotting for ES2 and OVCAR3 cells. Data were normalised to 
control (normoxia). NC – normoxia with cysteine, H – hypoxia, HC – hypoxia with cysteine. 	  
Supplement figure 4 
 
Supplement figure 4. Cytosolic and mitochondrial MpST protein levels in ES2 and OVCAR3 cells. 
Western blotting for A. cytosolic MpST and B. mitochondrial MpST in ES2 and OVCAR3 cells. 
For western blotting for cytosolic MpST, briefly, cells (2.5 × 106) were cultured in 25-cm2 tissue culture 
flasks in control conditions and exposed either to 0.402 mM L-cysteine and/or 0.100mM cobalt chloride 
for 16 h. Cells were collected with trypsin and western blot analysis was performed. Anti-MpST (1:250; 
HPA001240 from sigma) and anti-β-actin (1:5000; A5441 from Sigma Aldrich) antibodies were used. 
Secondary antibodies (1:5000; anti-rabbit, 31460, from Thermo Scientific or anti-mouse 31430 from 
Thermo Scientific) were used. For the western blotting presented, 100 µg of total protein was used. For 
western bloting with isolated mitochondria, the methods are described previously in the materials and 
methods section. 
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CHAPTER 5 
 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
“Though I'm past one hundred thousand miles,  
I'm feeling very still 
And I think my spaceship knows which way to go”  
David Bowie 
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GENERAL DISCUSSION 
 
The present thesis aimed to clarify the relevance of cysteine metabolism in ovarian cancer 
cells capacity of adapting to both hypoxia and carboplatin, both of which responsible for 
imposing strong evolutionary selection pressures on cancer cells.  
In the next sections, we will discuss the most relevant results obtained during this thesis. 
 
5.1 HYPOXIA ADAPTATION FAVOURS A GENERALIST PHENOTYPE IN 
OVARIAN CANCER CELLS AND DRIVES CARBOPLATIN RESISTANCE 
 
The adaptation to a specific environment is widely associated to deterioration in other 
non-selective environments, being accompanied by an evolutionary trade-off [1–4]. In fact, in 
the second chapter, our results supported an evolutionary trade-off in ovarian cancer cells 
selection under normoxic conditions, where these cells presented decreased survival in novel 
environments. However, in hypoxia-selected cells, no evolutionary trade-offs in non-selective 
environments were found, as cells did not present increased mortality, hence showing a 
generalist phenotype. Albeit no trade-offs were found in other non-selective environments, 
cells selected under hypoxia exhibited a trade-off among survival and cell growth, as the 
increased survival was accompanied by lower proliferation rates. This observation, together 
with the evidence that each patient’s tumours exhibit large variation in proliferation rates [5] 
may have clinical implications for cancer patients, as therapy protocols effectiveness may 
depend on the evolutionary strategy of cancer cells. For instance, the rational that cytotoxic 
drugs kills preferentially cells with increased proliferation rates, such as paclitaxel, might not 
be effective for quiescent or low proliferating cancer cells such as hypoxic or chemoresistant 
ones. Therefore, the maintenance of quiescent cells, as the cancer stem cells, will allow its 
proliferation once the chemotherapy drugs are removed, leading to disease relapse and 
metastasis [6]. Interestingly, we observed induced CD133 levels, a cancer stem cell marker, 
both upon hypoxia and carboplatin exposure in several ovarian cancer cell lines. CD133 is a 
membrane glycoprotein already reported as an ovarian cancer stem cell marker and associated 
with increased tumour initiating capacity and chemoresistance [7]. Interestingly, upon 
carboplatin exposure, the already resistant A2780 cisR cells did not increase CD133 levels in 
the majority of treatments, whereas A2780 parental, the chemosensitive cells, did. These 
results support that CD133 positive phenotype is part of the process of carboplatin acquiring 
resistance that is lost when cells become chemoresistant. It would be interesting, therefore, to 
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assess the dynamics of other ovarian cancer stem cell markers such as CD44 and CD117 [7,8] 
in chemosensitive and chemoresistant cells. 
Strikingly, our data supported that 48h of hypoxia exposure were sufficient to drive 
carboplatin adaptation in ES2 cells, independent of the regime of selection. This observation 
shows that this simple exposure of cancer cells to a hypoxic environment, without 
considering all the complex microenvironmental interactions that also favours 
chemoresistance [9], is sufficient to alter the ovarian cancer cells outcome. It is well known 
the importance of hypoxia during the normal mammalian development, which is 
accompanied by a moderate-to-severe hypoxic environment, being HIF expression and 
activity tightly regulated in space and time by oxygen availability in several developmental 
processes, making oxygen a crucial morphogen regulating cell fate [10]. As Nobre and 
colleagues argued, cancer cells recapitulate this process in an abnormal way, where hypoxia 
strongly regulates cancer cells fate [10]. Hence, it is obvious to reason that hypoxia severity 
and duration and intermittent hypoxia dynamics (cycles of re-oxygenation) impact differently 
the outcome of cancer cells. However, no clear definitions for the duration of acute and 
chronic hypoxia exist in experimental oncology; in vitro and in vivo exposure times for both 
hypoxia regimes reported in the literature vary greatly and even overlap [11]. There are 
controversies also when trying to associate one or the other hypoxia regime to a poorer 
disease outcome, but generally an acute cellular exposure to hypoxia is linked to a more 
aggressive phenotype compared to a chronic exposure, as the former was associated with the 
induction of spontaneous metastasis [11–13]. However, the opposite was also reported in a 
recent review [10].  
Hence, we argue that the fluctuation of oxygen rate might be more important in cancer 
cells outcome, as a moderate rate of hypoxia-reoxygenation. Thus, such a moderate rate of 
microenvironmental change might contribute for the maintenance of metabolic diversity and 
for a faster metabolic response/higher adaptive capacity in novel environments. An extreme 
lower rate of environmental change can contribute for a reduced cellular diversity due to the 
selection of an exclusive phenotype that is better adapted to that specific environment. We 
argue that, albeit in vitro 2D culture assays do not recapitulate the in vivo complexity, our 
model of selection under hypoxia represents a chronic hypoxia exposure with a high rate of 
oxygen fluctuations, as oxygen is continuously entering and reacting with CoCl2. Hence, this 
environment allowed the selection of an aggressive phenotype with a high degree of 
metabolic adaptability in novel environments. Therefore, it would be interesting to further 
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address the effects of different hypoxia regimes in the outcome of ovarian cancer cells not 
only in 2D but also in 3D cell culture models. 
 
5.2 CYSTEINE FACILITATES THE ADAPTATION OF OVARIAN CANCER CELLS 
TO BOTH HYPOXIA AND CARBOPLATIN 
 
The second chapter of this thesis provided evidence that cysteine metabolism has a 
biological role in ovarian cancer cells, as it allows a fast response and adaptation to hypoxic 
conditions that, in turn, are capable of driving chemoresistance. Noticeably, data supported 
that cysteine was even able to suppress the evolutionary trade-off of normoxia adaptation 
under hypoxia conditions, hence showing that normoxia selected cells still present metabolic 
diversity, allowing them to use cysteine and survive in a novel hypoxic environment. 
In the third chapter, cysteine role upon hypoxia and carboplatin exposure was 
strengthened, where cysteine showed to present a widespread protective effect against both 
hypoxia and carboplatin-induced death among ovarian cancer cell lines. Interestingly, 
cysteine was advantageous for the cisplatin resistant A2780 cells but not for A2780 parental, 
sensitive cells, reinforcing that cysteine accounts for the selective process of platinum 
resistance in ovarian cancer cells. 
Therefore, these results support that targeting cysteine can be an effective strategy to 
fight several histological types of ovarian carcinomas, as it allows a metabolic response to 
microenvironmental conditions associated to a poorer disease prognosis.  
 
5.3 CYSTEINE MECHANISTIC ROLE IN HYPOXIC OVARIAN CANCER CELLS 
 
Given the protective role of cysteine under hypoxic conditions, we aimed to clearer the 
mechanism by which cysteine protects ovarian cancer cells from hypoxia-induced death.  
In the third chapter, results supported that thiols dynamics of synthesis and degradation 
underlie mainly ES2 cells hypoxia adaptation, as a higher rate of GSH degradation was found 
under hypoxia with cysteine supplementation. These results have also proposed that ovarian 
cancer cells from different origins may manage hypoxic stress by different mechanisms, 
where ES2 cells present a metabolism that is more dependent on cysteine than OVCAR3 
cells. This evidence, on the other hand, points that cysteine metabolism can be related to a 
worse outcome of the disease, as OCCC is generally associated with a worse disease 
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prognosis compared to serous carcinomas and other histological types [14,15]. This 
hypothesis should be further explored, as this confirmation brings a valuable tool to manage 
the different ovarian carcinomas that have been, so far, treated mainly with identical clinical 
approaches. Nevertheless, what we disclosed in this thesis was the fact that ovarian 
carcinoma cells, whose metabolism relies more on cysteine bioavailability, exhibit a higher 
capacity to adapt to metabolic and toxic stressful conditions. 
In the fourth chapter, we additionally aimed to explore other possible mechanisms by 
which cysteine can benefit hypoxic ovarian cancer cells. Our results have pointed to a role of 
cysteine also in energy production mediated by the xc- system, emphasizing the importance of 
cysteine metabolism beyond the production of H2S per se. These data are in accordance with 
recent findings supporting a role of Nrf2 in the regulation of mitochondrial ATP synthesis 
(reviewed in [16]). Nrf2 is a transcription factor that was already reported as pivotal in the 
regulation of xCT expression and consequently in the activation of the xc- system in response 
to oxidative stress [17]. Therefore, our results support that ATP synthesis can be also 
mediated by cystine/cysteine uptake via the xCT transporter. The mitochondrial localization 
of xCT together with the absence of de novo synthesis of GSH in the mitochondrial matrix 
[18], strongly supports a role of this transporter in energy production mediated by cysteine 
uptake, besides its pivotal role in redox maintenance. Whether cysteine has a direct or indirect 
role in energy production, the relative importance of CBS, CSE and MpST activities are still 
unclear.  
The direct role of cysteine in ATP production is still uncertain as this amino acid can 
have an indirect contribution to ATP synthesis driven by increased GSH content, allowing the 
redox equilibrium crucial for the overall metabolic flow. In fact, as already mentioned, in the 
chapter three our results have supported a role of a higher thiols turnover in hypoxia 
adaptation, especially in ES2 cells [19]. Moreover, in the fourth chapter, 1H-NMR results 
have suggested that under hypoxia, the presence of cysteine augments glycine and glutamate 
content in ES2 cells, the other components of GSH besides cysteine. Besides that, these 
amino acids also contribute to de novo purine synthesis [20], proposing other indirect role of 
cysteine in energy production mediated by the increased bioavailability of these amino acids 
that can also account for ATP synthesis. Nonetheless, a role of cysteine in cellular 
metabolism reprogramming under hypoxia, especially in ES2 cells was observed. Strikingly, 
data supports an extremely pronounced metabolic impact of cysteine under hypoxia in ES2 
cells, as seen by the remarkable number of metabolic pathways that were significantly altered 
in these cells. In the figure 1, we present a summarized model with all the possible 
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contributions of cysteine in ovarian cancer cells metabolism and adaptation to hypoxic 
environments. 
 
Figure 1. Proposed model for cysteine protective effect under hypoxia in ovarian cancer cells. 
A. In a basal condition, cystine can be imported by the xCT transporter [21]. In the intracellular 
compartment, cystine is reduced into cysteine [22], which can be further canalized to GSH synthesis, to 
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protein synthesis and cysteinylation, to coenzyme A, to H2S, to pyruvate and to taurine. In basal 
conditions, CBS, CSE and MpST are the main enzymes involved in H2S generation in the cytosol. CBS 
and CSE were already reported to re-localize to the mitochondria in conditions of oxidative stress 
[23,24]. In basal conditions, in the mitochondria, MpST in conjunction with CAT are the main enzymes 
responsible for H2S generation [24]. CBS was also reported to be involved in the regulation of protein 
cysteinylation [25]. Cysteine can also be catabolized by cysteine dioxygenase (CDO), into cysteine 
sulfinate, that subsequently can originate pyruvate, sulfite and hypotaurine, which then can originate 
taurine and H2S [26]. In cancer, CDO was reported to be downregulated in several cancer types, 
including ovarian cancer [27,28]. However, when both CBS and CSE were inhibited with AOAA in 
combination with PAG, one possible route to increase H2S levels would be an increased CDO activity. 
Importantly, CDO activity was reported to be modulated dependently on cysteine concentration in human 
hepatic cell lines [29], suggesting that with cysteine, this enzyme can be increased in ovarian cancer cells, 
increasing H2S production. With CBS and CSE inhibitors, other possible mechanism to increase H2S 
levels would be an enhanced MpST activity. Adapted from [26]. 
B. Under normoxia, cells canalize cysteine especially to GSH synthesis that is oxidized to GSSG and also 
to H2S, which is increased under hypoxia (possibly both cytosolic and mitochondrial). With cysteine 
supplementation, a higher GSH turnover under hypoxia was found. This mechanism is particularly 
relevant for ES2 cells. With increased ROS, GSH oxidation (GSSG) can also increase and it is not only a 
source of cystine through its extracellular catabolism, but was also reported to increase HIF-1α 
stabilization [30]. This high thiols turnover, together with increased H2S levels under hypoxia, explains 
cysteine role in ATP synthesis and in cellular metabolism reprogramming, as seen by the high number of 
metabolic pathways that cysteine altered under hypoxia compared to normoxia. HC - hypoxia with 
cysteine. 
C. Sulphasalazine inhibits the xCT transporter, and 5-Aminosalicylic acid (the main metabolite of 
sulphasalazine) [31] was also reported to induce both the mRNA and protein expression of the nuclear 
receptor peroxisome proliferator-activated receptor-gamma (PPAR-γ) [32]. Hypoxia was also reported to 
induce this nuclear receptor [33]. PPAR-γ has important roles in lipid and carbohydrate metabolism [34], 
hence possibly inducing β-oxidation of fatty acids upon sulphasalazine and hypoxia exposure. Under 
hypoxia, upon sulphasalazine exposure, it is expected an impaired cystine uptake, leading to decreased 
cysteine concentrations available for cells, which consequently, would lead to GSH depletion, decreased 
H2S synthesis and impaired ATP synthesis. With cysteine supplementation, the cells possibly canalize 
this extra cysteine to GSH synthesis, hence allowing to counteract oxidative stress, allowing an increased 
ATP generation resulting in an increased cellular metabolism. 
 
Remarkably, Shin and colleagues have reported a new function of the xCT transporter in 
the regulation of nutrient requirements in cancer cells [35]. They have shown that the Nrf2 
and xc- system upregulation was responsible for a glucose addicted phenotype [35]. 
Therefore, they have reported that the downregulation of xc- system led to an enhanced cell 
viability under glucose-deficient conditions due to an improved ability of cells to use 
intracellular glutamate [35]. Glutamate is converted into α-ketoglutarate, replenishing 
intermediates for the mitochondrial tricarboxylic acid cycle (TCA), thus maintaining the 
respiratory chain activity [36]. The authors argued that, since tumours are often subject to 
high oxidative stress, the upregulation of Nrf2 and xCT/SLC7A11 allows the redox 
homoeostasis maintenance at the cost of a reduced efficacy of glutamine metabolism, 
affecting also mitochondrial respiration [35]. Nonetheless, albeit the glucose addiction 
phenotype, the upregulation of system xc- should be beneficial when glucose is abundant 
[35]. Other study develop by Koppula and colleagues have also proposed a role of glutamate 
export driven by xCT in increased sensitivity to glucose or glutamine starvation [37]. 
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Furthermore, recently, Khamari and colleagues have reported a role of the Nrf2 pathway, 
together with an increased xCT expression, on melanoma with acquired resistance to BRAF 
inhibitors, where its strong activation was found to be responsible for an increased pentose 
phosphate pathway (PPP) [38]. PPP is crucial for several molecular processes as the 
regeneration of reduced GSH [38] to maintain the redox balance, the synthesis of nucleotides 
[39] supporting cell proliferation and gene expression, and also the histidine synthesis, which 
has a role in the protection against metals toxicity [40,41]. Importantly, the acquisition of 
BRAF inhibitors resistance was linked with both an increased mitochondrial OXPHOS and 
with glutamine metabolism [38]. Thus, they have linked chemoresistance with mitochondrial 
metabolism adaptations that favours glucose-derived-glutamate synthesis, cysteine uptake 
and GSH synthesis [38]. 
In our study, we did not address the role of cysteine uptake through xCT in ATP 
generation simultaneously under hypoxia and glucose withdrawal. Nevertheless, we can 
predict that cysteine benefits would remain or be even higher in ATP synthesis, as cysteine 
not only contributes for GSH and H2S synthesis, allowing redox homeostasis but also for 
TCA intermediates such as pyruvate and glutamate (the latter in the mitochondria via CAT 
activity) [42,43], hence replenishing glutamine functions. However, another study reported 
that cystine was responsible for glutamine dependence via xCT [44]. They found that cystine 
administration to tumour bearing mice increased glutamine use by tumour cells in vivo [44]. 
If glutamate derived from cysteine catabolism is sufficient to balance glutamate export via 
xCT action under glucose deprivation is an interesting issue that should be further addressed 
in ovarian cancer cells. 
Shin and colleagues also analysed 59 breast cancer cell lines and found a strong negative 
correlation between xCT/SLC7A11 expression and mitochondrial OXPHOS genes expression 
[35]. These results are contradictory with a role of xCT in mitochondrial ATP generation 
via OXPHOS, because: 1) xCT is a direct transcriptional target of Nrf2 (reviewed in [16]); 
2) a role of Nrf2 on respiration was reported, since Nrf2 deficiency resulted in a decreased 
efficacy of OXPHOS, whereas Nrf2 activation led to the opposite effect in both brain and 
liver mitochondria (reviewed in [16]); 3) data also supports a role of Nrf2 in β-oxidation 
enhancement (reviewed in [16]) and 4) this also opposes a role of H2S in mitochondrial ATP 
production by stimulating electron transport chain. Hence, the assessment of OXPHOS 
related genes expression in ovarian cancer cells with overexpression and down-regulation of 
xCT should allow gaining further insights on the effects of xCT in OXPHOS. Nonetheless, 
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the study of gene expression by Shin and co-workers was based on mRNA expression [35], 
and mRNA profiles may not be reliable to predict the protein profile which in fact represents 
the metabolic functioning [45].  
Recently, cysteine import via xc- system and its metabolism were reported to be pivotal 
in pancreatic cancer. This disease is characterized by its remarkably poor prognosis, where 
after initial diagnosis, only 8.2% of patients survive over 5 years [46]. In this study, a critical 
role of cysteine in the proliferation of several pancreatic cancer cell lines, by avoiding ROS 
accumulation, especially lipid ROS was reported [46]. In a mouse model of pancreatic cancer, 
the authors also found that the deletion of SLC7A11/xCT was able to delay and decrease 
tumour growth, leading to an increase in the overall median survival of mice [46]. 
Confirming the importance of cystine (the oxidized form of cysteine) and cysteine in the 
context of pancreatic cancer, Kshattry and colleagues have reported that their extracellular 
depletion by using the human enzyme Cyst(e)inase genetically engineered, led to cell growth 
inhibition and that Cyst(e)inase sensitivity was related to ROS accumulation [47]. The 
beneficial effects of this altered enzyme were also supported using an in vivo model of 
pancreatic cancer cell xenografts in nude mice [47]. The authors suggested the possible use of 
this compound in a clinical context of pancreatic cancer as a monotherapy or in combination 
with other drugs [47]. In the context of breast cancer, Tang and colleagues have reported that 
the epithelial-mesenchymal transition, process with a pivotal role in tumour progression of 
this disease, was accompanied by a cystine-addiction phenotype of the breast cancer cells 
[48]. Importantly, whereas the authors found this cystine addictive phenotype in the basal-
type breast cancer cells that are characteristic of triple negative breast cancer, they did not 
find this phenotype in luminal-type breast cancer cells [48], hence supporting a role of 
cystine/cysteine in more aggressive histotypes also in breast cancer context. 
In here, we did not address the role of cysteine hydropersulphide (CysSSH) in hypoxia 
adaptation. Since it simultaneously functions as a strong nucleophile and an antioxidant that 
may also be important in cellular oxidative stress and redox signalling regulation [49,50], we 
can speculate a critical role of CysSSH in ovarian cancer cells adaptation to hypoxia and also 
to platinum drugs. Fujii and colleagues have reported that besides CBS and CSE contribution 
to CysSSH using cystine as a substrate, cysteinyl-tRNA synthetase is crucial in CysSSH 
generation using L-cysteine. They reported that cysteinyl-tRNA synthetase is involved in the 
direct incorporation of CysSSH into proteins during translation, resulting in the formation of 
protein persulphides and polysulphides [50,51]. Moreover, they noticeably reported a novel 
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role for CysSSH in the regulation of mitochondrial biogenesis and bioenergetics and they 
firstly demonstrated sulphur respiration, a bacterial feature, in mammalian cells [50,51]. 
Together, these observations can pave the path to demonstrate that cysteine, directly or 
through CysSSH, can play an important role in cancer cells adaptation to hypoxia, 
functioning as a donor of sulphur to sustain sulphur respiration. This adaptive mechanism will 
undoubtedly change the paradigm of cells respiration as using exclusively oxygen as the 
electron acceptor and will open several different cues of research in order to change the way 
cancer metabolic remodelling is seen.  
In addition to the role of cysteine in interfering with the function of proteins through a 
cysteinylation process, the introduction of cysteines in the protein sequence driven by gene 
mutation seems to be also pivotal in cancer. Strikingly, Visscher and colleagues have reported 
that many oncogenic mutations cause the switch of the natural amino acid in the protein 
sequence by a cysteine [52]. They also reported that these cysteines account for at least 12% 
of all activating mutations found in Kirsten ras oncogene (KRAS) in cancer, and 88% of 
mutations in fibroblast growth factor receptor (FGFR). They suggested that when acquired 
cysteines are found that often, they should play a role in tumourigenesis [52]. Tsuber and co-
workers have confirmed this cysteine gain by analysing two thousand proteins in over 18000 
cancer samples [53]. Moreover, the authors have also found a gain in histidine, and 
tryptophan at the expense of an arginine loss [53]. They hypothesised that the gain of 
cysteine, histidine, and tryptophan can be related to an increased antioxidant and metal-
binding capacity of the proteome of the cancer cells, hence compensating oxidative stress and 
re-establishing the redox balance required for cell survival. They explained the loss of 
arginine due to the remarkably high mutation rate in four of the six codons that code for this 
amino acid or due to a targeted loss of arginine in essential tumour suppressor proteins that 
are frequently mutated in cancer [53]. Remarkably, Sojourner and colleagues have reported 
that mutations disturbing the histidine-proline-aspartic acid motif and cysteine-rich region of 
yeast DNAJ, a J-domain heat-shock protein 40 lead to the sensitization of S. cerevisiae cells 
both to doxorubicin and cisplatin, and that this sensitivity was specifically due to oxidative 
stress and not to DNA double-strand breaks [54]. This observation strengthens a functional 
role of cysteine gain in cancer, interfering structurally with the cellular machinery supported 
by proteins. 
Together, evidence reinforces a profound impact of cysteine in tumourigenesis, allowing 
metabolism reprogramming and consequently, an enhanced ability of ovarian cancer cells to 
adapt to novel and changing environments. In one hand, the environmental cysteine provides 
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the opportunity to sulphur and carbon metabolism reprograming and protein cysteinylation. In 
the other hand, mutation-derived cysteine incorporation can also contribute to the modulation 
of the function of proteins that are crucial for the carcinogenic phenotype. Cysteine-mutated 
proteins with roles in cell signalling (Kras) and cell cycle control (p53) [52] were reported 
and these mutations may also be involved in an increased redox homeostasis capacity [53]. In 
certain conditions, the incorporation of a new-inserted cysteine in a protein sequence might 
turn proteins more susceptible to abnormal structutral conformational changes or other 
protein thiolation modifications, enabling these mutated variants to form disulphide bonds 
that can switch their natural structure and function; and allows the interaction with other 
compounds as a thiol, interfering in the redox intracellular balance and building new 
molecular partnerships. Hence, cysteine can have wide effects on cancer cells, favouring their 
survival and disease progression within their microenvironment.  
 
5.4 CYSTEINE AS A SUITABLE BIOMARKER FOR OVARIAN CANCER 
SCREENING, DIAGNOSIS, PROGNOSIS AND TARGETED-THERAPY 
 
Given the established role of cysteine in ovarian cancer cell lines, we also aimed to 
address if this thiolic amino acid has a clinical significance. For that, we quantified thiols in 
serum from peripheral blood of patients with ovarian benign and malignant tumours and from 
healthy individuals (women). In the third chapter, our data have shown, with the exception of 
GSH, an overall increase of thiols concentration in serum from patients with ovarian 
neoplasms, regardless malignancy. Strikingly, total and free serum levels of homocysteine 
(HCys) distinguished serum from the three groups of individuals and the free levels of 
cysteine (Cys) and protein-S-cysteinylation (CysSSP) were also able to distinguish all the 
three groups, hence suggesting that cysteine and homocysteine levels can be putative 
biomarkers for ovarian cancer screening and early diagnosis. This is undoubtedly a major 
outcome of this thesis, constituting a step forward for ovarian cancer research, as the late 
diagnosis represents one of the most important barriers responsible for ovarian cancer poor 
prognosis.  
We also aimed to address cysteine role in disease progression. Therefore, we have 
quantified thiols in the ascitic fluid derived from patients with advanced disease, an important 
compartment of the ovarian cancer cells microenvironment. Strikingly, our data showed that 
cysteine was the prevalent thiol and that S-cysteinylation was the most abundant form of S-
thiolated proteins showing, once again, a clinical relevance of cysteine in disease progression. 
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We have thus hypothesised that cysteine acts as a first protection barrier for ovarian 
malignant cells against hypoxia and chemotherapy, therefore contributing for disease 
progression and recurrence.  
It would be interesting to additionally explore which proteins are being thiolated, not only 
in serum from patients with ovarian neoplasms, but also in the ascitic fluid, in order to gain 
further insights on the role of this post-translational modification of proteins in ovarian 
cancer. The knowledge of how far this alteration interferes with the function of proteins 
would give us more insights on ovarian cancer and cancer biology in general. 
Together, our data endorses cysteine targeting as a promising tool to fight not only 
ovarian cancer, but several cancer types. Inhibitors of cystine transporters like sulphasalazine 
are already used in the context of other diseases, such as Crohn’s disease and rheumatoid 
arthritis, suggesting that its use may be also a valuable strategy in cancer. However, albeit 
several pre-clinical models have shown promising results, indicating the use of sulphasalazine 
as an efficient and advantageous drug in the management of several cancer types [55–60], 
two clinical trials have reported the opposite [61]. Thus, Robe and co-workers have reported a 
phase 1/2 clinical study of sulphasalazine for the treatment of recurrent grade 3 and 4 
astrocytic gliomas in adults [61]. The authors concluded that sulphasalazine should not be 
generally used for the treatment of glioblastoma patients, as no clinical response was found 
and adverse side effects were common [61]. Shitara and colleagues have reported similar 
findings in a phase 1 study of sulphasalazine combined with cisplatin in patients with 
advanced gastric cancer with CD44v-positive cells that did not respond to cisplatin-based 
chemotherapy and exhibited gastrointestinal toxicity [62]. Only one patient was able to 
complete six cycles of treatment with stable disease for more than 4 months and with 
decreased intratumoral GSH levels [62]. In ovarian cancer, as far as we know, no clinical 
trials with sulphasalazine were reported. These two clinical trials show the complexity and 
the difficulties of the bench to the bedside applications, where, for example, the drug 
concentration used, the schedule of administration and the side and adverse effects impose 
extreme difficulties and may vary the outcome of the therapy. The development of 
sulphasalazine analogous with decreased side and adverse effects would be of extreme 
importance. In fact, several sulphasalazine analogous were already develop and, in the 
context of inflammatory bowel diseases, these analogous allow a differently distribution of 
drug delivery in the gastrointestinal tract, via pH-sensitive coating or delayed-release 
formulations [63], hence avoiding the adverse systemic effects of 5-ASA, the main metabolite 
of sulphasalazine [31]. Regarding ovarian cancer context, the development of such strategies 
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using for instance a formulation conjugated to a specific biomarker of ovarian cancer cells 
would allow targeted therapies, possibly allowing a more effective drug action, decreasing the 
damage of normal cell and increasing the drug delivery to cancer cells. Recently, Bolli and 
colleagues have developed a virus-like-particle immunotherapy that targeted the xCT protein 
and have shown that this system inhibited xCT activity, impaired breast cancer stem cells 
biology and decreased metastatic progression in preclinical models [64], hence opening new 
therapeutic approaches that target cysteine metabolism via the xCT transporter.  
The follow up of cancer cells metabolic features and adaptations should be considered in 
cancer management, as they can present a valuable mean to predict and overcome cancer 
chemoresistance. Together, our results support that cysteine metabolism can offer a good 
panel of biomarkers for ovarian cancer screening, diagnosis and prognosis and for targeted-
therapy. 
 
5.5 FINAL REMARKS 
 
With this thesis we aimed to disclose the role of cysteine in ovarian cancer progression 
and chemoresistance. Taken together, our data supports a protective effect of cysteine in 
ovarian cancer cells, allowing their adaptation and survival upon hypoxia and carboplatin 
exposure. Cysteine role in the mediation of GSH synthesis and ATP production via xCT-
mediated cysteine transport and also by its degradation in the mitochondria are presented in 
the figure 2. Specifically under hypoxia, cysteine is responsible for a cellular metabolism 
rescue mainly in ES2 cells, hence supporting its role in cells viability and proliferation. Our 
findings were also supported in a clinical context, hence strengthening the use of cysteine not 
only as a biomarker for early diagnosis and disease progression but also in a targeted-therapy. 
Taken together, we have disclosed a pivotal role of cysteine metabolism in ovarian cancer 
cells adaptation to hypoxia and resistance to carboplatin. These two features are highly linked 
with poor disease prognosis, hence, this thesis allowed gaining new insights not only on a 
novel possible therapeutic strategy, but also on a new powerful tool in screening, early 
diagnosis and outcome of this disease. Since the late diagnosis is profoundly associated with 
the poor prognosis of ovarian cancer, cysteine contribution as novel biomarker for an early 
diagnosis should be of extreme importance. Also, since cysteine metabolism was found to 
alter both hypoxia and anti-cancer drugs resistance, its’ targeting can constitute a potential 
strategy to overcome resistance. Moreover, since xCT was found overexpressed in several 
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types of cancer, this suggests that cysteine metabolism dependence is a common feature of 
cancer cells biology, opening the opportunity for a general therapeutic use in cancer. Thus, 
this thesis has opened new diagnostic, prognostic and therapeutic paths in cancer research, 
where cysteine metabolic profile allows the design of new and useful approaches to fight 
these diseases. 
This thesis raises the veil of new exciting aspects of the biological processes, supporting 
carcinogenesis and disease progression, with cancer metabolism and cysteine as core players. 
 
Figure 2. Proposed model for the protective effect of cysteine in ovarian cancer cells upon hypoxia 
and carboplatin exposure. 
Cysteine role in ovarian cancer cells adaptation to hypoxia can be mediated by GSH synthesis and also 
by its catabolism. Under hypoxia, the dynamics of thiol synthesis and degradation contribute to hypoxia 
adaptation mainly in ES2 cells. Cysteine catabolism can also have a role in ATP production via its 
degradation in the mitochondria. Thus, xCT transporter can mediate cysteine mitochondrial uptake and 
the enzymes CBS, CSE and MpST can lead to H2S synthesis. Pyruvate and glutamate also results from 
cysteine catabolism, hence allowing the replenishing of the TCA cycle. Under hypoxia, cysteine allowed 
a cellular metabolism rescue mainly in ES2 cells, having effects in several metabolic pathways. 
Since carboplatin also involves ROS generation, a similar protective effect of cysteine upon carboplatin 
exposure would drive ovarian cancer cells resistance. 
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5.6 FUTURE PERSPECTIVES 
 
This thesis left several open questions that merit additional attention. Some of them were 
already mentioned but others are also relevant, such as the clarification of the role of cysteine 
as a carbon source. This would allow gaining additional insight into the protective role of 
cysteine in hypoxic ovarian cancer cells, as it would enable following all the metabolites 
directly derived from cysteine. 
It would be also interesting to analyse the relative importance of each H2S-generating 
enzymes in ATP production in hypoxic ovarian cancer cells. Interestingly, the biological 
consequences of the modulation of MpST, together with its partner CAT, in cancer cells were 
not addressed yet, thus the knock-down and re-expression of this enzyme in ovarian cancer 
cells would bring new insights into its role in cancer biology. The validation of the activity of 
enzymes involved in cysteine metabolism (CBS, CSE and MpST) as a tool to follow and 
predict chemoresistance would be of a capital relevance in clinics. The design of new and 
fully specific inhibitors for these enzymes would for certain contribute for a more reliable 
evaluation of cancer reliance on these cysteine-dependent metabolic pathways. It would be 
also interesting to address the role of other cystine transporters such as SLC3A1 and 
cystinosin in ovarian cancer cells adaptation to hypoxia. Cystinosin is a lysosomal 
transmembrane protein involved in the transport of cystine from the lysosomes to the cytosol 
[65]. In the kidney proximal tubular cells, which highly express cystinosin, lysosomal cystine 
is a major source of cytosolic cysteine, by the degradation of cystine-containing proteins 
catalyzed by chatepsins [65]. Therefore, it would be interesting to investigate the role of this 
protein in the redox homeostasis of hypoxic ovarian cancer cells. 
The effect of sulphasalazine in ovarian cancer cells chemoresistance should be also 
investigated, not only in the presence of carboplatin but also in the presence of paclitaxel, in 
order to address its role on chemoresistance reversion. 
The role of Nrf2 in the orchestration of the dynamics, involving the role of cysteine 
uptake and metabolism, is undoubtedly an interesting cue to follow in order to understand the 
molecular mechanisms underlying the whole metabolic remodelling network. 
The biochemical process and alterations supporting the role of cysteine and CysSSH in 
sulphur respiration and the evidence that this adaptation can be the key to cancer cells 
survival in hypoxia is an open repertoire of experimental and biological questions. 
The proteomic profiling of S-cysteinylated proteins with the objective of identifying 
which proteins are preferentially targeted by this process, will be a good tool to identify 
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mechanistic alterations interfering with the various phases of the oncologic disease. This 
definition may serve as a starting point for the design of new therapeutic approaches and 
follow-up methods. In order to validate the use of cysteine as a biomarker for ovarian cancer 
screening, early diagnosis and progression of the disease, we also propose a pilot clinical 
observational study including women in different stages of the disease and healthy controls, 
matched for age. Women with endometriosis should be also included, since endometriosis 
was already associated with an increased risk for both endometrioid and clear cell carcinomas 
[66]. Free levels and protein bound levels of cysteine and homocysteine should be quantified 
in serum from patients within these groups in order to evaluate if the levels of these thiols 
vary among groups and within ovarian cancer patients, in order to address if their levels 
increase along with the progression of the disease. A follow-up should also be considered, 
performing the quantification of these thiols at diagnosis and over time, before and after 
chemotherapy (figure 3). This proof-of-concept would possibly allow the use of 
cysteine/cysteinylated proteins and homocysteine/homocysteinylated proteins as indicators of 
ovarian cancer cells chemoresistance, guiding therapeutic interventions in the view of 
precision medicine. 
 
Figure 3. Proposed groups for a pilot clinical study to validate cysteine (and homocysteine) as 
biomarkers for ovarian cancer screening, early diagnosis and progression. 
In this strategy, we propose to include groups of women in different stages of the disease per histological 
type, healthy controls and also women with endometriosis, matched for age. Cysteine and homocysteine 
levels (free and bound to proteins) should be measured over time in order to address if the levels of these 
thiols increase along with the progression of the disease. 
 
Furthermore, the effect of cysteine metabolism in the adaptability to hypoxia and 
chemoresistance in other cancer types should be analysed in order to assess if the protective 
effect of cysteine is a widespread metabolic feature of cancer cells. This would ultimately 
impact cancer management, as a general cancer cells targeted-therapy may be developed. 
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